Characterization and localization of cannabinoid recept vitro autoradiographic study

Journal of Neuroscience

11, 563-583

DOI: 10.1523/jneurosci.11-02-00563.1991

Citation Report

#	Article	IF	Citations
1	Overview: Challenges in the Search for CNS Therapeutics in the 1990's. Current Opinion in Therapeutic Patents, 1991, 1, 693-723.	0.2	4
2	Î”9-Tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent mannier in rat brain. European Journal of Pharmacology, 1991, 202, 373-378.	1.7	57
3	Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Research, 1991, 552, 301-310.	1.1	97
4	Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3825-3829.	3.3	643
5	Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guineaâ€pig small intestine. British Journal of Pharmacology, 1992, 105, 980-984.	2.7	143
6	Initial observations on the distribution of cannabinoid receptor binding sites in the human adult basal ganglia using autoradiography. Neuroscience Letters, 1992, 139, 7-9.	1.0	19
7	The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain, 1992, 51, 19-26.	2.0	15
8	Cannabinoid Receptor Localization in Brain: Relationship to Motor and Reward Systems. Annals of the New York Academy of Sciences, 1992, 654, 19-32.	1.8	129
9	Neurobiology of marijuana abuse. Trends in Pharmacological Sciences, 1992, 13, 201-206.	4.0	207
10	Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience, 1992, 48, 655-668.	1.1	626
11	Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-1949.	6.0	4,989
12	Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Research, 1992, 575, 93-102.	1.1	137
13	Localization of cannabinoid receptor mRNA in rat brain. Journal of Comparative Neurology, 1993, 327, 535-550.	0.9	582
14	Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal ?9-tetrahydrocannabinol treatments. Neurochemical Research, 1993, 18, 1183-1191.	1.6	47
15	Dopaminergic Regulation of Cannabinoid Receptor mRNA Levels in the Rat Caudate-Plitamen: An In Situ Hybridization Study. Journal of Neurochemistry, 1993, 61, 1705-1712.	2.1	123
16	Cannabinoids inhibit agonist-stimulated formation of inositol phosphates in rat hippocampal cultures. European Journal of Pharmacology, 1993, 246, 19-24.	2.7	16
17	Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacology Biochemistry and Behavior, 1993, 46, 967-972.	1.3	222
18	Development of behavioral tolerance to Î”9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacology Biochemistry and Behavior, 1993, 46, 575-579.	1.3	81

#	Article	IF	Citations
19	The evidence for the existence of cannabinoid receptors. General Pharmacology, 1993, 24, 811-824.	0.7	88
20	Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Molecular Reproduction and Development, 1993, 36, 507-516.	1.0	98
21	Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Research, 1993, 616, 293-302.	1.1	173
22	In vitro reinforcement of hippocampal bursting by the cannabinoid receptor agonist (âˆ')-CP-55,940. Brain Research, 1993, 626, 272-277.	1.1	6
23	An acute dose of Î'9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behavioural Brain Research, 1993, 57, 37-46.	1.2	79
24	Loss of cannabinoid receptors in the substantia nigra in huntington's disease. Neuroscience, 1993, 56, 523-527.	1.1	216
25	Cellular Targets of Brain Reinforcement Systems. Annals of the New York Academy of Sciences, 1993, 702, 41-60.	1.8	4
26	Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7656-7660.	3.3	427
27	Overview: Recent Advances in the Medicinal Chemistry of Cannabinoids. Current Opinion in Therapeutic Patents, 1993, 3, 403-416.	0.2	0
28	Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Annals of Neurology, 1994, 36, 577-584.	2.8	178
29	Downregulation of rat brain cannabinoid binding sites after chronic Î"9-tetrahydrocannabinol treatment. Pharmacology Biochemistry and Behavior, 1994, 47, 33-40.	1.3	166
30	Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience, 1994, 63, 637-652.	1.1	251
31	Expression of a cannabinoid receptor in baculo virus-infected insect cells. Biochemical Pharmacology, 1994, 48, 1231-1243.	2.0	20
32	The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. European Journal of Pharmacology, 1994, 259, R7-R8.	1.7	65
33	Cannabinoid receptors in rat brain areas: Sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sciences, 1994, 54, 159-170.	2.0	255
34	Progress toward Understanding the Cannabinoid Receptor and Its Second Messenger Systems. Advances in Pharmacology, 1994, 25, 341-397.	1.2	24
35	In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7242-7246.	3.3	427
36	Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology, 1995, 119, 282-290.	1.5	283

#	Article	IF	Citations
37	Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacology Biochemistry and Behavior, 1995, 51, 3-7.	1.3	63
38	Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Î´9-tetrahydrocannabinol. Pharmacology Biochemistry and Behavior, 1995, 51, 731-737.	1.3	100
39	The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicology and Teratology, 1995, 17, 25-30.	1.2	141
40	Cannabinoids selectively decrease paired-pulse facilitation of perforant path synaptic potentials in the dentate gyrus in vitro. Brain Research, 1995, 688, 114-120.	1.1	19
41	The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Research, 1995, 691, 106-114.	1.1	53
42	Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Research, 1995, 694, 223-232.	1.1	77
43	Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. Journal of Neuroscience, 1995, 15, 6552-6561.	1.7	543
44	Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells. Journal of Biological Chemistry, 1995, 270, 13973-13980.	1.6	159
45	Neurobehavioral effects of Î”9-THC and cannabinoid (CB1) receptor gene expression in mice. Behavioural Brain Research, 1995, 72, 115-125.	1.2	71
46	Prevention by the cannabinoid antagonist, SR141716A, of cannabinoidâ€mediated blockade of longâ€term potentiation in the rat hippocampal slice. British Journal of Pharmacology, 1995, 115, 869-870.	2.7	83
47	Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. European Journal of Pharmacology, 1995, 279, 179-185.	1.7	85
48	Physical withdrawal in rats tolerant to Î”9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. European Journal of Pharmacology, 1995, 280, R13-R15.	1.7	152
49	Anandamide Amidohydrolase Activity in Rat Brain Microsomes. Journal of Biological Chemistry, 1995, 270, 6030-6035.	1.6	304
50	Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sciences, 1995, 56, 2041-2048.	2.0	66
51	An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sciences, 1995, 56, 2103-2109.	2.0	149
52	Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sciences, 1995, 56, 2111-2118.	2.0	116
53	the ottawa prenatal prospective study (OPPS): Methodological issues and findings â€” it's easy to throw the baby out with the bath water. Life Sciences, 1995, 56, 2159-2168.	2.0	94
54	The prenatal exposure to Î´9-tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development. Life Sciences, 1995, 56, 2177-2184.	2.0	46

#	Article	IF	Citations
55	Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. British Journal of Pharmacology, 1996, 119, 107-114.	2.7	66
56	Endogenous cannabinoid ligands â€" chemical and biological studies. Journal of Lipid Mediators and Cell Signalling, 1996, 14, 45-49.	1.0	49
57	Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Behavioural Brain Research, 1996, 75, 91-98.	1.2	62
58	Cannabinoid receptor genes. Progress in Neurobiology, 1996, 48, 275-305.	2.8	62
59	Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1, receptor ligand. Life Sciences, 1996, 58, 1249-1257.	2.0	57
60	Cannabinoid receptor stimulation of guanosine-5â€²-O-(3-[35S]thio)triphosphate binding in rat brain membranes. Life Sciences, 1996, 59, 659-668.	2.0	93
61	Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. European Journal of Pharmacology, 1996, 304, 29-35.	1.7	46
62	Differences in G-protein activation by Î¼- and Î´-opioid, and cannabinoid, receptors in rat striatum. European Journal of Pharmacology, 1996, 307, 97-105.	1.7	132
63	123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. European Journal of Pharmacology, 1996, 307, 331-338.	1.7	222
64	Neuronal responses to Î”9-tetrahydrocannabinol in the solitary tract nucleus. European Journal of Pharmacology, 1996, 312, 273-279.	1.7	40
65	What is the role of the gamma-hydroxybutyrate receptor?. Medical Hypotheses, 1996, 47, 455-459.	0.8	6
66	Posttranslational Regulation of Ca2+-Activated K+ Currents by a Target-Derived Factor in Developing Parasympathetic Neurons. Neuron, 1996, 17, 115-124.	3.8	41
67	Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience, 1996, 70, 791-798.	1.1	105
68	Effects of Chronic Treatment with Î”⁹-Tetrahydrocannabinol on Cannabinoid-Stimulated [³⁵S]GTPÎ³S Autoradiography in Rat Brain. Journal of Neuroscience, 1996, 16, 8057-8066.	1.7	283
69	Suppression of Noxious Stimulus-Evoked Activity in the Ventral Posterolateral Nucleus of the Thalamus by a Cannabinoid Agonist: Correlation between Electrophysiological and Antinociceptive Effects. Journal of Neuroscience, 1996, 16, 6601-6611.	1.7	171
70	Molecular Neurobiology of The Cannabinoid Receptor. International Review of Neurobiology, 1996, 39, 197-221.	0.9	59
71	Ontogenetic development of the response to anandamide and Î”9-tetrahydrocannabinol in mice. Developmental Brain Research, 1996, 95, 131-134.	2.1	44
72	Developmental aspects of anandamide: ontogeny of response and prenatal exposure. Psychoneuroendocrinology, 1996, 21, 157-172.	1.3	50

#	Article	IF	Citations
73	Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacology Biochemistry and Behavior, 1996, 53, 657-664.	1.3	159
74	Roles of dopamine D1 receptors inÎ”9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Research, 1996, 710, 234-240.	1.1	34
75	Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Research, 1996, 733, 184-192.	1.1	44
76	C-Attached aminoalkylindoles: potent cannabinoid mimetics. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 17-22.	1.0	31
77	Î”9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology, 1996, 126, 125-131.	1.5	197
78	Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology, 1996, 126, 165-172.	1.5	268
79	Preparation of iodine-123 labeled AM251: A potential SPECT radioligand for the brain cannabinoid CB1 receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 875-881.	0.5	20
80	Cannabis: pharmacology and toxicology in animals and humans. Addiction, 1996, 91, 1585-1614.	1.7	172
81	Isotope Dilution Mass Spectrometric Measurements Indicate That Arachidonylethanolamide, the Proposed Endogenous Ligand of the Cannabinoid Receptor, Accumulates in Rat Brain Tissue Post Mortem but Is Contained at Low Levels in or Is Absent from Fresh Tissue. Journal of Biological Chemistry, 1996, 271, 17287-17295.	1.6	106
82	Cognitive Correlates of Long-term Cannabis Use in Costa Rican Men. Archives of General Psychiatry, 1996, 53, 1051.	13.8	170
83	Chapter II The basal ganglia. Handbook of Chemical Neuroanatomy, 1996, , 371-468.	0.3	202
84	A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. Journal of Biological Chemistry, 1997, 272, 22330-22339.	1.6	411
85	Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor,N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain. Journal of Neuroscience, 1997, 17, 1226-1242.	1.7	380
86	Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport, 1997, 8, 491-496.	0.6	279
87	Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. NeuroReport, 1997, 8, 649-652.	0.6	330
88	Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. European Journal of Pharmacology, 1997, 324, 187-192.	1.7	70
89	Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: Evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochemical Pharmacology, 1997, 53, 1919-1927.	2.0	84
90	Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. FEBS Letters, 1997, 403, 263-267.	1.3	35

#	Article	IF	Citations
91	Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sciences, 1997, 61, PL191-PL197.	2.0	124
92	THE ACTIVATION OF CANNABINOID RECEPTORS IN STRIATONIGRAL GABAERGIC NEURONS INHIBITED GABA UPTAKE. Life Sciences, 1997, 62, 351-363.	2.0	83
93	Action of Î´-9-tetrahydrocannabinol on gabaa receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice. Neuropharmacology, 1997, 36, 1387-1392.	2.0	20
94	Effects of chronic exposure to Î”9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Molecular Brain Research, 1997, 46, 100-108.	2.5	138
95	Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neuroscience Letters, 1997, 238, 84-86.	1.0	66
96	Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neuroscience Letters, 1997, 223, 125-128.	1.0	149
97	Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997, 77, 299-318.	1.1	903
98	Maternal Exposure to Î” 9 -Tetrahydrocannabinol (Î” 9 -THC) Alters Indolamine Levels and Turnover in Adult Male and Female Rat Brain Regions. Brain Research Bulletin, 1997, 43, 173-178.	1.4	32
100	Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a G_sLinkage to the CB1 Receptor. Journal of Neuroscience, 1997, 17, 5327-5333.	1.7	565
101	Cannabinoids Inhibit N- and P/Q-Type Calcium Channels in Cultured Rat Hippocampal Neurons. Journal of Neurophysiology, 1997, 78, 43-50.	0.9	475
102	Role of the Subthalamic Nucleus in Cannabinoid Actions in the Substantia Nigra of the Rat. Journal of Neurophysiology, 1997, 77, 1635-1638.	0.9	95
103	Modulation of Neurotransmission by Cannabinoids in the Basal Ganglia. European Journal of Neuroscience, 1997, 9, 199-203.	1.2	67
104	Î”9-Tetrahydrocannabinol Increases Prefrontal Cortical Catecholaminergic Utilization and Impairs Spatial Working Memory in the Rat: Blockade of Dopaminergic Effects with HA966. Neuropsychopharmacology, 1997, 16, 426-432.	2.8	149
105	Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, 74, 129-180.		1,245
106	Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System. Pharmacology Biochemistry and Behavior, 1997, 56, 803-807.	1.3	201
107	Cannabinoid-Induced Alterations in Regional Cerebral Blood Flow in the Rat. Pharmacology Biochemistry and Behavior, 1997, 57, 625-631.	1.3	39
108	Binding of aminoalkylindoles to noncannabinoid binding sites in NG108-15 cells. Cellular and Molecular Neurobiology, 1997, 17, 483-493.	1.7	7
109	Marijuana. Clinical Reviews in Allergy and Immunology, 1997, 15, 243-269.	2.9	44

#	Article	IF	Citations
111	Atypical location of cannabinoid receptors in white matter areas during rat brain development. , 1997, 26, 317-323.		129
112	Cannabinoid Receptor and WIN-55,212-2-Stimulated [³⁵S]GTPÎ³S Binding and Cannabinoid Receptor mRNA Levels in the Basal Ganglia and the Cerebellum of Adult Male Rats Chronically Exposed to Î”⁹-Tetrahydrocannabinol. Journal of Molecular Neuroscience, 1998, 11, 109-120.	1.1	36
113	Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. Journal of Physiology, 1998, 510, 867-879.	1.3	199
114	Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. European Journal of Neuroscience, 1998, 10, 2825-2830.	1.2	124
115	Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic Î³-aminobutyric acid (GABA) inputs. Biochemical Pharmacology, 1998, 56, 1331-1338.	2.0	51
116	Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. Brain Research, 1998, 790, 236-244.	1.1	78
117	Inhibition of hippocampal acetylcholine release after acute and repeated Î”9-tetrahydrocannabinol in rats. Brain Research, 1998, 809, 1-4.	1.1	68
118	Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. European Journal of Pharmacology, 1998, 352, 199-205.	1.7	22
119	Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. European Journal of Pharmacology, 1998, 359, 49-54.	1.7	31
120	Differential Effects on Cognitive Functioning in 9- to 12-Year Olds Prenatally Exposed to Cigarettes and Marihuana. Neurotoxicology and Teratology, 1998, 20, 293-306.	1.2	238
121	Immunohistochemical localization of the neural cannabinoid receptor in rat brain. Journal of Neuroscience Research, 1998, 51, 391-402.	1.3	204
122	Effects of intrapallidal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Synapse, 1998, 28, 27-32.	0.6	55
123	Effects of intrastriatal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Synapse, 1998, 30, 221-226.	0.6	64
124	Cardiovascular actions of cannabinoids and their generation during shock. Journal of Molecular Medicine, 1998, 76, 824-836.	1.7	100
125	The cannabinoid CB 1 receptor antagonist SR141716A attenuates the memory impairment produced by ? 9 -tetrahydrocannabinol or anandamide. Psychopharmacology, 1998, 140, 11-19.	1.5	165
126	Differential regulation of FAK+ and PYK2/CakÎ²2, two related tyrosine kinases, in rat hippocampal slices: effects of LPA, carbachol, depolarization and hyperosmolarity. European Journal of Neuroscience, 1998, 10, 1667-1675.	1.2	58
127	Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTPÎ³S binding in morphine-dependent mice. Drug and Alcohol Dependence, 1998, 50, 241-249.	1.6	34
128	Cannabis and endogenous cannabinoid systems. Drug and Alcohol Dependence, 1998, 51, 173-187.	1.6	137

#	Article	IF	Citations
129	Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Molecular Brain Research, 1998, 55, 126-132.	2.5	82
130	Effects of long-term exposure to Î”9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Molecular Brain Research, 1998, 62, 141-149.	2.5	104
131	Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neuroscience Letters, 1998, 242, 33-36.	1.0	130
132	Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neuroscience Letters, 1998, 248, 171-174.	1.0	75
133	Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neuroscience Letters, 1998, 252, 13-16.	1.0	103
134	Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neuroscience Letters, 1998, 257, 119-122.	1.0	106
135	Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 1998, 75, 111-119.	2.0	441
136	Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 1998, 83, 393-411.	1.1	1,429
137	Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35s]guanylyl-5â€²-O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience, 1998, 84, 1075-1083.	1.1	80
138	Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1998, 1407, 205-214.	1.8	59
139	Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation. Life Sciences, 1998, 63, 351-356.	2.0	31
140	CANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS. Annual Review of Pharmacology and Toxicology, 1998, 38, 179-200.	4.2	348
141	Introduction The Neurobiology of Cannabinoid Transmission: From Anandamide Signaling to Higher Cerebral Functions and Disease. Neurobiology of Disease, 1998, 5, 379-385.	2.1	5
142	Role of the Endogenous Cannabinoid System in the Regulation of Motor Activity. Neurobiology of Disease, 1998, 5, 483-501.	2.1	147
143	Cannabinoid Transmission and Pain Perception. Neurobiology of Disease, 1998, 5, 447-461.	2.1	117
144	Cannabinoid Transmission and Reward-Related Events. Neurobiology of Disease, 1998, 5, 502-533.	2.1	230
145	Role of Cannabinoid Receptors in Memory Storage. Neurobiology of Disease, 1998, 5, 474-482.	2.1	117
146	Function of Cannabinoid Receptors in the Neuroendocrine Regulation of Hormone Secretion. Neurobiology of Disease, 1998, 5, 432-446.	2.1	159

#	Article	IF	Citations
147	The Functional Neuroanatomy of Brain Cannabinoid Receptors. Neurobiology of Disease, 1998, 5, 417-431.	2.1	179
148	A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain.. Proceedings of the Royal Society B: Biological Sciences, 1998, 265, 2081-2085.	1.2	282
149	Antihyperalgesic effects of spinal cannabinoids. European Journal of Pharmacology, 1998, 345, 145-153.	1.7	245
150	Potent effects of a selective cannabinoid receptor agonist on some guinea pig medial vestibular nucleus neurons. European Journal of Pharmacology, 1998, 348, R1-R2.	1.7	9
151	Novel Analogues of Arachidonylethanolamide (Anandamide):â€‰ Affinities for the CB1 and CB2 Cannabinoid Receptors and Metabolic Stability. Journal of Medicinal Chemistry, 1998, 41, 5353-5361.	2.9	132
152	Selective Effects of the Endogenous Cannabinoid Arachidonylethanolamide (Anandamide) on Regional Cerebral Blood Flow in the Rat. Neuropsychopharmacology, 1998, 19, 481-491.	2.8	22
153	The therapeutic applications of cannabinoid agonists and antagonists. Expert Opinion on Emerging Drugs, 1998, 3, 39-54.	1.1	4
154	Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. NeuroReport, 1998, 9, 671-675.	0.6	100
155	CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. NeuroReport, 1998, 9, 3397-3402.	0.6	137
156	Hippocampal Neurotoxicity of Î”⁹-Tetrahydrocannabinol. Journal of Neuroscience, 1998, 18, 5322-5332.	1.7	249
157	Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia. Journal of Neuroscience, 1998, 18, 451-457.	1.7	178
158	Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons. Journal of Neuroscience, 1999, 19, 6795-6805.	1.7	251
159	Cannabinoid Suppression of Noxious Heat-Evoked Activity in Wide Dynamic Range Neurons in the Lumbar Dorsal Horn of the Rat. Journal of Neurophysiology, 1999, 81, 575-583.	0.9	125
160	Mechanisms of Cannabinoid-Receptorâ€“Mediated Inhibition of Synaptic Transmission in Cultured Hippocampal Pyramidal Neurons. Journal of Neurophysiology, 1999, 82, 1286-1294.	0.9	154
161	The CB1 Cannabinoid Receptor Can Sequester G-Proteins, Making Them Unavailable to Couple to Other Receptors. Journal of Neuroscience, 1999, 19, 9271-9280.	1.7	144
162	Regulation of Peripheral Cannabinoid Receptor CB2Phosphorylation by the Inverse Agonist SR 144528. Journal of Biological Chemistry, 1999, 274, 20397-20405.	1.6	89
163	Pain modulation by release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 12198-12203.	3.3	450
164	Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5786-5790.	3.3	117

#	Article	IF	Citations
165	Cannabinoid CB1 receptors and ligands in vertebrate retina: Localization and function of an endogenous signaling system. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14565-14570.	3.3	182
166	Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience, 1999, 2, 358-363.	7.1	731
167	Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. British Journal of Pharmacology, 1999, 127, 935-940.	2.7	124
168	The cannabinoid CB1receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. British Journal of Pharmacology, 1999, 127, 1765-1767.	2.7	71
169	Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. British Journal of Pharmacology, 1999, 128, 684-688.	2.7	12
170	A light and electron microscopic study of the CB1 cannabinoid receptor in the primate spinal cord. , 1999, 28, 39-45.		61
171	A light and electron microscopic study of the CB1 cannabinoid receptor in monkey basal forebrain. Journal of Neurocytology, 1999, 28, 1045-1051.	1.6	25
172	Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Research, 1999, 822, 17-25.	1.1	178
173	Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Research, 1999, 822, 237-242.	1.1	161
174	Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Î”9-tetrahydrocannabinol in rats. Brain Research, 1999, 839, 173-179.	1.1	150
175	Effects of Î”9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells. Brain Research, 1999, 841, 114-122.	1.1	25
176	Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Research, 1999, 848, 183-190.	1.1	155
177	Cannabinoid penetration into mouse brain as determined by ex vivo binding. European Journal of Pharmacology, 1999, 374, 417-421.	1.7	27
178	Cannabimimetic Activity in Rats and Pigeons of HU 210, a Potent Antiemetic Drug. Pharmacology Biochemistry and Behavior, 1999, 62, 75-80.	1.3	47
179	Cannabis. Pharmacology Biochemistry and Behavior, 1999, 64, 257-260.	1.3	58
180	Learning Impairment Produced in Rats by the Cannabinoid Agonist HU 210 in a Water-Maze Task. Pharmacology Biochemistry and Behavior, 1999, 64, 555-561.	1.3	106
181	Perinatal Î” 9 -Tetrahydrocannabinol Exposure Augmented the Magnitude of Motor Inhibition Caused by GABA B , but not GABA A , Receptor Agonists in Adult Rats. Neurotoxicology and Teratology, 1999, 21, 277-283.	1.2	47
182	Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. , 1999, 33, 181-191.		247

#	Article	IF	Citations
183	Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina. , 1999, 415, 80-90.		111
184	Human neuroimaging of acute and chronic marijuana use: implications for frontocerebellar dysfunction. Human Psychopharmacology, 1999, 14, 291-304.	0.7	48
185	The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain, 1999, 81, 25-33.	2.0	78
186	Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain, 1999, 82, 199-205.	2.0	144
187	Building blocks of pain: the regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy. Pain, 1999, 82, S71-S85.	2.0	48
188	Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience, 1999, 90, 923-931.	1.1	292
189	Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience, 1999, 91, 607-620.	1.1	81
190	A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience, 1999, 92, 1177-1191.	1.1	134
191	Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience, 1999, 93, 969-975.	1.1	306
192	Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience, 1999, 92, 1171-1175.	1.1	180
193	Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences, 1999, 20, 287-294.	4.0	364
194	Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to Î”9-tetrahydrocannabinol. Drug and Alcohol Dependence, 1999, 55, 127-136.	1.6	29
195	The effects of cannabinoids on the brain. Progress in Neurobiology, 1999, 58, 315-348.	2.8	739
196	Inhibition of luteinizing hormone secretion by Î”9-tetrahydrocannabinol in the ovariectomized rat: Effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists. Steroids, 1999, 64, 664-671.	0.8	9
197	Cannabinoids as potential new analgesics. Life Sciences, 1999, 65, 675-685.	2.0	65
198	Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sciences, 1999, 65, 703-713.	2.0	144
199	Cannabinoids, hippocampal function and memory. Life Sciences, 1999, 65, 715-723.	2.0	196
200	Role of endocannabinoids in brain development. Life Sciences, 1999, 65, 725-736.	2.0	100

#	Article	IF	Citations
201	Influence of the cannabinoid agonist HU 210 on cocaine- and CQP 201-403- induced behavioural effects in rat. Life Sciences, 1999, 65, 823-831.	2.0	39
202	Cannabinoid receptor CB1 activates the Na+/H+exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Letters, 1999, 449, 61-65.	1.3	69
203	Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study. Biological Psychiatry, 1999, 45, 1307-1312.	0.7	43
204	Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand. AAPS PharmSci, 1999, 1, 39-45.	1.3	71
205	A role for the endogenous cannabinoid system in the peripheal control of pain initiation. Progress in Brain Research, 2000, 129, 471-482.	0.9	28
206	Cannabinoid receptors on goldfish retinal bipolar cells: Electron-microscope immunocytochemistry and whole-cell recordings. Visual Neuroscience, 2000, 17, 391-401.	0.5	76
207	Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. , 2000, 422, 159-171.		322
208	In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: Behavioral and cellular responses after acute and chronic treatments. , 2000, 35, 8-14.		46
209	Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study. Synapse, 2000, 37, 71-80.	0.6	194
210	Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse, 2000, 38, 477-482.	0.6	53
211	The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chemistry and Physics of Lipids, 2000, 108, 151-158.	1.5	50
212	Activation of spinal cannabinoid1receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPÎ³S binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. European Journal of Neuroscience, 2000, 12, 2079-2086.	1.2	76
213	Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. European Journal of Neuroscience, 2000, 12, 3239-3249.	1.2	466
214	The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. European Journal of Neuroscience, 2000, 12, 1123-1127.	1.2	88
215	Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves. British Journal of Pharmacology, 2000, 130, 1720-1726.	2.7	20
216	Cannabinoid receptors and the regulation of immune response. Chemistry and Physics of Lipids, 2000, 108, 169-190.	1.5	253
217	Endogenous cannabinoid signaling and psychomotor disorders. Prostaglandins and Other Lipid Mediators, 2000, 61, 63-70.	1.0	10
218	Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacology Biochemistry and Behavior, 2000, 67, 265-270.	1.3	142

#	Article	IF	Citations
219	Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacology Biochemistry and Behavior, 2000, 67, 567-573.	1.3	43
220	Role of the superior colliculus in the motor effects of cannabinoids and dopamine. Brain Research, 2000, 853, 207-214.	1.1	15
221	Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Brain Research, 2000, 857, 56-65.	1.1	55
222	CB1 cannabinoid receptor expression in brain regions associated with zebra finch song control. Brain Research, 2000, 857, 151-157.	1.1	61
223	The effect of Î´-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Research, 2000, 857, 183-187.	1.1	54
224	Activational role of cannabinoids on movement. European Journal of Pharmacology, 2000, 391, 269-274.	1.7	178
225	Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats. European Journal of Pharmacology, 2000, 391, 275-279.	1.7	39
226	Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. European Journal of Pharmacology, 2000, 396, 141-149.	1.7	480
227	Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. European Journal of Pharmacology, 2000, 396, 85-92.	1.7	90
228	SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. European Journal of Pharmacology, 2000, 404, 175-179.	1.7	152
229	Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens. Pituitary, 2000, 3, 221-227.	1.6	16
230	Endocannabinoids and Peripheral Pain. Pharmacy and Pharmacology Communications, 2000, 6, 259-262.	0.3	0
231	Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology, 2000, 149, 121-128.	1.5	38
232	Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and Âµ-opioid receptor binding in the basal ganglia. Experimental Brain Research, 2000, 130, 142-150.	0.7	47
233	The effects of acute treatment with Î”9-THC on exploratory behaviour and memory in the rat. Journal of Physiology and Biochemistry, 2000, 56, 17-24.	1.3	46
234	Cannabinoid Receptor Modulation of Synapses Received by Cerebellar Purkinje Cells. Journal of Neurophysiology, 2000, 83, 1167-1180.	0.9	157
235	Cannabinoid Withdrawal Syndrome Is Reduced in Pre-Proenkephalin Knock-Out Mice. Journal of Neuroscience, 2000, 20, 9284-9289.	1.7	105
236	Cannabinoids Modulate Synaptic Strength and Plasticity at Glutamatergic Synapses of Rat Prefrontal Cortex Pyramidal Neurons. Journal of Neurophysiology, 2000, 83, 3287-3293.	0.9	259

#	Article	IF	Citations
237	Cellular and Molecular Mechanisms Underlying Learning and Memory Impairments Produced by Cannabinoids. Learning and Memory, 2000, 7, 132-139.	0.5	156
238	Pharmacology of the Intraocular Pressure (IOP) Lowering Effect of Systemic Dexanabinol (HU-211), A Non-Psychotropic Cannabinoid. Journal of Ocular Pharmacology and Therapeutics, 2000, 16, 217-230.	0.6	28
239	Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland. Biochemical and Biophysical Research Communications, 2000, 270, 260-266.	1.0	172
240	Cannabinoid CB1 Receptor Expression in Rat Spinal Cord. Molecular and Cellular Neurosciences, 2000, 15, 510-521.	1.0	241
241	Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience, 2000, 98, 253-262.	1.1	90
242	Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience, 2000, 99, 661-667.	1.1	65
243	Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience, 2000, 100, 685-688.	1.1	283
244	Median eminence nitric oxide signaling. Brain Research Reviews, 2000, 34, 27-41.	9.1	47
245	The endogenous cannabinoid system and brain development. Trends in Neurosciences, 2000, 23, 14-20.	4.2	303
246	Biodistribution of [18f] SR144385 and [18f] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nuclear Medicine and Biology, 2000, 27, 757-762.	0.3	39
247	Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sciences, 2000, 66, 485-494.	2.0	100
248	Effects of chronic Î”9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology, 2000, 39, 391-398.	2.0	105
249	Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour. Physiology and Behavior, 2000, 69, 547-554.	1.0	48
250	THE CANNABINOID AGONIST HU 210 MODIFIES RAT BEHAVIOURAL RESPONSES TO NOVELTY AND STRESS. Pharmacological Research, 2000, 41, 45-51.	3.1	65
251	Cannabinoids modulate pain by multiple mechanisms of action. Journal of Pain, 2000, 1, 2-14.	0.7	82
252	Rat Cognitive Functions During and After Treatment with the Cannabinoid Agonist, HU 210. Pharmacy and Pharmacology Communications, 2000, 6, 243-246.	0.3	1
253	Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO Journal, 2001, 20, 7033-7040.	3.5	244
254	Autoradiographic Study of Pre- and Postnatal Distribution of Cannabinoid Receptors in Human Brain. NeuroImage, 2001, 14, 1463-1468.	2.1	108

#	Article	IF	Citations
255	CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 2001, 93, 239-245.	2.0	346
256	Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience, 2001, 104, 923-926.	1.1	144
257	Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience, 2001, 106, 1-4.	1.1	404
258	Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience, 2001, 107, 641-652.	1.1	152
259	The role of Cannabinoids in neurodegenerative diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 743-765.	2.5	65
260	Cannabinoid receptors and pain. Progress in Neurobiology, 2001, 63, 569-611.	2.8	680
261	Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neuroscience Letters, 2001, 309, 197-201.	1.0	109
262	Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neuroscience Research, 2001, 40, 205-210.	1.0	124
263	Endogenous Cannabinoids Mediate Retrograde Signals from Depolarized Postsynaptic Neurons to Presynaptic Terminals. Neuron, 2001, 29, 729-738.	3.8	754
264	Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sciences, 2001, 70, 97-108.	2.0	52
265	Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology, 2001, 40, 918-926.	2.0	96
266	Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology, 2001, 41, 870-877.	2.0	27
267	The neurobiology and evolution of cannabinoid signalling. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 381-408.	1.8	338
268	Understanding the Pharmacology and Physiology of Cannabis Dependence. , 2001, , 37-57.		1
269	Cannabinoids and Pain. Pain Research and Management, 2001, 6, 74-79.	0.7	40
270	Cannabinoid-Induced Presynaptic Inhibition of Glutamatergic EPSCs in Substantia Gelatinosa Neurons of the Rat Spinal Cord. Journal of Neurophysiology, 2001, 86, 40-48.	0.9	146
271	Ultrastructural Localization of the CB1 Cannabinoid Receptor in Î¼-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus. Journal of Neuroscience, 2001, 21, 823-833.	1.7	326
272	Direct Actions of Cannabinoids on Synaptic Transmission in the Nucleus Accumbens: A Comparison With Opioids. Journal of Neurophysiology, 2001, 85, 72-83.	0.9	182

#	Article	IF	Citations
273	Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration. Journal of Neuroscience, 2001, 21, 5344-5350.	1.7	347
274	Absence of Î”-9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice. Journal of Neuroscience, 2001, 21, 9499-9505.	1.7	130
275	Î”9-tetrahydrocannabinol-induced alterations in limbic system glucose use in the rat. NeuroReport, 2001, 12, 3573-3577.	0.6	9
276	Characteristics of Learning and Memory Impairment Induced by âŠ¿9-Tetrahydrocannabinol in Rats. The Japanese Journal of Pharmacology, 2001, 87, 297-308.	1.2	72
277	Differential effects of Î” 9 -THC on spatial reference and working memory in mice. Psychopharmacology, 2001, 157, 142-150.	1.5	146
278	Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology, 2001, 159, 111-116.	1.5	132
279	VanilloÃ¯des, cannabinoÃ¯des et nociception: aspects anatomiques. Douleur Et Analgesie, 2001, 14, 181-192.	0.2	0
280	Les rÃ©cepteurs CB1 et leurs ligands. Douleur Et Analgesie, 2001, 14, 233-242.	0.2	0
281	Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation. Journal of Neurochemistry, 2001, 77, 1048-1057.	2.1	27
282	Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. European Journal of Neuroscience, 2001, 14, 96-102.	1.2	78
283	Î”9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activationin vivodepends on dopaminergic transmission. European Journal of Neuroscience, 2001, 14, 342-352.	1.2	144
284	Changes in cannabinoid CB1receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse, 2001, 41, 195-202.	0.6	62
285	CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. Journal of Neuroscience Research, 2001, 65, 346-353.	1.3	39
286	Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. Pharmaceutical Research, 2001, 18, 494-499.	1.7	23
287	Cannabinoids and Neuroprotection. Molecular Neurobiology, 2001, 24, 029-052.	1.9	89
288	Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues. British Journal of Pharmacology, 2001, 132, 525-535.	2.7	9
289	Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. British Journal of Pharmacology, 2001, 134, 664-672.	2.7	142
290	Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 2001, 410, 822-825.	13.7	1,468

#	Article	IF	Citations
291	Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. Journal of Physiology, 2001, 534, 805-812.	1.3	61
292	Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. Journal of Physiology, 2001, 532, 731-748.	1.3	224
293	Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia, 2001, 56, 1059-1068.	1.8	28
294	Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacology Biochemistry and Behavior, 2001, 69, 239-249.	1.3	97
295	Cannabinoid-induced motor incoordination through the cerebellar CB1 receptor in mice. Pharmacology Biochemistry and Behavior, 2001, 69, 251-259.	1.3	63
296	CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Research, 2001, 908, 67-74.	1.1	67
297	The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Research, 2001, 921, 240-255.	1.1	75
298	Inhibitory effects of SR141716A on G-protein activation in rat brain. European Journal of Pharmacology, 2001, 414, 135-143.	1.7	84
299	Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. European Journal of Pharmacology, 2001, 429, 93-100.	1.7	74
300	The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. European Journal of Pharmacology, 2001, 430, 49-58.	1.7	77
301	A literature review of the consequences of prenatal marihuana exposure. Neurotoxicology and Teratology, 2001, 23, 1-11.	1.2	290
302	From the Cover: Progesterone receptor and dopamine receptors are required in Delta 9-tetrahydrocannabinol modulation of sexual receptivity in female rats. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1249-1254.	3.3	58
303	Progesterone receptor and dopamine receptors are required in Î” ⁹ -tetrahydrocannabinol modulation of sexual receptivity in female rats. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1249-1254.	3.3	80
304	How might cannabinoids influence sexual behavior?. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 793-795.	3.3	11
305	Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10819-10824.	3.3	1,206
306	The Potent Emetogenic Effects of the Endocannabinoid, 2-AG (2-Arachidonoylglycerol) Are Blocked by Î”9-Tetrahydrocannabinol and Other Cannnabinoids. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 34-42.	1.3	76
307	Effect of Chronic Administration ofR-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Î”9-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 36-44.	1.3	121
308	Mechanisms of inhibition of LHRH release by alcohol and cannabinoids. Progress in Brain Research, 2002, 141, 175-181.	0.9	7

#	Article	IF	Citations
309	Pain and cannabinoids: science and evidence. Pain Reviews, 2002, 9, 41-67.	0.0	15
310	Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. European Journal of Endocrinology, 2002, 147, 255-261.	1.9	46
311	CB1 Receptors in the Preoptic Anterior Hypothalamus Regulate WIN 55212-2		

#	Article	IF	Citations
330	Endocannabinoids in cognition and dependence. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 269-285.	1.0	125
331	Endocannabinoids in the central nervous system-an overview. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 221-233.	1.0	161
332	Endocannabinoids in pain modulation. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 235-242.	1.0	75
333	Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 243-256.	1.0	165
335	Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. Nuclear Medicine and Biology, 2002, 29, 671-677.	0.3	27
336	Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Molecular Brain Research, 2002, 100, 85-93.	2.5	78
337	Topical cannabinoid agonist, WIN55,212-2, reduces cornea-evoked trigeminal brainstem activity in the rat. Pain, 2002, 99, 547-556.	2.0	33
338	Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience, 2002, 110, 755-764.	1.1	107
339	Neonatal anandamide treatment results in prolonged mitochondrial damage in the vanilloid receptor type 1-immunoreactive B-type neurons of the rat trigeminal ganglion. Neuroscience, 2002, 115, 805-814.	1.1	26
340	Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels. Drug and Alcohol Dependence, 2002, 66, 77-84.	1.6	127
341	Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 91-96.	2.5	7
342	SR 141716A prevents Î”9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 321-325.	2.5	97
343	Endocannabinoids and cannabinoid receptor genetics. Progress in Neurobiology, 2002, 66, 307-344.	2.8	112
344	The CB1 receptor antagonist SR141716 enhances stimulus-induced activation of the primary somatosensory cortex of the rat. Neuroscience Letters, 2002, 335, 95-98.	1.0	14
345	Endocannabinoid Signaling in the Brain. Science, 2002, 296, 678-682.	6.0	1,124
346	Short-Term Retrograde Inhibition of GABAergic Synaptic Currents in Rat Purkinje Cells Is Mediated by Endogenous Cannabinoids. Journal of Neuroscience, 2002, 22, 200-208.	1.7	186
347	The Cannabinoid CB1 Receptor Mediates Retrograde Signals for Depolarization-Induced Suppression of Inhibition in Cerebellar Purkinje Cells. Journal of Neuroscience, 2002, 22, 1690-1697.	1.7	159
348	Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling. Scientific World Journal, The, 2002, 2, 1922-1936.	0.8	11

#	Article	IF	Citations
349	Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling. Journal of Neuroscience, 2002, 22, 9742-9753.	1.7	390
350	Cannabinoids on the Brain. Scientific World Journal, The, 2002, 2, 632-648.	0.8	21
351	Presynaptic Cannabinoid Sensitivity Is a Major Determinant of Depolarization-Induced Retrograde Suppression at Hippocampal Synapses. Journal of Neuroscience, 2002, 22, 3864-3872.	1.7	269
352	Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission. Journal of Neuroscience, 2002, 22, 6900-6907.	1.7	303
353	A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding. Journal of Neuroscience, 2002, 22, 9612-9617.	1.7	492
354	Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. European Journal of Pharmacology, 2002, 443, 43-46.	1.7	73
355	Involvement of 5-hydroxytryptamine neuronal system in Î”9-tetrahydrocannabinol-induced impairment of spatial memory. European Journal of Pharmacology, 2002, 445, 221-229.	1.7	76
356	Reversal of Î”9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacology Biochemistry and Behavior, 2002, 71, 333-340.	1.3	161
357	Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats. Pharmacology Biochemistry and Behavior, 2002, 73, 835-842.	1.3	31
358	Cannabinoid analgesia. , 2002, 95, 127-135.		172
359	The endogenous cannabinoid system and the basal ganglia. , 2002, 95, 137-152.		126
360	Cannabinoids and multiple sclerosis. , 2002, 95, 165-174.		174
361	Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntingtonâ€™s disease. Brain Research, 2002, 929, 236-242.	1.1	107
362	Î”9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Research, 2002, 948, 155-158.	1.1	201
363	Intracerebral microinjections of Î”9-tetrahydrocannabinol: search for the impairment of spatial memory in the eight-arm radial maze in rats. Brain Research, 2002, 952, 239-245.	1.1	83
364	Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research, 2002, 954, 73-81.	1.1	253
365	Immunization with a cannabinoid receptor type 1 peptide results in experimental allergic meningocerebellitis in the Lewis rat: A model for cell-mediated autoimmune neuropathology. Journal of Neuroscience Research, 2002, 70, 150-160.	1.3	2
366	Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders, 2002, 17, 1180-1187.	2.2	156

#	Article	IF	Citations
367	Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology, 2002, 159, 379-387.	1.5	444
368	Metabolic mapping of the time-dependent effects of Î” 9 -tetrahydrocannabinol administration in the rat. Psychopharmacology, 2002, 161, 129-136.	1.5	48
369	Involvement of the opioid system in the anxiolytic-like effects induced by Î”9-tetrahydrocannabinol. Psychopharmacology, 2002, 163, 111-117.	1.5	205
370	Characterization of CB1 Receptors on Rat Neuronal Cell Cultures: Binding and Functional Studies Using the Selective Receptor Antagonist SR 141716A. Journal of Neurochemistry, 1997, 68, 402-409.	2.1	28
371	Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse, 2002, 44, 23-35.	0.6	114
372	Dose-dependent effects of ?9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse, 2002, 45, 134-142.	0.6	47
373	CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Molecular Psychiatry, 2002, 7, 515-518.	4.1	208
375	Never fear, cannabinoids are here. Nature, 2002, 418, 488-489.	13.7	12
376	Core values. Nature, 2002, 418, 489-491.	13.7	6
377	Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 2002, 136, 550-557.	2.7	674
378	Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chemistry and Physics of Lipids, 2002, 121, 191-200.	1.5	96
379	Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chemistry and Physics of Lipids, 2002, 121, 73-82.	1.5	122
380	A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chemistry and Physics of Lipids, 2002, 121, 149-158.	1.5	285
381	Endocannabinoids and related fatty acid derivatives in pain modulation. Chemistry and Physics of Lipids, 2002, 121, 159-172.	1.5	105
382	Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chemistry and Physics of Lipids, 2002, 121, 173-190.	1.5	150
383	Relationships between CB1 Cannabinoid Receptors and Pituitary Endocrine Cells in Xenopus laevis: An Immunohistochemical Study. General and Comparative Endocrinology, 2002, 125, 17-24.	0.8	23
384	Exposure to cannabinoids in the development of endogenous cannabinoid system. Neurotoxicity Research, 2002, 4, 363-372.	1.3	16
385	Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntingtonâ€™s disease. Neurotoxicity Research, 2002, 4, 601-608.	1.3	32

#	Article	IF	Citations
386	Acute Neuronal Injury, Excitotoxicity, and the Endocannabinoid System. Molecular Neurobiology, 2002, 26, 317-346.	1.9	127
387	Cannabis and the brain. Brain, 2003, 126, 1252-1270.	3.7	666
388	The cannabinoid receptor antagonist SRï¿½141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology, 2003, 168, 314-323.	1.5	40
389	Expression of cannabinoid CB 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. Journal of Neural Transmission, 2003, 110, 1279-1288.	1.4	105
390	SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. European Journal of Pharmacology, 2003, 477, 213-217.	1.7	91
391	The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology, 2003, 480, 133-150.	1.7	249
392	Cannabinoid-induced Fos expression within A10 dopaminergic neurons. Brain Research, 2003, 963, 15-25.	1.1	63
393	Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study. Brain Research, 2003, 962, 169-179.	1.1	19
394	Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. European Journal of Pharmacology, 2003, 459, 97-105.	1.7	72
395	Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes. European Journal of Pharmacology, 2003, 469, 47-55.	1.7	31
396	Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. European Journal of Pharmacology, 2003, 472, 1-21.	1.7	52
397	Perinatal exposure to Î”9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats. Pharmacology Biochemistry and Behavior, 2003, 75, 565-575.	1.3	31
398	Effects of the synthetic cannabinoid nabilone on spatial learning and hippocampal neurotransmission. Pharmacology Biochemistry and Behavior, 2003, 75, 585-591.	1.3	17
399	Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Movement Disorders, 2003, 18, 138-149.	2.2	75
400	Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. Journal of Neurochemistry, 2003, 85, 1018-1025.	2.1	145
401	Cellular mechanisms of Î”9-tetrahydrocannabinol behavioural sensitization. European Journal of Neuroscience, 2003, 17, 325-330.	1.2	29
402	â€˜One-trial sensitizationâ€™ to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. European Journal of Neuroscience, 2003, 17, 1279-1286.	1.2	78
403	Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. European Journal of Neuroscience, 2003, 17, 1747-1754.	1.2	184

#	Article	IF	Citations
404	Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. European Journal of Neuroscience, 2003, 18, 2197-2202.	1.2	41
405	Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats. British Journal of Pharmacology, 2003, 140, 384-394.	2.7	62
406	Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nature Neuroscience, 2003, 6, 1048-1057.	7.1	210
407	Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 2003, 3, 745-755.	12.8	616
408	How safe is cannabis?. Side Effects of Drugs Annual, 2003, 26, xxxiii-xlviii.	0.6	2
409	Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. European Neuropsychopharmacology, 2003, 13, 401-410.	0.3	53
410	Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology, 2003, 45, 594-604.	2.0	128
411	Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain, 2003, 102, 211-216.	2.0	141
412	Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain, 2003, 105, 275-283.	2.0	164
413	A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 2003, 117, 659-670.	1.1	96
414	Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience, 2003, 118, 681-694.	1.1	132
415	Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience, 2003, 119, 309-318.	1.1	167
416	Comparative analysis of fatty acid amide hydrolase and cb1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience, 2003, 119, 481-496.	1.1	315
417	Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience, 2003, 119, 803-812.	1.1	155
418	Modulation of electrically evoked acetylcholine release through cannabinoid cb1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience, 2003, 120, 455-465.	1.1	39
419	n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 69, 51-59.	1.0	130
420	CB cannabinoid receptor agonists: pain relief without psychoactive effects?. Current Opinion in Pharmacology, 2003, 3, 62-67.	1.7	193
421	Therapeutic Potential of Cannabinoids in CNS Disease. CNS Drugs, 2003, 17, 179-202.	2.7	211

#	Article	IF	Citations
422	Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10529-10533.	3.3	457
423	Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. Journal of the International Neuropsychological Society, 2003, 9, 679-689.	1.2	349
424	Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor. Journal of Biological Chemistry, 2003, 278, 23731-23737.	1.6	159
425	Biphasic modulation of voltage-dependent currents of retinal cones by cannabinoid CB1 receptor agonist WIN 55212-2. Visual Neuroscience, 2003, 20, 177-188.	0.5	70
426	The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in Rats. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 93-102.	1.3	157
427	Role of Endogenous Cannabinoids in Synaptic Signaling. Physiological Reviews, 2003, 83, 1017-1066.	13.1	1,399
428	Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behavioural Pharmacology, 2003, 14, 573-582.	0.8	176
429	Regulation of Cannabinoid CB1 Receptors in the Central Nervous System by Chronic Cannabinoids. Critical Reviews in Neurobiology, 2003, 15, 91-119.	3.3	225
430	Capsaicin Infused Into the PAG Affects Rat Tail Flick Responses to Noxious Heat and Alters Neuronal Firing in the RVM. Journal of Neurophysiology, 2003, 90, 2702-2710.	0.9	108
431	Cannabinoid CB₂Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains. Journal of Neuroscience, 2003, 23, 11136-11141.	1.7	547
432	Functional Tolerance and Blockade of Long-Term Depression at Synapses in the Nucleus Accumbens after Chronic Cannabinoid Exposure. Journal of Neuroscience, 2003, 23, 4815-4820.	1.7	183
433	Cannabinoid â€˜modelâ€™ psychosis, dopamineâ€“cannabinoid interactions and implications for schizophrenia. , 2004, , 142-165.		19
434	Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies. Current Neuropharmacology, 2004, 2, 75-89.	1.4	18
435	Cannabinoid Receptor G Protein-Coupling and Inverse Agonism. Current Neuropharmacology, 2004, 2, 31-36.	1.4	2
436	How cannabis works in the brain. , 2004, , 19-40.		5
437	Evidence for an Interaction between CB1 Cannabinoid and Melanocortin MCR-4 Receptors in Regulating Food Intake. Endocrinology, 2004, 145, 3224-3231.	1.4	102
438	Involvement of the Endocannabinoid System in Motor Disorders. Current Medicinal Chemistry - Central Nervous System Agents, 2004, 4, 175-182.	0.6	1
439	The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology, 2004, 29, 1558-1572.	2.8	895

#	Article	IF	Citations
440	Functional Organization of Dorsal Horn Interneurons. , 2004, , 271-560.		4
441	Membrane Phospholipids and Cytokine Interaction in Schizophrenia. International Review of Neurobiology, 2004, 59, 297-326.	0.9	49
442	Long-Term Administration of Î”9-Tetrahydrocannabinol Desensitizes CB1-, Adenosine A1-, and GABAB-Mediated Inhibition of Adenylyl Cyclase in Mouse Cerebellum. Molecular Pharmacology, 2004, 66, 1275-1284.	1.0	32
443	Differential Effects of Î”9-Tetrahydrocannabinol and Methanandamide in CB1 Knockout and Wild-Type Mice. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 86-91.	1.3	49
444	DIFFERENCES IN BASAL CANNABINOID CB1 RECEPTOR FUNCTION IN SELECTIVE BRAIN AREAS AND VULNERABILITY TO VOLUNTARY ALCOHOL CONSUMPTION IN FAWN HOODED AND WISTAR RATS. Alcohol and Alcoholism, 2004, 39, 297-302.	0.9	46
445	Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. European Journal of Neuroscience, 2004, 20, 2203-2213.	1.2	74
446	Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. European Journal of Neuroscience, 2004, 20, 2737-2748.	1.2	106
447	Î²-Endorphin elevations in the ventral tegmental area regulate the discriminative effects of Î”-9-tetrahydrocannabinol. European Journal of Neuroscience, 2004, 19, 3183-3192.	1.2	78
448	Human cannabinoid receptor 1: 5â€² exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Molecular Psychiatry, 2004, 9, 916-931.	4.1	239
449	Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats. British Journal of Pharmacology, 2004, 142, 943-952.	2.7	55
450	Marijuana and cannabinoid regulation of brain reward circuits. British Journal of Pharmacology, 2004, 143, 227-234.	2.7	227
451	Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. British Journal of Pharmacology, 2004, 143, 455-464.	2.7	73
452	Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. European Journal of Neuroscience, 2004, 20, 848-852.	1.2	76
453	Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo. European Journal of Neuroscience, 2004, 20, 859-863.	1.2	50
454	Mechanisms underlying cannabinoid inhibition of presynaptic Ca2+influx at parallel fibre synapses of the rat cerebellum. Journal of Physiology, 2004, 557, 159-174.	1.3	50
455	Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice. Pharmacology Biochemistry and Behavior, 2004, 77, 117-125.	1.3	42
456	Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacology Biochemistry and Behavior, 2004, 77, 567-573.	1.3	86
457	Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. European Journal of Pharmacology, 2004, 488, 201-212.	1.7	83

#	Article	IF	Citations
458	Enhancement of anxiety-like responsiveness to the cannabinoid CB1 receptor agonist HU-210 following chronic stress. European Journal of Pharmacology, 2004, 499, 291-295.	1.7	92
459	Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. European Journal of Pharmacology, 2004, 500, 37-49.	1.7	71
460	Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Research, 2004, 1007, 152-159.	1.1	91
461	The dopamine receptor antagonist SCH 23390 attenuates feeding induced by Î”9-tetrahydrocannabinol. Brain Research, 2004, 1020, 188-195.	1.1	48
462	Immunohistochemical characterisation and localisation of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and the effects of unilateral vestibular deafferentation. Brain Research, 2004, 1021, 264-271.	1.1	28
463	Inhibition by Anandamide and Synthetic Cannabimimetics of the Release of [3H]d-Aspartate and [3H]GABA from Synaptosomes Isolated from the Rat Hippocampus. Neurochemical Research, 2004, 29, 1553-1561.	1.6	20
464	Gene-environment interplay in affect and dementia: Emotional modulation of cognitive expression in personal outcomes. Neurotoxicity Research, 2004, 6, 159-173.	1.3	17
465	Role of endocannabinoid system in mental diseases. Neurotoxicity Research, 2004, 6, 213-224.	1.3	44
466	Cannabinoids and gene expression during brain development. Neurotoxicity Research, 2004, 6, 389-401.	1.3	101
467	Pharmacological and therapeutic targets for ?9 tetrahydrocannabinol and cannabidiol. Euphytica, 2004, 140, 73-82.	0.6	53
468	Differential effects of acute cannabinoid drug treatment, mediated by CB 1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 516-524.	1.4	62
469	Anandamide inhibits the DOI-induced head-twitch response in mice. Psychopharmacology, 2004, 171, 382-389.	1.5	24
470	The opioid antagonist naltrexone reduces the reinforcing effects of ? 9 -tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology, 2004, 173, 186-194.	1.5	100
471	Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology, 2004, 177, 141-150.	1.5	45
472	Vanilloid receptor like 1 (VRL1) immunoreactivity in mammalian retina: Colocalization with somatostatin and purinergic P2X1 receptors. Journal of Comparative Neurology, 2004, 474, 407-418.	0.9	34
473	Cannabis-Associated Psychosis. CNS Drugs, 2004, 18, 895-910.	2.7	53
474	Endocannabinoids and exercise. British Journal of Sports Medicine, 2004, 38, 536-541.	3.1	301
475	Endocannabinoid Receptor Antagonists. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 345-360.	1.8	32

#	Article	IF	Citations
476	Basal Ganglia. , 2004, , 455-508.		83
478	Local application of the cannabinoid receptor agonist, WIN 55,212â€“2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons. Pain, 2004, 107, 267-275.	2.0	24
479	Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology, 2004, 46, 115-125.	2.0	114
480	Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology, 2004, 47, 81-91.	2.0	45
481	The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology, 2004, 47, 390-400.	2.0	96
482	Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology, 2004, 47, 593-603.	2.0	58
483	Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology, 2004, 47, 345-358.	2.0	531
484	Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology, 2004, 47, 1157-1169.	2.0	42
485	Compartment-specific localization of cannabinoid 1 (CB1) and Î¼-opioid receptors in rat nucleus accumbens. Neuroscience, 2004, 127, 101-112.	1.1	224
486	Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortexâ€”involvement of Na+/K+-ATPase. Neurochemistry International, 2004, 44, 529-538.	1.9	70
487	Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection. Neuroscience Letters, 2004, 359, 17-20.	1.0	40
488	Cannabinoids enhance N-methyl-d-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. Neuroscience Letters, 2004, 363, 1-5.	1.0	38
489	Synergistic interactions between cannabinoid and opioid analgesics. Life Sciences, 2004, 74, 1317-1324.	2.0	247
490	The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sciences, 2004, 75, 2959-2970.	2.0	115
491	Modulation of extracellular signal-regulated kinases cascade by chronic Î”9-tetrahydrocannabinol treatment. Molecular and Cellular Neurosciences, 2004, 25, 355-362.	1.0	73
492	New Perspectives in the Studies on Endocannabinoid and Cannabis: Abnormal Behaviors Associate With CB1 Cannabinoid Receptor and Development of Therapeutic Application. Journal of Pharmacological Sciences, 2004, 96, 362-366.	1.1	74
493	Experimental Methods to Study the Role of the Peripheral Cannabinoid Receptor in Immune Function. , 2006, 123, 19-40.		5
494	Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behavioural Pharmacology, 2005, 16, 333-352.	0.8	169

#	Article	IF	Citations
495	The role of the endocannabinoid system in the regulation of energy homeostasis. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 338-351.	0.6	31
496	Endocannabinoids in the regulation of appetite and body weight. Behavioural Pharmacology, 2005, 16, 297-313.	0.8	183
497	Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na??ve and plus-maze-experienced mice. Behavioural Pharmacology, 2005, 16, 405-413.	0.8	79
498	Long-term behavioural and neuroendocrine effects of perinatal activation or blockade of CB1 cannabinoid receptors. Behavioural Pharmacology, 2005, 16, 423-430.	0.8	17
499	Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats. Behavioural Pharmacology, 2005, 16, 441-446.	0.8	15
500	Cannabinoids and Dopamine Receptors' Action on Calcium Current in Rat Neurons. Canadian Journal of Neurological Sciences, 2005, 32, 529-537.	0.3	2
501	Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behavioural Pharmacology, 2005, 16, 275-296.	0.8	44
502	Endocannabinoids and Dopamine-Related Functions in the CNS. , 2005, , .		0
503	Behavioral Effects of Endocannabinoids. , 2005, , .		0
504	The Relationship between Endocannabinoid Conformation and Endocannabinoid Interaction at the Cannabinoid Receptors. , 2005, , .		0
505	Endocannabinoids and Endocrine Function. , 2005, , .		1
506	Endocannabinoid Receptor Genetics and Marijuana Use. , 2005, , .		1
507	Man-Made Marijuana. , 2005, , .		1
508	Endocannabinoids and Gastrointestinal Function. , 2005, , .		1
509	Cannabinoid Receptors and Their Role in Neuroprotection. NeuroMolecular Medicine, 2005, 7, 037-050.	1.8	169
510	Regional distribution and age-dependent expression of N-acylphosphatidylethanolamine-hydrolyzing phospholipase D in rat brain. Journal of Neurochemistry, 2005, 94, 753-762.	2.1	66
511	GABABand CB1cannabinoid receptor expression identifies two types of septal cholinergic neurons. European Journal of Neuroscience, 2005, 21, 3034-3042.	1.2	49
512	Î¹- and Î˜-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1receptor knockout mice. European Journal of Neuroscience, 2005, 22, 2106-2110.	1.2	23

#	Article	IF	Citations
513	Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. Chemical Biology and Drug Design, 2005, 66, 138-150.	1.2	26
514	Cannabinoids Modulate Synaptic Activity in the Rat Supraoptic Nucleus. Journal of Neuroendocrinology, 2005, 17, 609-615.	1.2	15
515	Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. British Journal of Pharmacology, 2005, 145, 636-645.	2.7	42
516	An endocannabinoid mechanism for stress-induced analgesia. Nature, 2005, 435, 1108-1112.	13.7	655
517	AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. European Journal of Pharmacology, 2005, 508, 139-146.	1.7	33
518	Developmental expression of cannabinoid receptors in the chick retinotectal system. Developmental Brain Research, 2005, 156, 176-182.	2.1	22
519	Chronic Î”9-tetrahydrocannabinol treatment produces antinociceptive tolerance in mice without altering Protein Kinase A activity in mouse brain and spinal cord. Biochemical Pharmacology, 2005, 70, 152-160.	2.0	2
520	Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Research, 2005, 1046, 195-206.	1.1	33
521	Central glucocorticoid receptors modulate the expression of spinal cannabinoid receptors induced by chronic morphine exposure. Brain Research, 2005, 1059, 20-27.	1.1	20
522	Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacology Biochemistry and Behavior, 2005, 81, 360-368.	1.3	146
523	Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior, 2005, 81, 331-342.	1.3	405
524	Functional neuroanatomy of the endocannabinoid system. Pharmacology Biochemistry and Behavior, 2005, 81, 239-247.	1.3	96
525	Endocannabinoid system and opioid addiction: Behavioural aspects. Pharmacology Biochemistry and Behavior, 2005, 81, 343-359.	1.3	97
526	Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacology Biochemistry and Behavior, 2005, 81, 263-284.	1.3	350
527	Acute Î”-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion. Pharmacology Biochemistry and Behavior, 2005, 81, 71-77.	1.3	14
528	Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?. Journal of Neuroimmunology, 2005, 166, 3-18.	1.1	221
529	Subchronic haloperidol increases CB1 receptor binding and G protein coupling in discrete regions of the basal ganglia. Journal of Neuroscience Research, 2005, 82, 264-272.	1.3	20
530	Clozapine decreases [3H] CP 55940 binding to the cannabinoid1 receptor in the rat nucleus accumbens. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 371, 428-433.	1.4	41

#	Article	IF	Citations
531	Disruption of CB1 receptor signaling impairs extinction of spatial memory in mice. Psychopharmacology, 2005, 179, 863-872.	1.5	114
532	Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology, 2005, 182, 527-536.	1.5	58
533	Î”9-THC administered into the medial prefrontal cortex disrupts the spatial working memory. Psychopharmacology, 2005, 183, 54-64.	1.5	26
534	Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo. Psychopharmacology, 2005, 183, 368-377.	1.5	71
535	Preclinical Science Regarding Cannabinoids as Analgesics: An Overview. Pain Research and Management, 2005, 10, 7A-14A.	0.7	17
536	Cannabinoid suppressed bicuculline-induced convulsion without respiratory depression in the brainstem-spinal cord preparation from newborn rats. Biomedical Research, 2005, 26, 241-247.	0.3	12
537	Regulation of Gonadotropin-Releasing Hormone Secretion by Cannabinoids. Endocrinology, 2005, 146, 4491-4499.	1.4	94
538	ETHANOL INDUCES HIGHER BEC IN CB1 CANNABINOID RECEPTOR KNOCKOUT MICE WHILE DECREASING ETHANOL PREFERENCE. Alcohol and Alcoholism, 2005, 40, 54-62.	0.9	38
539	Role of Endogenous Cannabinoids in Cognition and Emotionality. Mini-Reviews in Medicinal Chemistry, 2005, 5, 659-670.	1.1	75
540	Cannabinoid Agonists but not Inhibitors of Endogenous Cannabinoid Transport or Metabolism Enhance the Reinforcing Efficacy of Heroin in Rats. Neuropsychopharmacology, 2005, 30, 2046-2057.	2.8	92
541	ROLE OF THE ENDOCANNABINOID SYSTEM IN THE DEVELOPMENT OF TOLERANCE TO ALCOHOL. Alcohol and Alcoholism, 2005, 40, 15-24.	0.9	55
542	Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration. Neuropsychopharmacology, 2005, 30, 1670-1680.	2.8	197
543	Acute Î”9-Tetrahydrocannabinol-Induced Deficits in Reversal Learning: Neural Correlates of Affective Inflexibility. Neuropsychopharmacology, 2005, 30, 1895-1905.	2.8	49
544	Cannabis consumption and risk of developing schizophrenia: myth or reality?. Epidemiology and Psychiatric Sciences, 2005, 14, 184-187.	1.8	11
545	A role for endocannabinoids in the generation of parkinsonism and levodopaâ€induced dyskinesia in MPTPâ€lesioned nonâ€human primate models of Parkinson's disease. FASEB Journal, 2005, 19, 1140-1142.	0.2	189
546	Motivational Effects of Cannabinoids and Opioids on Food Reinforcement Depend on Simultaneous Activation of Cannabinoid and Opioid Systems. Neuropsychopharmacology, 2005, 30, 2035-2045.	2.8	158
547	Endocannabinoids in the intact retina:³H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide. Visual Neuroscience, 2005, 22, 693-705.	0.5	28
548	Endocannabinoid Signaling in Rat Somatosensory Cortex: Laminar Differences and Involvement of Specific Interneuron Types. Journal of Neuroscience, 2005, 25, 6845-6856.	1.7	297

#	Article	IF	Citations
549	Differential Regulation of Synaptic Inputs by Constitutively Released Endocannabinoids and Exogenous Cannabinoids. Journal of Neuroscience, 2005, 25, 9746-9751.	1.7	132
550	Downregulation of Endocannabinoid Signaling in the Hippocampus Following Chronic Unpredictable Stress. Neuropsychopharmacology, 2005, 30, 508-515.	2.8	313
551	Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis. Journal of Neuroscience, 2005, 25, 2874-2884.	1.7	221
552	The endocannabinoid system and the treatment of obesity. Annals of Medicine, 2005, 37, 270-275.	1.5	84
554	Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opinion on Investigational Drugs, 2005, 14, 695-703.	1.9	58
555	THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. Alcohol and Alcoholism, 2005, 40, 2-14.	0.9	305
556	Synthesis and Structureâ˜Activity Relationship of a Novel Series of Aminoalkylindoles with Potential for Imaging the Neuronal Cannabinoid Receptor by Positron Emission Tomography. Journal of Medicinal Chemistry, 2005, 48, 5813-5822.	2.9	38
557	Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiology of Disease, 2005, 19, 96-107.	2.1	339
558	The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neuroscience Letters, 2005, 380, 270-275.	1.0	106
559	Evaluation of the effect of age on cannabinoid receptor functionality and expression in guinea-pig ileum longitudinal muscleâ€“myenteric plexus preparations. Neuroscience Letters, 2005, 383, 176-181.	1.0	14
560	Lipids, lipid rafts and caveolae: Their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sciences, 2005, 77, 1625-1639.	2.0	100
561	Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders. Life Sciences, 2005, 77, 1569-1583.	2.0	33
562	Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Molecular and Cellular Neurosciences, 2005, 28, 189-194.	1.0	67
563	A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy. Pain, 2005, 118, 3-5.	2.0	9
564	Central control of penile erection: Role of the paraventricular nucleus of the hypothalamus. Progress in Neurobiology, 2005, 76, 1-21.	2.8	202
565	Endocannabinoids Control the Induction of Cerebellar LTD. Neuron, 2005, 48, 647-659.	3.8	240
566	Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology, 2005, 48, 1105-1116.	2.0	216
567	Paraventricular hypothalamic CB1 cannabinoid receptors are involved in the feeding stimulatory effects of Î”9-tetrahydrocannabinol. Neuropharmacology, 2005, 49, 1101-1109.	2.0	73

#	Article	IF	Citations
568	Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology, 2005, 49, 646-652.	2.0	95
569	Repeated exposure to Î”9-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity. Neuropharmacology, 2005, 49, 1189-1200.	2.0	34
570	Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus. Neuroscience, 2005, 133, 305-313.	1.1	23
571	Amnestic effect of intrahippocampal AM251, a CB1-selective blocker, in the inhibitory avoidance, but not in the open field habituation task, in rats. Neurobiology of Learning and Memory, 2005, 83, 119-124.	1.0	95
572	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry, 2005, 57, 594-608.	0.7	524
573	Cannabinoids in neurodegeneration and neuroprotection. , 2005, , 79-109.		32
574	Effects on Development. Handbook of Experimental Pharmacology, 2005, , 643-656.	0.9	12
575	Cannabinoid Receptor Signaling. , 2005, , 53-79.		361
576	Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System. , 2005, , 299-325.		527
577	Cannabinoid Mechanisms of Pain Suppression. , 2005, , 509-554.		141
578	Cannabinoid Control of Motor Function at the Basal Ganglia. , 2005, , 479-507.		58
583	Neuromodulators: Sections 4.1â€“ 4.18. , 0, , 143-254.		0
584	Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. FASEB Journal, 2006, 20, 1003-1005.	0.2	142
585	Cannabinoids. , 2006, , 289-337.		1
586	Endocannabinoid mechanisms of pain modulation. AAPS Journal, 2006, 8, E693-E708.	2.2	186
587	Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1072-1078.	1.3	115
588	Cannabinoid Analgesia as a Potential New Therapeutic Option in the Treatment of Chronic Pain. Annals of Pharmacotherapy, 2006, 40, 251-260.	0.9	74
589	Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS Journal, 2006, 8, E112-E117.	2.2	52

#	Article	IF	Citations
590	Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against â€˜morning sicknessâ€™. Complementary Therapies in Clinical Practice, 2006, 12, 27-33.	0.7	116
591	Endocannabinoids and their receptors as targets for treating metabolic and psychiatric disorders. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 561-567.	0.5	1
592	3D-QSAR Studies of Arylpyrazole Antagonists of Cannabinoid Receptor Subtypes CB1 and CB2. A Combined NMR and CoMFA Approach. Journal of Medicinal Chemistry, 2006, 49, 625-636.	2.9	59
593	The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats. Behavioural Brain Research, 2006, 169, 274-281.	1.2	41
594	The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 2006, 58, 389-462.	7.1	2,274
595	Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochemistry International, 2006, 49, 619-625.	1.9	94
596	Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neuroscience Letters, 2006, 397, 180-184.	1.0	69
597	Morphine reduces penile erection induced by the cannabinoid receptor antagonist SR 141617A in male rats: Role of paraventricular glutamic acid and nitric oxide. Neuroscience Letters, 2006, 404, 1-5.	1.0	18
598	Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. Neuroscience Letters, 2006, 408, 236-241.	1.0	38
599	Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1466-1471.	2.5	168
600	The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: Involvement of paraventricular glutamic acid and nitric oxide. Neuropharmacology, 2006, 50, 219-228.	2.0	39
601	Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology, 2006, 50, 372-379.	2.0	69
602	Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. Neuropharmacology, 2006, 50, 788-806.	2.0	39
603	Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience, 2006, 137, 337-361.	1.1	161
604	Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience, 2006, 139, 1405-1415.	1.1	434
605	The cannabinoid receptor agonist, WIN 55,212-2, inhibits cool-specific lamina I medullary dorsal horn neurons. Neuroscience, 2006, 143, 265-272.	1.1	4
606	Endocannabinoids in Appetite Control and the Treatment of Obesity. CNS and Neurological Disorders - Drug Targets, 2006, 5, 275-292.	0.8	55
607	Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. International Journal of Neuropsychopharmacology, 2006, 9, 277.	1.0	79

#	Article	IF	Citations
608	Cannabinoids Biology: The Search for New Therapeutic Targets. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 149-161.	3.4	42
609	Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. European Journal of Neuroscience, 2006, 23, 2385-2394.	1.2	109
610	Retrograde suppression of GABAergic currents in a subset of SCN neurons. European Journal of Neuroscience, 2006, 23, 3209-3216.	1.2	7
611	The Pharmacology of SR 141716A: A Review. CNS Neuroscience & Therapeutics, 1999, 5, 43-58.	4.0	17
612	HU 210: A Potent Tool for Investigations of the Cannabinoid System. CNS Neuroscience & Therapeutics, 2001, 7, 131-145.	4.0	45
613	AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. British Journal of Pharmacology, 2006, 147, 109-116.	2.7	58
614	Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. Journal of Physiology, 2006, 575, 789-806.	1.3	55
615	The Endocannabinoid System as a Target for the Treatment of Visceral Obesity and Metabolic Syndrome. Annals of the New York Academy of Sciences, 2006, 1083, 270-305.	1.8	29
616	Retrograde endocannabinoid signaling in the cerebellar cortex. Cerebellum, 2006, 5, 134-145.	1.4	65
617	Short-term ischemia usually used for ischemic preconditioning down-regulates central cannabinoid receptors in the gerbil hippocampus. Acta Neuropathologica, 2006, 111, 8-14.	3.9	19
618	Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathologica, 2006, 112, 277-286.	3.9	37
619	Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists. Psychopharmacology, 2006, 187, 245-259.	1.5	44
620	Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Psychopharmacology, 2006, 189, 59-69.	1.5	28
621	Cannabinoids and prefrontal cortical function: Insights from preclinical studies. Neuroscience and Biobehavioral Reviews, 2006, 30, 680-695.	2.9	139
622	Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genetics and Cytogenetics, 2006, 171, 31-38.	1.0	154
623	Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. European Journal of Pharmacology, 2006, 534, 83-88.	1.7	50
624	Involvement of 5-hydroxytryptamine1A receptors in Î”9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. European Journal of Pharmacology, 2006, 550, 117-122.	1.7	25
625	AM251, a selective antagonist of the CB1 receptor, inhibits the induction of long-term potentiation and induces retrograde amnesia in rats. Brain Research, 2006, 1075, 60-67.	1.1	74

#	Article	IF	Citations
626	Cannabinoid system in the budgerigar brain. Brain Research, 2006, 1087, 105-113.	1.1	14
627	Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Research, 2006, 1107, 199-205.	1.1	34
628	Despite strong behavioral disruption, Î”9-tetrahydrocannabinol does not affect cell proliferation in the adult mouse dentate gyrus. Brain Research, 2006, 1113, 86-93.	1.1	33
629	Cannabinoids, opioids and eating behavior: The molecular face of hedonism?. Brain Research Reviews, 2006, 51, 85-107.	9.1	288
631	Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure. Psychoneuroendocrinology, 2006, 31, 526-536.	1.3	39
632	Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. Journal of Comparative Neurology, 2006, 495, 299-313.	0.9	122
633	Developmental pattern of CB1 cannabinoid receptor immunoreactivity in brain regions important to zebra finch (Taeniopygia guttata) song learning and control. Journal of Comparative Neurology, 2006, 496, 739-758.	0.9	26
634	Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert Opinion on Therapeutic Targets, 2006, 10, 203-210.	1.5	36
635	Cannabinoid Modulation of Opiate Reinforcement through the Ventral Striatopallidal Pathway. Neuropsychopharmacology, 2006, 31, 804-813.	2.8	114
636	Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. Current Neuropharmacology, 2006, 4, 239-257.	1.4	216
637	Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R349-R358.	0.9	173
638	Immunocytochemical Distribution of the Cannabinoid CB1 Receptor in the Primate Neocortex: A Regional and Laminar Analysis. Cerebral Cortex, 2006, 17, 175-191.	1.6	211
639	The Endocannabinoid System: A New Player in the Neurochemical Control of Vestibular Function?. Audiology and Neuro-Otology, 2006, 11, 207-212.	0.6	8
640	Characterization of Peripheral Human Cannabinoid Receptor (hCB2) Expression and Pharmacology Using a Novel Radioligand, [35S]Sch225336. Journal of Biological Chemistry, 2006, 281, 28143-28151.	1.6	25
641	Effects of Exogenous and Endogenous Cannabinoids on GABAergic Neurotransmission between the Caudate-Putamen and the Globus Pallidus in the Mouse. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 608-617.	1.3	53
642	Two Brain Sites for Cannabinoid Reward. Journal of Neuroscience, 2006, 26, 4901-4907.	1.7	164
643	Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid Administration. Molecular Pharmacology, 2006, 70, 986-996.	1.0	90
644	Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks. Circulation, 2006, 114, 974-984.	1.6	91

#	Article	IF	Citations
645	Cannabinoid agonist WIN 55212-2 speeds up the cone response to light offset in goldfish retina. Visual Neuroscience, 2006, 23, 285-293.	0.5	35
646	Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. International Journal of Obesity, 2006, 30, S19-S23.	1.6	86
647	Metabotropic Glutamate and Cannabinoid Receptor Crosstalk in Periaqueductal Grey Pain Processing. Current Neuropharmacology, 2006, 4, 225-231.	1.4	12
648	Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions. Journal of Psychopharmacology, 2006, 20, 67-74.	2.0	25
649	The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. Endocrine Reviews, 2006, 27, 73-100.	8.9	751
650	New Natural Noncannabinoid Ligands for Cannabinoid Type-2 (CB2) Receptors. Journal of Receptor and Signal Transduction Research, 2006, 26, 709-730.	1.3	37
651	[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9800-9805.	3.3	300
652	Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects. Molecular Pharmacology, 2007, 71, 1445-1456.	1.0	71
653	Nicotinic Facilitation of Î”9-Tetrahydrocannabinol Discrimination Involves Endogenous Anandamide. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1127-1134.	1.3	40
654	Subcellular Arrangement of Molecules for 2-Arachidonoyl-Glycerol-Mediated Retrograde Signaling and Its Physiological Contribution to Synaptic Modulation in the Striatum. Journal of Neuroscience, 2007, 27, 3663-3676.	1.7	340
655	Understanding Cannabinoid Psychoactivity with Mouse Genetic Models. PLoS Biology, 2007, 5, e280.	2.6	17
656	Combination of Rimonabant and Donepezil Prolongs Spatial Memory Duration. Neuropsychopharmacology, 2007, 32, 1805-1812.	2.8	46
657	39th Annual European Brain and Behaviour Society Abstracts. Neural Plasticity, 2007, 2007, 1-136.	1.0	1
658	A possible role for the endocannabinoid system in the neurobiology of depression. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 25.	0.6	43
659	Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function. Endocrinology, 2007, 148, 1574-1581.	1.4	186
660	Cannabinoids Excite Hypothalamic Melanin-Concentrating Hormone But Inhibit Hypocretin/Orexin Neurons: Implications for Cannabinoid Actions on Food Intake and Cognitive Arousal. Journal of Neuroscience, 2007, 27, 4870-4881.	1.7	94
661	Endocannabinoids and Energy Homeostasis. , 2007, , 49-67.		0
662	Canabinoides. , 2007, , 533-551.		0

#	Article	IF	Citations
663	Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity. Current Neuropharmacology, 2007, 5, 81-97.	1.4	98
664	Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?. Current Neuropharmacology, 2007, 5, 268-277.	1.4	41
665	2,5-Dimethoxy-4-iodoamphetamine (DOI) Inhibits Î”9-Tetrahydrocannabinol-Induced Catalepsy-Like Immobilization in Mice. Journal of Pharmacological Sciences, 2007, 105, 361-366.	1.1	12
666	Regulation of brain anandamide by acute administration of ethanol. Biochemical Journal, 2007, 404, 97-104.	1.7	101
668	Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers. Anesthesiology, 2007, 107, 785-796.	1.3	198
669	Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behavioural Pharmacology, 2007, 18, 431-438.	0.8	65
670	Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats. International Journal of Neuropsychopharmacology, 2007, 10, 727-39.	1.0	11
671	WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids. Behavioural Pharmacology, 2007, 18, 515-520.	0.8	15
672	Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. Pain, 2007, 131, 96-105.	2.0	44
673	Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain, 2007, 132, 23-32.	2.0	44
674	CB1 cannabinoid receptors inhibit the glutamatergic component of KCl-evoked excitation of locus coeruleus neurons in rat brain slices. Neuropharmacology, 2007, 52, 617-625.	2.0	31
675	Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology, 2007, 52, 958-965.	2.0	140
676	Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience, 2007, 145, 323-334.	1.1	116
677	Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience, 2007, 146, 1232-1244.	1.1	73
678	Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: Immunocytochemistry, autoradiography and behavioral studies. Neuroscience, 2007, 147, 197-206.	1.1	37
679	The Endocannabinoid System and the Therapeutic Potential of Cannabinoids. , 2007, , 125-143.		2
680	The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neuroscience Letters, 2007, 419, 231-235.	1.0	122
681	Cannabinoid receptor down-regulation in the ventral cochlear nucleus in a salicylate model of tinnitus. Hearing Research, 2007, 228, 105-111.	0.9	44

#	Article	IF	Citations
683	Endocannabinoids in the dentate gyrus. Progress in Brain Research, 2007, 163, 319-815.	0.9	9
685	Functional neurochemistry of the basal ganglia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 19-66.	1.0	12
686	Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacological Research, 2007, 56, 360-366.	3.1	66
687	Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacological Research, 2007, 56, 393-405.	3.1	86
688	Endocannabinoid signaling is critical for habit formation. Frontiers in Integrative Neuroscience, 2007, 1, 6.	1.0	142
689	Analgesic, Anti-inflammatory, and Anti-pyretic Activity. , 2007, , 983-1116.		6
690	Expression and Function of Cannabinoid Receptors CB1 and CB2 and Their Cognate Cannabinoid Ligands in Murine Embryonic Stem Cells. PLoS ONE, 2007, 2, e641.	1.1	68
691	Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses. Neural Plasticity, 2007, 2007, 1-12.	1.0	106
692	Role of the Endocannabinoid System in Management of Patients with Type 2 Diabetes Mellitus and Cardiovascular Risk Factors. Endocrine Practice, 2007, 13, 790-804.	1.1	3
693	From Active Ingredients to the Discovery of the Targets: The Cannabinoid Receptors. Chemistry and Biodiversity, 2007, 4, 1693-1706.	1.0	12
694	Medicinal Chemistry Endeavors around the Phytocannabinoids. Chemistry and Biodiversity, 2007, 4, 1707-1728.	1.0	29
695	CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes/Metabolism Research and Reviews, 2007, 23, 507-517.	1.7	116
696	Localization of CiCBR in the invertebrate chordateCiona intestinalis: Evidence of an ancient role for cannabinoid receptors as axonal regulators of neuronal signalling. Journal of Comparative Neurology, 2007, 502, 660-672.	0.9	13
697	Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: Short-term regulation by intrinsic and extrinsic pathways. Journal of Neuroscience Research, 2007, 85, 656-667.	1.3	26
698	Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology, 2007, 151, 427-440.	2.7	78
699	Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. British Journal of Pharmacology, 2007, 152, 633-648.	2.7	68
700	Alzheimer's disease; taking the edge off with cannabinoids?. British Journal of Pharmacology, 2007, 152, 655-662.	2.7	108
701	CB1 RECEPTOR ACTIVATION IN THE BASOLATERAL AMYGDALA PRODUCES ANTINOCICEPTION IN ANIMAL MODELS OF ACUTE AND TONIC NOCICEPTION. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 439-449.	0.9	40

#	Article	IF	Citations
702	Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. European Journal of Neuroscience, 2007, 25, 2093-2102.	1.2	28
703	Visualization of 2â€arachidonoylglycerol accumulation and cannabinoid CB 1 receptor activity in rat brain cryosections by functional autoradiography. Journal of Neurochemistry, 2007, 101, 972-981.	2.1	30
704	Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. Journal of Neurochemistry, 2007, 102, 1996-2007.	2.1	26
705	Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. Journal of Neurochemistry, 2007, 103, 070611013409001-???.	2.1	38
706	The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. Journal of Neurochemistry, 2007, 103, 2505-2517.	2.1	20
707	Therapeutic Potential of Endocannabinoid-Hydrolysing Enzyme Inhibitors. Basic and Clinical Pharmacology and Toxicology, 2007, 101, 287-293.	1.2	55
708	Acute activation of CB1 cannabinoid receptors transiently decreases PSA-NCAM expression in the dentate gyrus of the rat hippocampus. Brain Research, 2007, 1148, 43-52.	1.1	23
709	A comparison of the apoptotic effect of Î”9-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Research, 2007, 1175, 39-47.	1.1	25
710	The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Î”9-tetrahydrocannabinol in cultured cortical neurons. European Journal of Pharmacology, 2007, 564, 57-65.	1.7	24
711	Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. European Journal of Pharmacology, 2007, 573, 11-19.	1.7	32
712	Early maternal deprivation and neonatal single administration with a cannabinoid agonist induce long-term sex-dependent psychoimmunoendocrine effects in adolescent rats. Psychoneuroendocrinology, 2007, 32, 636-650.	1.3	79
713	The endocannabinoid system and its protective role in ischemic and cytotoxic injuries of brain neurons. Neurochemical Journal, 2007, 1, 93-112.	0.2	1
714	The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. Psychopharmacology, 2007, 191, 223-231.	1.5	96
715	Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures. Psychopharmacology, 2007, 194, 139-149.	1.5	17
716	Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology, 2007, 194, 161-171.	1.5	41
717	Cannabinoids and Neuroprotection in Basal Ganglia Disorders. Molecular Neurobiology, 2007, 36, 82-91.	1.9	79
718	Cannabinoids in Eating Disorders and Obesity. Molecular Neurobiology, 2007, 36, 113-128.	1.9	17
719	Roles of Transient Receptor Potential Vanilloid Subtype 1 and Cannabinoid Type 1 Receptors in the Brain: Neuroprotection versus Neurotoxicity. Molecular Neurobiology, 2007, 35, 245-254.	1.9	37

#	Article	IF	Citations
720	Cannabinoid CB2 Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain. Molecular Neurobiology, 2007, 36, 26-35.	1.9	79
721	Cat odour-induced anxietyâ€"a study of the involvement of the endocannabinoid system. Psychopharmacology, 2008, 198, 509-520.	1.5	18
722	Gene expression of opioid and dopamine systems in mouse striatum: effects of CB1 receptors, age and sex. Psychopharmacology, 2008, 198, 497-508.	1.5	12
723	Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. Psychopharmacology, 2008, 198, 375-385.	1.5	51
724	Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. Psychopharmacology, 2008, 198, 405-411.	1.5	68
725	Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology, 2008, 199, 223-230.	1.5	259
726	An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology, 2008, 200, 333-346.	1.5	52
727	The Cannabinoid Delta-9-tetrahydrocannabinol Mediates Inhibition of Macrophage Chemotaxis to RANTES/CCL5: Linkage to the CB2 Receptor. Journal of NeuroImmune Pharmacology, 2008, 3, 117-129.	2.1	54
728	Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. Journal of Neural Transmission, 2008, 115, 1501-1511.	1.4	50
729	Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. Journal of Neural Transmission, 2008, 115, 1673-1679.	1.4	66
730	Loss of Cannabinoid-Stimulated Guanosine 5â€²-O-(3-[35S]Thiotriphosphate) Binding Without Receptor Down-Regulation in Brain Regions of Anandamide-Tolerant Rats. Journal of Neurochemistry, 2008, 75, 2478-2484.	2.1	37
731	Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons. Journal of Neurochemistry, 2008, 79, 371-381.	2.1	41
732	Inhibition of endocannabinoid metabolism attenuates enhanced hippocampal neuronal activity induced by kainic acid. Synapse, 2008, 62, 746-755.	0.6	35
733	Study of the structureâ€activity relationship for theoretical molecular descriptors using density functional theory and chemometric methods in cannabinoid metabolites. International Journal of Quantum Chemistry, 2008, 108, 2530-2539.	1.0	3
734	Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. Journal of Comparative Neurology, 2008, 509, 400-421.	0.9	122
735	Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Developmental Neurobiology, 2008, 68, 1429-1440.	1.5	38
736	Cannabinoids enhance susceptibility of immature brain to ethanol neurotoxicity. Annals of Neurology, 2008, 64, 42-52.	2.8	73
737	Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neuroscience and Biobehavioral Reviews, 2008, 32, 1152-1160.	2.9	186

#	Article	IF	Citations
738	The rat pineal gland comprises an endocannabinoid system. Journal of Pineal Research, 2008, 45, 351-360.	3.4	18
739	The endocannabinoid system in brain reward processes. British Journal of Pharmacology, 2008, 154, 369-383.	2.7	211
740	Interactions between CB₁ receptors and TRPV1 channels mediated by 12â€HPETE are cytotoxic to mesencephalic dopaminergic neurons. British Journal of Pharmacology, 2008, 155, 253-264.	2.7	26
741	The neurocircuitry of addiction: an overview. British Journal of Pharmacology, 2008, 154, 261-274.	2.7	333
742	CB₂ receptors in the brain: role in central immune function. British Journal of Pharmacology, 2008, 153, 240-251.	2.7	274
743	Alcohol Inhibits Spontaneous Activity of Basolateral Amygdala Projection Neurons in the Rat: Involvement of the Endocannabinoid System. Alcoholism: Clinical and Experimental Research, 2008, 32, 443-449.	1.4	46
744	A role for p53 in the regulation of lysosomal permeability by Î”9-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration. Journal of Neurochemistry, 2008, 105, 1513-1524.	2.1	32
745	Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. Journal of Neurochemistry, 2008, 106, 2322-2336.	2.1	210
746	Blocking cannabinoid CB₁ receptors for the treatment of nicotine dependence: insights from preâ€clinical and clinical studies. Addiction Biology, 2008, 13, 239-252.	1.4	97
747	Cannabinoid Receptors: Where They are and What They do. Journal of Neuroendocrinology, 2008, 20, 10-14.	1.2	468
748	The Role of the Endocannabinoid System in the Regulation of Hypothalamicâ€Pituitaryâ€Adrenal Axis Activity. Journal of Neuroendocrinology, 2008, 20, 35-38.	1.2	68
749	Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors. Brain Research, 2008, 1200, 1-9.	1.1	13
750	Immunohistochemical localization of CB1 cannabinoid receptors in frontal cortex and related limbic areas in obese Zucker rats: Effects of chronic fluoxetine treatment. Brain Research, 2008, 1236, 57-72.	1.1	13
751	Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. European Journal of Pharmacology, 2008, 584, 78-86.	1.7	42
752	Modulation by female sex hormones of the cannabinoid-induced catalepsy and analgesia in ovariectomized mice. European Journal of Pharmacology, 2008, 586, 189-196.	1.7	20
753	The cannabinoid CB1 receptor antagonist CE prolongs spatial memory duration in a rat delayed radial arm maze memory task. European Journal of Pharmacology, 2008, 590, 246-249.	1.7	18
754	Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. European Journal of Pharmacology, 2008, 593, 73-78.	1.7	64
755	Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures â€" A short review. Pharmacology Biochemistry and Behavior, 2008, 90, 501-511.	1.3	367

#	Article	IF	Citations
756	Endocannabinoids in the retina: From marijuana to neuroprotection. Progress in Retinal and Eye Research, 2008, 27, 501-526.	7.3	146
757	An Historical Introduction to the Endocannabinoid and Endovanilloid Systems. , 2008, , 3-13.		1
758	A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain. Journal of Pain, 2008, 9, 506-521.	0.7	270
759	The Brainstem and Nociceptive Modulation. , 2008, , 593-626.		32
760	Cannabis, Cannabinoids and Schizophrenia: Integration of the Evidence. Australian and New Zealand Journal of Psychiatry, 2008, 42, 357-368.	1.3	80
761	Cannabinoids and the Brain. , 2008, , .		8
762	Signaling via CNS cannabinoid receptors. Molecular and Cellular Endocrinology, 2008, 286, S60-S65.	1.6	98
763	Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology, 2008, 286, S97-S107.	1.6	66
764	The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. Molecular and Cellular Neurosciences, 2008, 38, 89-97.	1.0	132
765	Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels. Neurochemistry International, 2008, 52, 80-88.	1.9	51
766	Reciprocal inhibition of G-protein signaling is induced by CB1 cannabinoid and GABAB receptor interactions in rat hippocampal membranes. Neurochemistry International, 2008, 52, 1402-1409.	1.9	34
767	CB2 cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: Role of CB2 receptor in pain. Neurochemistry International, 2008, 53, 309-316.	1.9	39
768	Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate. NeuroToxicology, 2008, 29, 1037-1043.	1.4	27
769	Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology, 2008, 54, 95-107.	2.0	163
770	Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. Neuropharmacology, 2008, 54, 23-30.	2.0	36
771	CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. Neuropharmacology, 2008, 54, 976-988.	2.0	35
772	Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A). Neuropharmacology, 2008, 55, 712-716.	2.0	74
773	Î”9-Tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience, 2008, 151, 320-328.	1.1	51

#	Article	IF	Citations
774	Identification of cannabinoid type 1 receptor expressing cocaine amphetamine-regulated transcript neurons in the rat hypothalamus and brainstem using in situ hybridization and immunohistochemistry. Neuroscience, 2008, 154, 641-652.	1.1	36
775	Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. Neuroscience, 2008, 154, 1554-1561.	1.1	24
776	Opposite action of hippocampal CB1 receptors in memory reconsolidation and extinction. Neuroscience, 2008, 154, 1648-1655.	1.1	125
777	Differential role of the hippocampal endocannabinoid system in the memory consolidation and retrieval mechanisms. Neurobiology of Learning and Memory, 2008, 90, 1-9.	1.0	87
778	Î”9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 499-506.	2.5	13
779	Synthesis, Ex Vivo Evaluation, and Radiolabeling of Potent 1,5-Diphenylpyrrolidin-2-one Cannabinoid Subtype-1 Receptor Ligands as Candidates for In Vivo Imaging. Journal of Medicinal Chemistry, 2008, 51, 5833-5842.	2.9	69
780	Inflammation and aging: Can endocannabinoids help?. Biomedicine and Pharmacotherapy, 2008, 62, 212-217.	2.5	27
781	Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18F]MK-9470 PET. NeuroImage, 2008, 39, 1533-1541.	2.1	117
782	Deficits in learning and memory: Parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users. NeuroImage, 2008, 40, 1328-1339.	2.1	95
783	Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Progress in Brain Research, 2008, 170, 397-432.	0.9	144
784	Novel aspects of adipocyte-induced skeletal muscle insulin resistance. Archives of Physiology and Biochemistry, 2008, 114, 287-298.	1.0	21
785	Discovery and Labeling of High-Affinity 3,4-Diarylpyrazolines as Candidate Radioligands for In Vivo Imaging of Cannabinoid Subtype-1 (CB₁) Receptors. Journal of Medicinal Chemistry, 2008, 51, 5608-5616.	2.9	25
786	PTEN-5-HT2C coupling: a new target for treating drug addiction. Progress in Brain Research, 2008, 172, 407-420.	0.9	16
787	Dose-Related Differences in the Regional Pattern of Cannabinoid Receptor Adaptation and in Vivo Tolerance Development to Î”⁹-Tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 664-673.	1.3	76
788	Cannabinoid CB₂receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Oto-Laryngologica, 2008, 128, 961-967.	0.3	48
789	The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction. CNS and Neurological Disorders - Drug Targets, 2008, 7, 468-481.	0.8	32
790	Activating Parabrachial Cannabinoid CB₁Receptors Selectively Stimulates Feeding of Palatable Foods in Rats. Journal of Neuroscience, 2008, 28, 9702-9709.	1.7	121
791	Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia. Archives of General Psychiatry, 2008, 65, 772.	13.8	208

#	Article	IF	Citations
792	Attenuation of Cue-Induced Heroin-Seeking Behavior by Cannabinoid CB1 Antagonist Infusions into the Nucleus Accumbens Core and Prefrontal Cortex, but Not Basolateral Amygdala. Neuropsychopharmacology, 2008, 33, 2483-2493.	2.8	55
793	Chapter 4.5 The endocannabinoid system and anxiety responses. Handbook of Behavioral Neuroscience, 2008, , 303-324.	0.7	7
795	The Endocannabinoid System in Amyotrophic Lateral Sclerosis. Current Pharmaceutical Design, 2008, 14, 2306-2316.	0.9	38
796	The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses. Current Pharmaceutical Design, 2008, 14, 2299-2305.	0.9	67
797	Modulation of Network Oscillatory Activity and GABAergic Synaptic Transmission by CB1 Cannabinoid Receptors in the Rat Medial Entorhinal Cortex. Neural Plasticity, 2008, 2008, 1-12.	1.0	16
798	The ins and outs of endocannabinoid signaling in healthy and diseased brain. Future Lipidology, 2008, 3, 435-452.	0.5	7
799	High on habits. Frontiers in Neuroscience, 2008, 2, 208-217.	1.4	46
800	Das endocannabinoide System des Gehirns â€“ von der Neurobiologie zur klinischen Relevanz. E-Neuroforum, 2008, 14, 256-267.	0.2	0
801	CANNABINOID-MEDIATED REGULATION OF THE HYPOTHALAMO-PITUITARY-ADRENAL AXIS in rats: AGE DEPENDENT ROLE OF VASOPRESSIN. Endocrine Regulations, 2009, 43, 13-21.	0.5	3
802	Cannabinoid Receptors: A brief history and "what's hot".. Frontiers in Bioscience - Landmark, 2009, Volume, 944.	3.0	59
803	Phytocannabinoids and Endocannabinoids. Current Drug Abuse Reviews, 2009, 2, 51-75.	3.4	45
804	Cannabinoid receptor activation reverses kainate-induced synchronized population burst firing in rat hippocampus. Frontiers in Integrative Neuroscience, 2009, 3, 13.	1.0	12
805	Basic neuroanatomy and neuropharmacology of cannabinoids. International Review of Psychiatry, 2009, 21, 113-121.	1.4	52
806	Cannabinoid Agonists Stimulate [3H]GABA Release in the Globus Pallidus of the Rat When Gi Protein-Receptor Coupling Is Restricted: Role of Dopamine D2 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 822-828.	1.3	38
807	Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies. , 2009, , 443-492.		1
808	Hippocampal CB1 Receptors Mediate the Memory Impairing Effects of Î”9-Tetrahydrocannabinol. Neuropsychopharmacology, 2009, 34, 2072-2080.	2.8	118
809	Antiaversive Effects of Cannabinoids: Is the Periaqueductal Gray Involved?. Neural Plasticity, 2009, 2009, 1-11.	1.0	49
811	Endocannabinoids Suppress Excitatory Synaptic Transmission to Dorsal Raphe Serotonin Neurons through the Activation of Presynaptic CB₁ Receptors. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 186-196.	1.3	62

#	Article	IF	Citations
812	A Role for the Endocannabinoid System in the Increased Motivation for Cocaine in Extended-Access Conditions. Journal of Neuroscience, 2009, 29, 4846-4857.	1.7	97
813	Role of the Endocannabinoid System in Abdominal Obesity and the Implications for Cardiovascular Risk. Cardiology, 2009, 114, 212-225.	0.6	11
814	The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders. CNS and Neurological Disorders - Drug Targets, 2009, 8, 451-458.	0.8	128
815	Dietary conjugated linoleic acid modifies the brain endocannabinoid system in mice. Nutritional Neuroscience, 2009, 12, 155-159.	1.5	11
816	Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats. Neuropsychopharmacology, 2009, 34, 2469-2476.	2.8	36
817	The Cannabinoid Receptor 2 Is Critical for the Host Response to Sepsis. Journal of Immunology, 2009, 183, 499-505.	0.4	113
818	The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiology of Disease, 2009, 33, 57-71.	2.1	107
819	Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Research, 2009, 1253, 81-91.	1.1	85
820	Chronic stress differentially regulates cannabinoid CB1 receptor binding in distinct hippocampal subfields. European Journal of Pharmacology, 2009, 614, 66-69.	1.7	36
821	Monoaminergic neurotransmission contributes to cannabinoid-induced activation of the hypothalamic-pituitary-adrenal axis. European Journal of Pharmacology, 2009, 624, 71-76.	1.7	52
822	Neuroanatomical basis for therapeutic applications of cannabinoid receptor 1 antagonists. Drug Development Research, 2009, 70, 527-554.	1.4	5
823	Are CB₁ receptor antagonists nootropic or cognitive impairing agents?. Drug Development Research, 2009, 70, 555-565.	1.4	18
824	Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands. Journal of Neuroscience Research, 2009, 87, 766-775.	1.3	19
825	Short- and long-term consequences of prenatal exposure to the cannabinoid agonist WIN55,212-2 on rat glutamate transmission and cognitive functions. Journal of Neural Transmission, 2009, 116, 1017-1027.	1.4	29
826	Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 395-412.	1.8	142
827	HU210-Induced Downregulation in Cannabinoid CB1 Receptor Binding Strongly Correlates with Body Weight Loss in the Adult Rat. Neurochemical Research, 2009, 34, 1343-1353.	1.6	28
828	Adaptations of Striatal Endocannabinoid System During Stress. Molecular Neurobiology, 2009, 39, 178-184.	1.9	7
829	Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 61-72.	1.4	42

#	Article	IF	Citations
830	Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test. Psychopharmacology, 2009, 205, 475-487.	1.5	21
831	Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administrationâ€"comparison with CB1 receptor blockade. Psychopharmacology, 2009, 205, 613-624.	1.5	106
832	Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology, 2009, 206, 531-549.	1.5	123
833	Evaluation of [¹¹C]PipISB and [¹⁸F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid typeâ€1 receptors in vivo. Synapse, 2009, 63, 22-30.	0.6	15
834	Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesionâ€induced dopamine dysregulation. Synapse, 2009, 63, 941-950.	0.6	18
835	Cannabinoid system in the skin â€“ a possible target for future therapies in dermatology. Experimental Dermatology, 2009, 18, 669-679.	1.4	78
836	Role of Endocannabinoid System in the Ventral Hippocampus of Rats in the Modulation of Anxietyâ€Like Behaviours. Basic and Clinical Pharmacology and Toxicology, 2009, 105, 333-338.	1.2	33
837	Involvement of hypothalamic peptides in the anorectic action of the CB₁ receptor antagonist rimonabant (SR 141716). European Journal of Neuroscience, 2009, 29, 2207-2216.	1.2	36
838	Neuronal and glial localization of the cannabinoidâ€1 receptor in the superficial spinal dorsal horn of the rodent spinal cord. European Journal of Neuroscience, 2009, 30, 251-262.	1.2	47
839	Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes, Obesity and Metabolism, 2010, 12, 591-603.	2.2	35
840	Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis. Epilepsia, 2009, 50, 1657-1669.	2.6	34
841	The endocannabinoid system as a target for the treatment of motor dysfunction. British Journal of Pharmacology, 2009, 156, 1029-1040.	2.7	168
842	Physiological evidence for interaction between the HIVâ€1 coâ€receptor CXCR4 and the cannabinoid system in the brain. British Journal of Pharmacology, 2009, 157, 1225-1231.	2.7	21
843	D₂ receptorâ€mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB₁ receptors: studies using fast cyclic voltammetry. Journal of Neurochemistry, 2009, 108, 545-551.	2.1	20
844	Altered CB₁ receptorâ€signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. Journal of Neurochemistry, 2009, 108, 1423-1433.	2.1	69
845	Sphingosineâ€1â€phosphate receptors mediate neuromodulatory functions in the CNS. Journal of Neurochemistry, 2009, 110, 1191-1202.	2.1	48
846	Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside. Neurotherapeutics, 2009, 6, 713-737.	2.1	267
847	Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity. European Journal of Medicinal Chemistry, 2009, 44, 593-608.	2.6	16

#	Article	IF	Citations
848	Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazoles. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 891-893.	1.0	34
849	Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6209-6212.	1.0	12
850	Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation. AAPS Journal, 2009, 11, 39-44.	2.2	143
851	The genetics of episodic memory. Cognitive Neuropsychiatry, 2009, 14, 356-376.	0.7	15
852	Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPARÎ³. Biochimie, 2009, 91, 457-465.	1.3	63
853	The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants. Trends in Pharmacological Sciences, 2009, 30, 484-493.	4.0	147
854	Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology, 2009, 56, 226-234.	2.0	82
855	The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology, 2009, 56, 235-243.	2.0	90
856	Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology, 2009, 57, 208-218.	2.0	56
857	Activation of CB1 cannabinoid receptors impairs memory consolidation and hippocampal polysialylated neural cell adhesion molecule expression in contextual fear conditioning. Neuroscience, 2009, 158, 1708-1716.	1.1	60
858	Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat. Neuroscience, 2009, 163, 1192-1200.	1.1	25
859	Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area. Neuroscience, 2009, 164, 424-434.	1.1	60
860	Role of cannabinoid CB1 receptors on macronutrient selection and satiety in rats. Physiology and Behavior, 2009, 96, 646-650.	1.0	25
861	Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1191-1199.	2.5	53
862	Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1517-1521.	2.5	127
863	A novel role for the endocannabinoid system during zebrafish development. Molecular and Cellular Endocrinology, 2009, 299, 172-177.	1.6	35
864	Evidence for a Re-Evaluation of the Neurochemical and Anatomical Bases of Chemotherapy-Induced Vomiting. Chemical Reviews, 2009, 109, 3158-3199.	23.0	100
865	Reprint of: Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against â€˜morning sicknessâ€™. Complementary Therapies in Clinical Practice, 2009, 15, 242-246.	0.7	12

#	Article	IF	Citations
866	Cannabinoid CB1 Receptors are Early DownRegulated Followed by a Further UpRegulation in the Basal Ganglia of Mice with Deletion of Specific Park Genes. , 2009, , 269-275.		23
867	ImplicaciÃ³n del sistema cannabinoide endÃ³geno en el alcoholismo. Trastornos Adictivos, 2009, 11, 85-95.	0.1	1
868	Dynamic Regulation of the Endocannabinoid System: Implications for Analgesia. Molecular Pain, 2009, 5, 1744-8069-5-59.	1.0	72
869	Gz Mediates the Long-Lasting Desensitization of Brain CB1 Receptors and is Essential for Cross-Tolerance with Morphine. Molecular Pain, 2009, 5, 1744-8069-5-11.	1.0	48
870	Chapter 16 Endocannabinoid System and Fear Conditioning. Vitamins and Hormones, 2009, 81, 421-440.	0.7	13
871	Suppression of Amygdalar Endocannabinoid Signaling by Stress Contributes to Activation of the Hypothalamicâ€“Pituitaryâ€“Adrenal Axis. Neuropsychopharmacology, 2009, 34, 2733-2745.	2.8	257
872	Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: Compound-specific and area-specific distribution within the brain. European Neuropsychopharmacology, 2009, 19, 533-541.	0.3	22
873	Endocannabinoid-Mediated Control of Synaptic Transmission. Physiological Reviews, 2009, 89, 309-380.	13.1	1,262
874	Delta(9)-tetrahydrocannabinol Enhances an Increase of Plasma Corticosterone Levels Induced by Forced Swim-Stress. Biological and Pharmaceutical Bulletin, 2009, 32, 2065-2067.	0.6	13
875	Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2009, 9, 539-559.	1.1	27
876	Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration. Mini-Reviews in Medicinal Chemistry, 2009, 9, 448-462.	1.1	71
877	The Neuroanatomical Organization of the Basal Ganglia. Handbook of Behavioral Neuroscience, 2010, , 3-28.	0.7	61
878	Protective effects of cannabinoid receptor agonists against cocaine and other convulsant-induced toxic behavioural symptoms. Journal of Pharmacy and Pharmacology, 2010, 53, 1525-1532.	1.2	27
879	Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. International Journal of Neuropsychopharmacology, 2010, 13, 1103-1113.	1.0	74
880	Altered parahippocampal functioning in cannabis users is related to the frequency of use. Psychopharmacology, 2010, 209, 361-374.	1.5	50
881	Cannabis constituents modulate â^†9-tetrahydrocannabinol-induced hyperphagia in rats. Psychopharmacology, 2010, 210, 97-106.	1.5	19
882	Contribution of limbic norepinephrine to cannabinoid-induced aversion. Psychopharmacology, 2010, 211, 479-491.	1.5	27
883	The G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients. Clinical and Translational Oncology, 2010, 12, 825-828.	1.2	1

#	Article	IF	Citations
884	The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. Journal of Neuroimmunology, 2010, 221, 32-41.	1.1	35
885	Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. Journal of Psychiatric Research, 2010, 44, 591-597.	1.5	97
886	Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat. Neurotoxicology and Teratology, 2010, 32, 515-524.	1.2	45
887	The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacology Biochemistry and Behavior, 2010, 95, 479-484.	1.3	45
888	Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Research - Neuroimaging, 2010, 182, 152-159.	0.9	127
889	Pharmacological characterization of the cannabinoid CB1 receptor PET ligand ortholog, [3H]MePPEP. European Journal of Pharmacology, 2010, 649, 44-50.	1.7	6
890	Characterization of cannabinoid-1 receptors in the locus coeruleus: Relationship with mu-opioid receptors. Brain Research, 2010, 1312, 18-31.	1.1	81
891	In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease. Brain Research, 2010, 1316, 153-162.	1.1	38
892	Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. Brain Research, 2010, 1339, 18-25.	1.1	25
893	GABAA receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. Brain Research, 2010, 1351, 238-245.	1.1	17
894	Endocannabinoid system in the adult rat circumventricular areas: An immunohistochemical study. Journal of Comparative Neurology, 2010, 518, 3065-3085.	0.9	44
895	Architecture of cannabinoid signaling in mouse retina. Journal of Comparative Neurology, 2010, 518, 3848-3866.	0.9	66
896	The constitutive production of the endocannabinoid 2â€arachidonoylglycerol participates in oligodendrocyte differentiation. Glia, 2010, 58, 1913-1927.	2.5	76
897	Recruitment of hippocampal neurons to encode behavioral events in the rat: Alterations in cognitive demand and cannabinoid exposure. Hippocampus, 2010, 20, 1083-1094.	0.9	19
898	Two opposite effects of Î”⁹-tetrahydrocannabinol on subthalamic nucleus neuron activity: Involvement of GABAergic and glutamatergic neurotransmission. Synapse, 2010, 64, 20-29.	0.6	11
899	Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding. Synapse, 2010, 64, 617-623.	0.6	13
900	Regulation of subthalamic neuron activity by endocannabinoids. Synapse, 2010, 64, 682-698.	0.6	8
901	Regulation of Fas receptor/Fasâ€associated protein with death domain apoptotic complex and associated signalling systems by cannabinoid receptors in the mouse brain. British Journal of Pharmacology, 2010, 160, 643-656.	2.7	21

#	Article	IF	Citations
902	Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. British Journal of Pharmacology, 2010, 160, 511-522.	2.7	186
903	Adenosineâ€“cannabinoid receptor interactions. Implications for striatal function. British Journal of Pharmacology, 2010, 160, 443-453.	2.7	113
904	CB₂: a cannabinoid receptor with an identity crisis. British Journal of Pharmacology, 2010, 160, 467-479.	2.7	523
905	Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex. British Journal of Pharmacology, 2010, 160, 736-746.	2.7	10
906	Cannabinoid CB₁ receptorâ€interacting proteins: novel targets for central nervous system drug discovery?. British Journal of Pharmacology, 2010, 160, 454-466.	2.7	104
907	Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Î”⁹â€tetrahydrocannabinol exposure. British Journal of Pharmacology, 2010, 161, 103-112.	2.7	138
908	Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Î”9â€THC exposureâ€impaired hippocampal synaptic plasticity. Journal of Neurochemistry, 2010, 112, 691-702.	2.1	76
909	Central and peripheral consequences of the chronic blockade of CB₁ cannabinoid receptor with rimonabant or taranabant. Journal of Neurochemistry, 2010, 112, 1338-13351.	2.1	24
910	Cannabinoid agonist WIN55,212 in vitro inhibits interleukin-6 (IL-6) and monocyte chemo-attractant protein-1 (MCP-1) release by rat pancreatic acini and in vivo induces dual effects on the course of acute pancreatitis. Neurogastroenterology and Motility, 2010, 22, 1248-e323.	1.6	17
911	Nongenomic Actions of Adrenal Steroids in the Central Nervous System. Journal of Neuroendocrinology, 2010, 22, 846-861.	1.2	56
912	Secondâ€order schedules of nicotine reinforcement in rats: effect of AM251. Addiction Biology, 2010, 15, 393-402.	1.4	10
913	The Role of Cannabinoid Receptors in the Descending Modulation of Pain. Pharmaceuticals, 2010, 3, 2661-2673.	1.7	48
914	Molecular Mechanisms Involved in the Antitumor Activity of Cannabinoids on Gliomas: Role for Oxidative Stress. Cancers, 2010, 2, 1013-1026.	1.7	25
915	A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. PLoS ONE, 2010, 5, e11464.	1.1	119
916	Endocannabinoid Signaling in the Striatum. Handbook of Behavioral Neuroscience, 2010, , 167-186.	0.7	6
917	Central cannabinoid receptors modulate acquisition of eyeblink conditioning. Learning and Memory, 2010, 17, 571-576.	0.5	22
918	Cannabinoids Excite Circadian Clock Neurons. Journal of Neuroscience, 2010, 30, 10061-10066.	1.7	50
919	Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. Pharmaceuticals, 2010, 3, 2930-2955.	1.7	27

#	Article	IF	Citations
920	FAAHâ^'/â^' Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Î"9-Tetrahydrocannabinol and Anandamide Administration. Neuropsychopharmacology, 2010, 35, 1775-1787.	2.8	74
921	Differential Regulation of Behavioral Tolerance to WIN55,212-2 by GASP1. Neuropsychopharmacology, 2010, 35, 1363-1373.	2.8	37
922	Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. Pharmaceuticals, 2010, 3, 2799-2820.	1.7	12
923	Cellular Mechanisms Underlying the Interaction between Cannabinoid and Opioid System. Current Drug Targets, 2010, 11, 393-405.	1.0	76
924	Cannabinoid CB1 receptors in the medial prefrontal cortex modulate the expression of contextual fear conditioning. International Journal of Neuropsychopharmacology, 2010, 13, 1163-1173.	1.0	70
925	Pharmacology and Toxicology of Cannabis Derivatives and Endocannabinoid Agonists. Recent Patents on CNS Drug Discovery, 2010, 5, 46-52.	0.9	30
926	Opioids and Cannabinoids Interactions: Involvement in Pain Management. Current Drug Targets, 2010, 11, 462-473.	1.0	49
927	Glucocorticoids, stress and obesity. Expert Review of Endocrinology and Metabolism, 2010, 5, 425-434.	1.2	7
928	Deficiency in Endocannabinoid Signaling in the Nucleus Accumbens Induced by Chronic Unpredictable Stress. Neuropsychopharmacology, 2010, 35, 2249-2261.	2.8	102
929	Functional Interactions between Stress and the Endocannabinoid System: From Synaptic Signaling to Behavioral Output. Journal of Neuroscience, 2010, 30, 14980-14986.	1.7	202
930	A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharmacological Research, 2010, 61, 419-429.	3.1	41
931	Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain. NeuroImage, 2010, 52, 1243-1251.	2.1	17
932	Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics Journal, 2010, 10, 232-242.	0.9	44
933	The Synthetic Cannabinoid WIN 55,212-2 Sensitizes Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis by Activating p8/CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)/Death Receptor 5 (DR5) Axis. Molecular Pharmacology, 2010, 77, 854-863.	1.0	38
934	A Selective Cannabinoid-1 Receptor Antagonist, PF-95453, Reduces Body Weight and Body Fat to a Greater Extent than Pair-Fed Controls in Obese Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 103-113.	1.3	23
935	Physical exercise in adolescence changes CB1 cannabinoid receptor expression in the rat brain. Neurochemistry International, 2010, 57, 492-496.	1.9	24
936	Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochemistry International, 2010, 57, 985-989.	1.9	59
937	Endocannabinoid signaling in neurotoxicity and neuroprotection. NeuroToxicology, 2010, 31, 562-571.	1.4	26

#	Article	IF	Citations
938	The effects of the synthetic cannabinoid receptor agonists, WIN55,212-2 and CP55,940, on salicylate-induced tinnitus in rats. Hearing Research, 2010, 268, 145-150.	0.9	30
939	Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance. Immunobiology, 2010, 215, 629-646.	0.8	73
940	Cannabinoids and experimental models of multiple sclerosis. Immunobiology, 2010, 215, 647-657.	0.8	33
941	Anandamide prior to sensitization increases cell-mediated immunity in mice. International Immunopharmacology, 2010, 10, 431-439.	1.7	23
942	Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine. Saudi Pharmaceutical Journal, 2010, 18, 207-215.	1.2	5
943	The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats. Life Sciences, 2010, 86, 510-517.	2.0	9
944	GPR155: Gene organization, multiple mRNA splice variants and expression in mouse central nervous system. Biochemical and Biophysical Research Communications, 2010, 398, 19-25.	1.0	17
945	Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology, 2010, 92, 370-385.	2.8	276
946	Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 791-797.	2.5	186
947	Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety-like behaviors depending on previous stress experience. Neuroscience, 2010, 167, 238-246.	1.1	62
948	Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats. Neuroscience, 2010, 168, 371-386.	1.1	71
949	SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents. Neurobiology of Learning and Memory, 2010, 93, 522-531.	1.0	43
950	Maleâ€“female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. Hormones and Behavior, 2010, 58, 91-99.	1.0	86
951	Cannabinoidâ€“hormone interactions in the regulation of motivational processes. Hormones and Behavior, 2010, 58, 100-110.	1.0	60
952	Cannabinoidâ€“Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders. CNS Neuroscience and Therapeutics, 2010, 16, e72-91.	1.9	135
953	CB1 modulation of hormone secretion, neuronal activation and mRNA expression following extracellular volume expansion. Experimental Neurology, 2010, 224, 114-122.	2.0	17
954	Alcohol and endocannabinoids: Neuroendocrine interactions in the reproductive axis. Experimental Neurology, 2010, 224, 15-22.	2.0	19
955	The endocannabinoid system and nondrug rewarding behaviours. Experimental Neurology, 2010, 224, 23-36.	2.0	78

#	Article	IF	Citations
956	The endocannabinoid system and amyloid-related diseases. Experimental Neurology, 2010, 224, 66-73.	2.0	16
957	The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Experimental Neurology, 2010, 224, 92-102.	2.0	63
958	Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. NeuroImage, 2010, 49, 1133-1143.	2.1	168
960	Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opinion on Pharmacotherapy, 2010, 11, 17-31.	0.9	56
961	The Central Cannabinoid CB1 Receptor Is Required for Dietâ€Induced Obesity and Rimonabant's Antiobesity Effects in Mice. Obesity, 2011, 19, 1923-1934.	1.5	35
962	GPR88: A putative signaling molecule predominantly expressed in the striatum: Cellular localization and developmental regulation. Basal Ganglia, 2011, 1, 83-89.	0.3	41
963	Effects of endocannabinoid system modulation on cognitive and emotional behavior. Frontiers in Behavioral Neuroscience, 2011, 5, 57.	1.0	167
964	Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB₁ cannabinoid receptors. Journal of Psychopharmacology, 2011, 25, 1676-1690.	2.0	97
965	Endocannabinoids and stress. Stress, 2011, 14, 384-397.	0.8	115
966	Involvement of the endocannabinoid system in alcohol dependence: The biochemical, behavioral and genetic evidence. Drug and Alcohol Dependence, 2011, 117, 102-110.	1.6	22
967	Increment of hypothalamic 2-arachidonoylglycerol induces the preference for a high-fat diet via activation of cannabinoid 1 receptors. Behavioural Brain Research, 2011, 216, 477-480.	1.2	21
968	Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behavioural Brain Research, 2011, 223, 125-134.	1.2	82
969	Disruption of Frontal Theta Coherence by Î”9-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms. Neuropsychopharmacology, 2011, 36, 827-836.	2.8	74
970	Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1575-1585.	2.5	91
971	Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1870-1876.	2.5	29
972	Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology, 2011, 61, 414-420.	2.0	93
973	Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampus. Neuropharmacology, 2011, 61, 1016-1025.	2.0	22
974	Effect of Î”FosB overexpression on opioid and cannabinoid receptor-mediated signaling in the nucleus accumbens. Neuropharmacology, 2011, 61, 1470-1476.	2.0	15

#	Article	IF	Citations
975	Neurochemical basis of cannabis addiction. Neuroscience, 2011, 181, 1-17.	1.1	93
976	Distribution of diacylglycerol lipase alpha, an endocannabinoid synthesizing enzyme, in the rat forebrain. Neuroscience, 2011, 192, 112-131.	1.1	28
977	Intrinsic and integrative properties of substantia nigra pars reticulata neurons. Neuroscience, 2011, 198, 69-94.	1.1	87
978	Pre-training anandamide infusion within the basolateral amygdala impairs plus-maze discriminative avoidance task in rats. Neurobiology of Learning and Memory, 2011, 95, 527-533.	1.0	15
979	The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration. CNS Neuroscience and Therapeutics, 2011, 17, 637-644.	1.9	90
980	The function of the endocannabinoid system. , 0, , 23-34.		1
981	Current and emerging “at-site” pain medications: a review. Journal of Pain Research, 2011, 4, 279.	0.8	4
982	The manifold actions of endocannabinoids on female and male reproductive events. Frontiers in Bioscience - Landmark, 2011, 16, 498.	3.0	83
983	Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light. Frontiers in Behavioral Neuroscience, 2011, 5, 1.	1.0	167
984	The Role of Cannabinoids in Modulating Emotional and Non-Emotional Memory Processes in the Hippocampus. Frontiers in Behavioral Neuroscience, 2011, 5, 34.	1.0	91
985	Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Frontiers in Behavioral Neuroscience, 2011, 5, 63.	1.0	101
986	Effects of opioids, cannabinoids, and vanilloids on body temperature. Frontiers in Bioscience - Scholar, 2011, S3, 822.	0.8	45
987	MK-7128, a novel CB1 receptor inverse agonist, improves scopolamine-induced learning and memory deficits in mice. Behavioural Pharmacology, 2011, 22, 91-100.	0.8	8
988	The Role of Endocannabinoids in Pain Modulation and the Therapeutic Potential of Inhibiting their Enzymatic Degradation. Current Pharmaceutical Biotechnology, 2011, 12, 1644-1659.	0.9	21
989	Cannabinoid-1 receptor agonists: a therapeutic option in severe, chronic anorexia nervosa?. Neuropsychiatry, 2011, 1, 467-476.	0.4	3
990	Tolerance to chronic delta-9-tetrahydrocannabinol (Î”â¹-THC) in rhesus macaques infected with simian immunodeficiency virus.. Experimental and Clinical Psychopharmacology, 2011, 19, 154-172.	1.3	58
991	Long-term behavioral and pharmacodynamic effects of delta-9-tetrahydrocannabinol in female rats depend on ovarian hormone status. Addiction Biology, 2011, 16, 64-81.	1.4	45
992	DAGLâ€dependent endocannabinoid signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis. European Journal of Neuroscience, 2011, 34, 1634-1646.	1.2	71

#	Article	IF	Citations
993	Differential gene expression in migratory streams of cortical interneurons. European Journal of Neuroscience, 2011, 34, 1584-1594.	1.2	41
994	Î”9â€¬THC increases endogenous AHA1 expression in rat cerebellum and may modulate CB1 receptor function during chronic use. Journal of Neurochemistry, 2011, 118, 1101-1112.	2.1	16
995	The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogenâ€related receptor Î± protein. British Journal of Pharmacology, 2011, 164, 1026-1040.	2.7	19
996	The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys. British Journal of Pharmacology, 2011, 164, 655-666.	2.7	16
997	Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. British Journal of Pharmacology, 2011, 163, 1520-1532.	2.7	95
998	Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. Acta Neuropsychiatrica, 2011, 23, 241-248.	1.0	62
999	The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. Journal of Physiology, 2011, 589, 2415-2431.	1.3	52
1000	Efficacy and Safety of CPâ€945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance. Obesity, 2011, 19, 1404-1414.	1.5	25
1001	Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration. Clinical Pharmacology and Therapeutics, 2011, 89, 400-407.	2.3	101
1002	Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain, 2011, 152, 1976-1987.	2.0	55
1003	A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. Pain, 2011, 152, 2495-2504.	2.0	29
1004	CB1 receptors regulate alcohol-seeking behavior and alcohol self-administration of alcohol-preferring (P) rats. Pharmacology Biochemistry and Behavior, 2011, 97, 669-675.	1.3	24
1005	Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacology Biochemistry and Behavior, 2011, 98, 21-27.	1.3	145
1006	Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacology Biochemistry and Behavior, 2011, 99, 718-725.	1.3	71
1007	Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception. Pharmacology Biochemistry and Behavior, 2011, 100, 340-346.	1.3	29
1008	Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. , 2011, 132, 215-241.		153
1009	Modulation of cortisol levels, endocannabinoid receptor 1A, proopiomelanocortin and thyroid hormone receptor alpha mRNA expressions by probiotics during sole (Solea solea) larval development. General and Comparative Endocrinology, 2011, 171, 293-300.	0.8	38
1010	The actions of benzophenanthridine alkaloids, piperonyl butoxide and (S)-methoprene at the G-protein coupled cannabinoid CB1 receptor in vitro. European Journal of Pharmacology, 2011, 654, 26-32.	1.7	15

#	Article	IF	Citations
1011	Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6856-6860.	1.0	4
1012	Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1Î”E9 double transgenic mice. Brain Research, 2011, 1376, 94-100.	1.1	40
1013	Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain. Brain Research, 2011, 1412, 44-54.	1.1	49
1014	Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology, 2011, 61, 1070-1087.	2.0	86
1015	Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of Neural Transmission, 2011, 118, 1661-1690.	1.4	75
1016	Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology, 2011, 215, 665-675.	1.5	19
1017	âˆ†9-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory. Psychopharmacology, 2011, 217, 485-494.	1.5	17
1018	Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse, 2011, 65, 278-286.	0.6	128
1019	Distribution of CB2 cannabinoid receptor in adult rat retina. Synapse, 2011, 65, 388-392.	0.6	48
1020	Decreased parvalbumin immunoreactivity in the cortex and striatum of mice lacking the CB1 receptor. Synapse, 2011, 65, 827-831.	0.6	18
1021	Cannabis sativa and the Endogenous Cannabinoid System: Therapeutic Potential for Appetite Regulation. Phytotherapy Research, 2011, 25, 170-188.	2.8	27
1022	Cannabinoids alter spontaneous firing, bursting, and cell synchrony of hippocampal principal cells. Hippocampus, 2011, 21, 520-531.	0.9	24
1023	Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence. Current Neuropharmacology, 2011, 9, 183-189.	1.4	13
1024	The Cannabinoid Receptor Agonist THC Attenuates Weight Loss in a Rodent Model of Activity-Based Anorexia. Neuropsychopharmacology, 2011, 36, 1349-1358.	2.8	63
1025	Target-Dependent Control of Synaptic Inhibition by Endocannabinoids in the Thalamus. Journal of Neuroscience, 2011, 31, 9222-9230.	1.7	20
1026	Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. Journal of Psychopharmacology, 2011, 25, 111-120.	2.0	140
1027	Comparison of Cannabinoid CB₁Receptor Binding in Adolescent and Adult Rats: A Positron Emission Tomography Study Using [¹⁸F]MK-9470. International Journal of Molecular Imaging, 2011, 2011, 1-11.	1.3	34
1028	Inhibition of Monoacylglycerol Lipase Attenuates Nonsteroidal Anti-Inflammatory Drug-Induced Gastric Hemorrhages in Mice. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 795-802.	1.3	79

#	Article	IF	Citations
1029	Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 423-430.	1.3	35
1030	Retention and extinction of delay eyeblink conditioning are modulated by central cannabinoids. Learning and Memory, 2011, 18, 634-638.	0.5	9
1031	'Macrophage' cannabinoid receptor goes up in smoke. Nature Neuroscience, 2011, 14, 1100-1102.	7.1	5
1032	Endocannabinoids mediate synaptic plasticity at glutamatergic synapses on spiny neurons within a basal ganglia nucleus necessary for song learning. Journal of Neurophysiology, 2011, 105, 1159-1169.	0.9	13
1033	Acute Immobilization Stress Modulate GABA Release from Rat Olfactory Bulb: Involvement of Endocannabinoidsâ€"Cannabinoids and Acute Stress Modulate GABA Release. International Journal of Cell Biology, 2011, 2011, 1-10.	1.0	2
1034	Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice. Neuropsychopharmacology, 2011, 36, 1489-1504.	2.8	178
1035	Medial prefrontal cortex endocannabinoid system modulates baroreflex activity through CB₁receptors. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R876-R885.	0.9	17
1036	CB1 â€“ Cannabinoid Receptor Antagonist Effects on Cortisol in Cannabis-Dependent Men. American Journal of Drug and Alcohol Abuse, 2012, 38, 114-119.	1.1	17
1037	Apparent Inverse Relationship between Cannabinoid Agonist Efficacy and Tolerance/Cross-Tolerance Produced by Î”⁹-Tetrahydrocannabinol Treatment in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 843-849.	1.3	47
1038	The role of the endocannabinoid system in eating disorders. Behavioural Pharmacology, 2012, 23, 526-536.	0.8	38
1039	Cannabinoid Receptor-Mediated Regulation of Neuronal Activity and Signaling in Glomeruli of the Main Olfactory Bulb. Journal of Neuroscience, 2012, 32, 8475-8479.	1.7	36
1040	Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives. Recent Patents on CNS Drug Discovery, 2012, 7, 25-40.	0.9	65
1041	Involvement of Cannabinoid CB1 Receptor in Associative Learning and in Hippocampal CA3-CA1 Synaptic Plasticity. Cerebral Cortex, 2012, 22, 550-566.	1.6	32
1042	Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids. Mini-Reviews in Medicinal Chemistry, 2012, 12, 1119-1126.	1.1	7
1043	Associations between Cannabinoid Receptor-1 (CNR1) Variation and Hippocampus and Amygdala Volumes in Heavy Cannabis Users. Neuropsychopharmacology, 2012, 37, 2368-2376.	2.8	108
1044	Cannabinoid Modulation of Neuroinflammatory Disorders. Current Neuropharmacology, 2012, 10, 159-166.	1.4	44
1045	SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance. Nature Neuroscience, 2012, 15, 284-293.	7.1	97
1046	Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3254-3263.	1.8	82

#	Article	IF	Citations
1047	Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3534-3539.	3.3	156
1048	The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. Journal of Psychopharmacology, 2012, 26, 114-124.	2.0	111
1049	Neuroanatomical substrates involved in cannabinoid modulation of defensive responses. Journal of Psychopharmacology, 2012, 26, 40-55.	2.0	22
1050	Adolescent exposure to cannabis as a risk factor for psychiatric disorders. Journal of Psychopharmacology, 2012, 26, 177-188.	2.0	125
1051	The Yin and Yang of Cannabis-induced Psychosis: the Actions of Δ 9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia. Current Pharmaceutical Design, 2012, 18, 5113-5130.	0.9	42
1052	Is There Any Clinically Relevant Cannabinoid-Induced Analgesia?. Pharmacology, 2012, 89, 237-246.	0.9	43
1053	Type-1 Cannabinoid Receptor Signaling in Neuronal Development. Pharmacology, 2012, 90, 19-39.	0.9	75
1054	A Novel Method for Determination of Drug Distribution in Rat Brain Tissue Sections by LC/MS/MS: Functional Tissue Microanalysis. Current Topics in Medicinal Chemistry, 2012, 12, 1243-1249.	1.0	16
1055	The endocannabinoid system: an overview. Frontiers in Behavioral Neuroscience, 2012, 6, 9.	1.0	153
1056	Inhibition of the slow afterhyperpolarization restores the classical spike timing-dependent plasticity rule obeyed in layer 2/3 pyramidal cells of the prefrontal cortex. Journal of Neurophysiology, 2012, 107, 205-215.	0.9	26
1057	Cannabinoid CB₁ receptors mediate the effects of corticotropinâ€releasing factor on the reinstatement of cocaine seeking and expression of cocaineâ€induced behavioural sensitization. British Journal of Pharmacology, 2012, 167, 196-206.	2.7	29
1058	Cannabinoid receptor 2 activation reduces intestinal leukocyte recruitment and systemic inflammatory mediator release in acute experimental sepsis. Critical Care, 2012, 16, R47.	2.5	48
1059	Regioselective synthesis and cannabinoid receptor binding affinity of N-alkylated 4,5-diaryl-1,2,3-triazoles. Medicinal Chemistry Research, 2012, 21, 4473-4484.	1.1	7
1060	CB1 receptor antagonism/inverse agonism increases motor system excitability in humans. European Neuropsychopharmacology, 2012, 22, 27-35.	0.3	9
1061	Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?. Current Obesity Reports, 2012, 1, 216-228.	3.5	11
1062	Cannabis-Induced Depersonalization Disorder in Adolescence. Neuropsychobiology, 2012, 65, 141-146.	0.9	20
1063	Opposing Roles for Cannabinoid Receptor Type-1 (CB1) and Transient Receptor Potential Vanilloid Type-1 Channel (TRPV1) on the Modulation of Panic-Like Responses in Rats. Neuropsychopharmacology, 2012, 37, 478-486.	2.8	97
1064	Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiology of Aging, 2012, 33, 421.e1-421.e16.	1.5	47

#	Article	IF	Citations
1065	Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiology of Aging, 2012, 33, 620.e1-620.e8.	1.5	82
1066	Differential role of CB1 and TRPV1 receptors on anandamide modulation of defensive responses induced by nitric oxide in the dorsolateral periaqueductal gray. Neuropharmacology, 2012, 62, 2455-2462.	2.0	40
1067	Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal. Neuroscience, 2012, 204, 125-133.	1.1	30
1068	Cannabinoids and emotionality: a neuroanatomical perspective. Neuroscience, 2012, 204, 134-144.	1.1	71
1069	Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. Neuroscience, 2012, 204, 117-124.	1.1	39
1070	Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxietyâ€"two sides of one coin?. Neuroscience, 2012, 204, 186-192.	1.1	92
1071	Timing is everything: evidence for a role of corticolimbic endocannabinoids in modulating hypothalamicâ€"pituitaryâ€"adrenal axis activity across developmental periods. Neuroscience, 2012, 204, 17-30.	1.1	65
1072	Cholinergic suppression of excitatory synaptic transmission in layers II/III of the parasubiculum. Neuroscience, 2012, 201, 1-11.	1.1	6
1073	Expression and localization of the cannabinoid receptor type 1 and the enzyme fatty acid amide hydrolase in the retina of vervet monkeys. Neuroscience, 2012, 202, 117-130.	1.1	38
1074	Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague–Dawley rats. Neuroscience, 2012, 204, 64-73.	1.1	45
1075	Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience, 2012, 204, 5-16.	1.1	278
1076	Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 78-87.	2.5	26
1077	Involvement of descending serotonergic and noradrenergic pathways in CB1 receptor-mediated antinociception. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 97-105.	2.5	40
1078	Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 59-67.	2.5	57
1079	New insights on endocannabinoid transmission in psychomotor disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 51-58.	2.5	17
1080	Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 260-269.	2.5	60
1081	The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fearâ€conditioned analgesia and controls fear expression in the presence of nociceptive tone. British Journal of Pharmacology, 2012, 165, 2549-2560.	2.7	58
1082	The CB₁ cannabinoid receptor Câ€terminus regulates receptor desensitization in autaptic hippocampal neurones. British Journal of Pharmacology, 2012, 165, 2652-2659.	2.7	21

#	Article	IF	Citations
1083	Effects of amphetamine on dopamine release in the rat nucleus accumbens shell region depend on cannabinoid CB1 receptor activation. Neurochemistry International, 2012, 60, 791-798.	1.9	27
1084	Presynaptic CB1 cannabinoid receptors control frontocortical serotonin and glutamate release â€“ Species differences. Neurochemistry International, 2012, 61, 219-226.	1.9	33
1085	Inhibition of forebrain Î¼-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves Î¼-opioid receptors. Neurochemistry International, 2012, 61, 378-388.	1.9	18
1086	Withdrawal from THC during adolescence: Sex differences in locomotor activity and anxiety. Behavioural Brain Research, 2012, 231, 48-59.	1.2	59
1087	Chronic cannabinoid treatment during young adulthood induces sex-specific behavioural deficits in maternally separated rats. Behavioural Brain Research, 2012, 233, 305-313.	1.2	31
1088	Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: A small animal PET imaging study with 18F-FDG. Brain Research Bulletin, 2012, 87, 172-179.	1.4	14
1089	The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D2/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015. Brain Research Bulletin, 2012, 87, 504-510.	1.4	20
1090	Cannabinoid Modulation of Midbrain Urocortin 1 Neurones During Acute and Chronic Stress. Journal of Neuroendocrinology, 2012, 24, 1447-1461.	1.2	8
1091	Tales of Drug Discovery. Annual Reports in Medicinal Chemistry, 2012, 47, 25-34.	0.5	0
1092	Endogenous Opioid and Cannabinoid Mechanisms Are Involved in the Analgesic Effects of Celecoxib in the Central Nervous System. Pharmacology, 2012, 89, 127-136.	0.9	23
1093	Î²-Arrestin2 Regulates Cannabinoid CB1 Receptor Signaling and Adaptation in a Central Nervous System Regionâ€“Dependent Manner. Biological Psychiatry, 2012, 71, 714-724.	0.7	91
1094	Effect of co-injection of arachydonilcyclopropylamide and ethanol on conditioned place preference in rats. Physiology and Behavior, 2012, 107, 301-308.	1.0	13
1095	CB1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of AÎ²PP/PS1 Mice. Journal of Alzheimer's Disease, 2012, 30, 439-459.	1.2	96
1096	The evolution and comparative neurobiology of endocannabinoid signalling. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3201-3215.	1.8	141
1097	Dual Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Blockade Produces THC-Like Morris Water Maze Deficits in Mice. ACS Chemical Neuroscience, 2012, 3, 369-378.	1.7	54
1098	Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology, 2012, 223, 117-129.	1.5	58
1099	Short- and Long-Term Cognitive Effects of Chronic Cannabinoids Administration in Late-Adolescence Rats. PLoS ONE, 2012, 7, e31731.	1.1	100
1100	Hypothalamic 2-Arachidonoylglycerol Regulates Multistage Process of High-Fat Diet Preferences. PLoS ONE, 2012, 7, e38609.	1.1	25

#	Article	IF	Citations
1101	CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation. Frontiers in Pharmacology, 2012, 3, 21.	1.6	74
1102	Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia. Frontiers in Pharmacology, 2012, 3, 101.	1.6	39
1103	The Cannabinoid 1 Receptor and Progenitor Cells in the Adult Central Nervous System. , 2012, , .		0
1104	Standardized Cannabis and Pain Management. , 0, , .		0
1105	Novel Aspects of Glucocorticoids Actions on Energy Homeostasis and Hydromineral Balance. , 2012, , .		0
1106	The Endocannabinoid System: Role in Energy Regulation. Pediatric Blood and Cancer, 2012, 58, 144-148.	0.8	25
1107	Mitigation of postâ€traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence. Drug Testing and Analysis, 2012, 4, 649-659.	1.6	103
1108	Differential distribution of diacylglycerol lipaseâ€alpha and Nâ€acylphosphatidylethanolamineâ€specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats. Glia, 2012, 60, 1316-1329.	2.5	23
1109	Cannabinoid Receptor 1 Gene is Associated with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2012, 36, 267-271.	1.4	39
1110	Lateral regions of the rodent striatum reveal elevated glutamate decarboxylase 1 mRNA expression in mediumâ€sized projection neurons. European Journal of Neuroscience, 2012, 35, 711-722.	1.2	8
1111	The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2â€arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiologica, 2012, 204, 267-276.	1.8	224
1112	Changes in the cannabinoid (CB1) receptor expression level and G-protein activation in kainic acid induced seizures. Epilepsy Research, 2012, 99, 64-68.	0.8	28
1113	The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain. Biochemical Pharmacology, 2012, 83, 260-268.	2.0	27
1114	The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Research, 2012, 1444, 45-54.	1.1	101
1115	Long-lasting increase in [3H]CP55,940 binding to CB1 receptors following cocaine self-administration and its withdrawal in rats. Brain Research, 2012, 1451, 34-43.	1.1	17
1116	Cannabinoid receptor 1 (CB₁R) expression in rat dental pulp. Oral Science International, 2012, 9, 17-20.	0.3	2
1117	Statistical parametric mapping reveals regional alterations in cannabinoid CB₁ receptor distribution and Gâ€protein activation in the 3D reconstructed epileptic rat brain. Epilepsia, 2012, 53, 897-907.	2.6	8
1118	Differential Effects of Single Versus Repeated Alcohol Withdrawal on the Expression of Endocannabinoid Systemâ€Related Genes in the Rat Amygdala. Alcoholism: Clinical and Experimental Research, 2012, 36, 984-994.	1.4	65

#	Article	IF	Citations
1119	Circulating Endocannabinoid Concentrations and Sexual Arousal in Women. Journal of Sexual Medicine, 2012, 9, 1588-1601.	0.3	25
1120	Expression pattern of the cannabinoid receptor genes in the frontal cortex ofÂmood disorder patients and mice selectively bred for high and low fear. Journal of Psychiatric Research, 2012, 46, 882-889.	1.5	68
1121	Prenatal tetrahydrocannabinol (THC) alters cognitive function and amphetamine response from weaning to adulthood in the rat. Neurotoxicology and Teratology, 2012, 34, 63-71.	1.2	35
1122	Endocannabinoid CB1 receptors modulate visual output from the thalamus. Psychopharmacology, 2012, 219, 835-845.	1.5	29
1123	Involvement of opioid system in cognitive deficits induced by âˆ†9-tetrahydrocannabinol in rats. Psychopharmacology, 2012, 219, 1111-1118.	1.5	10
1125	Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain. European Journal of Pharmacology, 2013, 709, 13-19.	1.7	19
1126	Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology, 2013, 225, 531-542.	1.5	21
1127	Involvement of the CA1 GABAA receptors in ACPA-induced impairment of spatial and non-spatial novelty detection in mice. Neurobiology of Learning and Memory, 2013, 100, 32-40.	1.0	35
1128	Dual Role of PPAR-Î³ in Induction and Expression of Behavioral Sensitization to Cannabinoid Receptor Agonist WIN55,212-2. NeuroMolecular Medicine, 2013, 15, 523-535.	1.8	10
1129	Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut. Journal of Basic and Clinical Physiology and Pharmacology, 2013, 24, 27-33.	0.7	23
1130	Complex interaction between anandamide and the nitrergic system in the dorsolateral periaqueductal gray to modulate anxiety-like behavior in rats. Neuropharmacology, 2013, 75, 86-94.	2.0	22
1131	Cannabinoids Inhibit T-cells via Cannabinoid Receptor 2 in an In Vitro Assay for Graft Rejection, the Mixed Lymphocyte Reaction. Journal of NeuroImmune Pharmacology, 2013, 8, 1239-1250.	2.1	44
1132	Downregulation of cannabinoid receptor 1 from neuropeptide <scp>Y</scp> interneurons in the basal ganglia of patients with Huntington's disease and mouse models. European Journal of Neuroscience, 2013, 37, 429-440.	1.2	46
1133	Cannabinoid receptor 1 promotes hepatic lipid accumulation and lipotoxicity through the induction of SREBP-1c expression in zebrafish. Transgenic Research, 2013, 22, 823-838.	1.3	38
1134	Novel song-stimulated dendritic spine formation and Arc/Arg3.1 expression in zebra finch auditory telencephalon are disrupted by cannabinoid agonism. Brain Research, 2013, 1541, 9-21.	1.1	9
1135	CB2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-Like Phenotype in AÎ²PP/PS1 Mice. Journal of Alzheimer's Disease, 2013, 35, 847-858.	1.2	167
1136	Sphingosine lysolipids in the CNS: Endogenous cannabinoid antagonists or a parallel pain modulatory system?. Life Sciences, 2013, 93, 187-193.	2.0	14
1137	Targeting the cannabinoid system for pain relief?. Acta Anaesthesiologica Taiwanica, 2013, 51, 161-170.	1.0	45

#	Article	IF	Citations
1138	The role of the endocannabinoid system in addictive behavior. Addiction Biology, 2013, 18, 904-907.	1.4	8
1139	Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology, 2013, 73, 388-396.	2.0	111
1140	The role of endocannabinoids in pain modulation. Fundamental and Clinical Pharmacology, 2013, 27, 64-80.	1.0	70
1141	Working memory performance in young adults is associated to the AATn polymorphism of the CNR1 gene. Behavioural Brain Research, 2013, 236, 62-66.	1.2	22
1142	Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB1 receptor antagonists. Journal of Neural Transmission, 2013, 120, 177-186.	1.4	29
1143	A cell population that strongly expresses the CB1 cannabinoid receptor in the ependyma of the rat spinal cord. Journal of Comparative Neurology, 2013, 521, 233-251.	0.9	16
1144	Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054. Pharmacology Biochemistry and Behavior, 2013, 109, 16-22.	1.3	15
1145	Long-term CB1 receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids. Neuropharmacology, 2013, 70, 268-277.	2.0	21
1146	The endocannabinoid system and emotional processing: A pharmacological fMRI study with âˆ†9-tetrahydrocannabinol. European Neuropsychopharmacology, 2013, 23, 1687-1697.	0.3	75
1147	Cannabinoids and glucocorticoids modulate emotional memory after stress. Neuroscience and Biobehavioral Reviews, 2013, 37, 2554-2563.	2.9	55
1148	In vivo SPECT and ex vivo autoradiographic brain imaging of the novel selective CB1 receptor antagonist radioligand [125I]SD7015 in CB1 knock-out and wildtype mouse. Brain Research Bulletin, 2013, 91, 46-51.	1.4	2
1149	Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal. Neuroscience, 2013, 248, 637-654.	1.1	169
1150	Î³-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug and Alcohol Dependence, 2013, 129, 232-239.	1.6	67
1151	Central functional response to the novel peptide cannabinoid, hemopressin. Neuropharmacology, 2013, 71, 27-36.	2.0	35
1152	Palmitoylethanolamide: From endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence. Medical Hypotheses, 2013, 81, 619-622.	0.8	8
1153	Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system?. Life Sciences, 2013, 92, 476-481.	2.0	209
1154	Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or adulthood reverses 3,4 methylenedioxymetamphetamine (MDMA)-induced deficits in recognition memory but not in effort-based decision making. Pharmacology Biochemistry and Behavior, 2013, 106, 91-100.	1.3	14
1155	Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents. Neuroscience, 2013, 247, 294-308.	1.1	49

#	Article	IF	Citations
1156	Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats. Pain, 2013, 154, 576-585.	2.0	38
1157	Bivalent Ligands That Target Î¼ Opioid (MOP) and Cannabinoid1 (CB₁) Receptors Are Potent Analgesics Devoid of Tolerance. Journal of Medicinal Chemistry, 2013, 56, 5505-5513.	2.9	72
1158	Involvement of prelimbic medial prefrontal cortex in panic-like elaborated defensive behaviour and innate fear-induced antinociception elicited by GABAA receptor blockade in the dorsomedial and ventromedial hypothalamic nuclei: role of the endocannabinoid CB1 receptor. International Journal of Neuropsychopharmacology, 2013, 16, 1781-1798.	1.0	41
1159	Endocannabinoids and Obesity. Vitamins and Hormones, 2013, 91, 325-368.	0.7	9
1160	Autocrine Endocannabinoid Signaling through CB₁Receptors Potentiates OX₁Orexin Receptor Signaling. Molecular Pharmacology, 2013, 83, 621-632.	1.0	34
1161	What can we learn about schizophrenia from studying the human model, drugâ€induced psychosis?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 661-670.	1.1	53
1162	Caffeine and Adenosine Receptor Modulation of Cannabinoid Influence Upon Cognitive Function. Journal of Caffeine Research, 2013, 3, 85-95.	1.0	3
1163	Crosstalk between Dopamine D₂ receptors and cannabinoid <scp>CB</scp>₁ receptors regulates <scp>CNR</scp>1 promoter activity via <scp>ERK</scp>1/2 signaling. Journal of Neurochemistry, 2013, 127, 163-176.	2.1	19
1164	Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction. Frontiers in Psychiatry, 2013, 4, 109.	1.3	34
1165	A Review of Magnetic Resonance Spectroscopy Studies in Marijuana using Adolescents and Adults. Journal of Addiction Research & Therapy, 2013, s4, .	0.2	19
1166	New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies. , 0, , .		1
1167	Localization of diacylglycerol lipase alpha and monoacylglycerol lipase during postnatal development of the rat retina. Frontiers in Neuroanatomy, 2014, 8, 150.	0.9	15
1168	Neurochemical Communication: The Case of Endocannabinoids. , 2014, , .		3
1170	Cannabis abuse and dependence. , 0, , 315-329.		0
1171	Neuroinflammation as a possible link between cannabinoids and addiction. Acta Neuropsychiatrica, 2014, 26, 334-346.	1.0	18
1172	Cannabinoid modulation of predator fear: involvement of the dorsolateral periaqueductal gray. International Journal of Neuropsychopharmacology, 2014, 17, 1193-1206.	1.0	16
1173	CB1 cannabinoid receptor in SF1-expressing neurons of the ventromedial hypothalamus determines metabolic responses to diet and leptin. Molecular Metabolism, 2014, 3, 705-716.	3.0	64
1174	The interaction between ghrelin and cannabinoid systems in penicillin-induced epileptiform activity in rats. Neuropeptides, 2014, 48, 345-352.	0.9	14

#	Article	IF	Citations
1175	Inhaling: endocannabinoids and food intake. Nature Neuroscience, 2014, 17, 336-337.	7.1	0
1176	Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid. Journal of Neurophysiology, 2014, 111, 1046-1055.	0.9	24
1177	The cannabinoid receptor 1 and its role in influencing peripheral metabolism. Diabetes, Obesity and Metabolism, 2014, 16, 294-304.	2.2	32
1178	Medical marijuana in neurology. Expert Review of Neurotherapeutics, 2014, 14, 1453-1465.	1.4	34
1179	Interplay between synaptic endocannabinoid signaling and metaplasticity in neuronal circuit function and dysfunction. European Journal of Neuroscience, 2014, 39, 1189-1201.	1.2	27
1180	Elevation of endogenous anandamide impairs LTP, learning, and memory through CB1 receptor signaling in mice. Hippocampus, 2014, 24, 808-818.	0.9	84
1181	Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future. Frontiers in Psychiatry, 2014, 5, 92.	1.3	67
1182	Control of synaptic function by endocannabinoid-mediated retrograde signaling. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2014, 90, 235-250.	1.6	98
1183	Endocannabinoid Signaling and Synaptic Plasticity During Stress. , 2014, , 99-124.		0
1184	Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor. Pharmaceuticals, 2014, 7, 339-352.	1.7	17
1185	Endocannabinoid-Dependent Modulation of Phasic Dopamine Signaling Encodes External and Internal Reward-Predictive Cues. Frontiers in Psychiatry, 2014, 5, 118.	1.3	17
1186	Endocannabinoid system and pain: an introduction. Proceedings of the Nutrition Society, 2014, 73, 106-117.	0.4	43
1187	Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. Pain, 2014, 155, 69-79.	2.0	45
1188	The endocannabinoid system: An emotional buffer in the modulation of memory function. Neurobiology of Learning and Memory, 2014, 112, 30-43.	1.0	119
1189	Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sciences, 2014, 97, 37-44.	2.0	167
1190	Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology, 2014, 76, 416-424.	2.0	128
1191	In vivo characterization of the highly selective monoacylglycerol lipase inhibitor <scp>KML</scp>29: antinociceptive activity without cannabimimetic side effects. British Journal of Pharmacology, 2014, 171, 1392-1407.	2.7	110
1192	Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 175-184.	1.4	62

#	Article	IF	Citations
1193	Cannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: A review. Journal of Advanced Research, 2014, 5, 137-145.	4.4	7
1194	A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. Neuroscience and Biobehavioral Reviews, 2014, 42, 116-131.	2.9	108
1195	Chronic exposure to WIN55,212-2 affects more potently spatial learning and memory in adolescents than in adult rats via a negative action on dorsal hippocampal neurogenesis. Pharmacology Biochemistry and Behavior, 2014, 120, 95-102.	1.3	33
1196	No more pain upon <scp>G</scp>_qâ€proteinâ€coupled receptor activation: role of endocannabinoids. European Journal of Neuroscience, 2014, 39, 467-484.	1.2	14
1197	Involvement of the endocannabinoid system in osteoarthritis pain. European Journal of Neuroscience, 2014, 39, 485-500.	1.2	41
1198	Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or âˆ†9-tetrahydrocannabinol (THC). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 53-69.	2.5	56
1199	Developmental but not adult cannabinoid treatments persistently alter axonal and dendritic morphology within brain regions important for zebra finch vocal learning. Brain Research, 2014, 1558, 57-73.	1.1	5
1200	Blunting of the HPA-axis underlies the lack of preventive efficacy of early post-stressor single-dose Delta-9-tetrahydrocannabinol (THC). Pharmacology Biochemistry and Behavior, 2014, 122, 307-318.	1.3	15
1201	Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine. British Journal of Pharmacology, 2014, 171, 961-972.	2.7	32
1203	Oxidative stress and cannabinoid receptor expression in typeâ€2 diabetic rat pancreas following treatment with Î”⁹â€THC. Cell Biochemistry and Function, 2014, 32, 612-619.	1.4	16
1204	The Endocannabinoid System and the Neuroendocrine Control of Hydromineral Balance. Journal of Neuroendocrinology, 2014, 26, 370-376.	1.2	4
1205	Reâ€definin G A ddi C CH3 T ion: genomics and epigenomics on substance use disorders. Molecular Genetics & Genomic Medicine, 2014, 2, 273-279.	0.6	2
1206	Sex, drugs, and adult neurogenesis: Sexâ€dependent effects of escalating adolescent cannabinoid exposure on adult hippocampal neurogenesis, stress reactivity, and amphetamine sensitization. Hippocampus, 2014, 24, 280-292.	0.9	44
1207	P.1.h.008 A new model of depression-like behaviour in rodents for screening of prospective drugs with antidepressant action. European Neuropsychopharmacology, 2014, 24, S274-S275.	0.3	0
1208	Endocannabinoid signaling and food addiction. Neuroscience and Biobehavioral Reviews, 2014, 47, 203-224.	2.9	104
1209	Impact of Stress on Prefrontal Glutamatergic, Monoaminergic and Cannabinoid Systems. Current Topics in Behavioral Neurosciences, 2014, 18, 45-66.	0.8	6
1210	CP55,940 attenuates spatial memory retrieval in mice. Pharmacological Reports, 2014, 66, 931-936.	1.5	7
1211	Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 564-566.	0.7	187

#	Article	IF	Citations
1212	Mechanisms of Exercise-Induced Hypoalgesia. Journal of Pain, 2014, 15, 1294-1304.	0.7	268
1213	Acute administration of THC impairs spatial but not associative memory function in zebrafish. Psychopharmacology, 2014, 231, 3829-3842.	1.5	31
1214	Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. Psychopharmacology, 2014, 231, 4323-4335.	1.5	44
1215	Endocannabinoids produced upon action potential firing evoke a Clâ˜ current via type-2 cannabinoid receptors in the medial prefrontal cortex. Pflugers Archiv European Journal of Physiology, 2014, 466, 2257-2268.	1.3	14
1217	P.1.h.007 Activation of CB1 cannabinoid receptors in ventromedial hypothalamus reduces the panic-like elaborated escape behaviour. European Neuropsychopharmacology, 2014, 24, S274.	0.3	0
1218	The Role of Omega-3 Fatty Acids in Hippocampal Neurogenesis. , 2014, , 251-263.		0
1219	Brain regional cannabinoid CB1 receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice. European Journal of Pharmaceutical Sciences, 2014, 51, 87-95.	1.9	17
1220	Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats. European Neuropsychopharmacology, 2014, 24, 1037-1045.	0.3	59
1221	Benzophenanthridine alkaloid, piperonyl butoxide and (S)-methoprene action at the cannabinoid-1 receptor (CB1-receptor) pathway of mouse brain: Interference with [3H]CP55940 and [3H]SR141716A binding and modification of WIN55212-2-dependent inhibition of synaptosomal l-glutamate release. European Journal of Pharmacology, 2014, 723, 431-441.	1.7	5
1222	The cannabinoid agonist HU-210: Pseudo-irreversible discriminative stimulus effects in rhesus monkeys. European Journal of Pharmacology, 2014, 727, 35-42.	1.7	15
1223	The inhibitory effect of anandamide on oxytocin and vasopressin secretion from neurohypophysis is mediated by nitric oxide. Regulatory Peptides, 2014, 188, 31-39.	1.9	17
1224	The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology, 2014, 77, 313-324.	2.0	65
1225	Is there a role for palmitoylethanolamide in the treatment of depression?. Medical Hypotheses, 2014, 82, 507-511.	0.8	14
1226	WIN induces apoptotic cell death in human colon cancer cells through a block of autophagic flux dependent on PPARÎ³ down-regulation. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1029-42.	2.2	41
1227	Endocannabinoid contribution to Î”9-tetrahydrocannabinol discrimination in rodents. European Journal of Pharmacology, 2014, 737, 97-105.	1.7	25
1228	Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. Experimental Gerontology, 2014, 55, 134-142.	1.2	16
1229	Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute d-amphetamine. Behavioural Brain Research, 2014, 270, 261-269.	1.2	20
1230	Morphological and behavioral evidence for impaired prefrontal cortical function in female CB1 receptor deficient mice. Behavioural Brain Research, 2014, 271, 106-110.	1.2	15

#	Article	IF	Citations
1231	3D-QSAR/CoMFA-Based Structure-Affinity/Selectivity Relationships of Aminoalkylindoles in the Cannabinoid CB1 and CB2 Receptors. Molecules, 2014, 19, 2842-2861.	1.7	17
1233	Endocannabinoid Signaling in the Stress Response of Male and Female Songbirds. Endocrinology, 2015, 156, 4649-4659.	1.4	6
1235	The role of cannabinoids and leptin in neurological diseases. Acta Neurologica Scandinavica, 2015, 132, 371-380.	1.0	17
1236	Neuropeptide VF Enhances Cannabinoid Agonist WIN55,212-2-Induced Antinociception in Mice. Anesthesia and Analgesia, 2015, 121, 1360-1368.	1.1	11
1237	Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain, 2015, 156, 2001-2012.	2.0	71
1238	Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids Signaling. Brain Sciences, 2015, 5, 456-493.	1.1	40
1239	To Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-Making. Frontiers in Behavioral Neuroscience, 2015, 9, 336.	1.0	13
1240	The Combined Inhibitory Effect of the Adenosine A₁and Cannabinoid CB₁Receptors on cAMP Accumulation in the Hippocampus Is Additive and Independent of A₁Receptor Desensitization. BioMed Research International, 2015, 2015, 1-9.	0.9	10
1241	Intestinal Microbiota as Modulators of the Immune System and Neuroimmune System: Impact on the Host Health and Homeostasis. Journal of Immunology Research, 2015, 2015, 1-14.	0.9	88
1242	The Influence of Synthetic Cannabinoid UR-144 on Human Psychomotor Performanceâ€"A Case Report Demonstrating Road Traffic Risks. Traffic Injury Prevention, 2015, 16, 754-759.	0.6	24
1243	Calcium-dependent inactivation of calcium channels in the medial striatum increases at eye opening. Journal of Neurophysiology, 2015, 113, 2979-2986.	0.9	5
1244	Cannabinoid-Nicotine Interactions. , 2015, , 329-361.		2
1245	Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. Journal of NeuroImmune Pharmacology, 2015, 10, 193-203.	2.1	79
1246	Metabolome disruption of the rat cerebrum induced by the acute toxic effects of the synthetic cannabinoid MAM-2201. Life Sciences, 2015, 137, 49-55.	2.0	31
1247	Behavioral and Neurochemical Changes in Mesostriatal Dopaminergic Regions of the Rat after Chronic Administration of the Cannabinoid Receptor Agonist WIN55,212-2. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	10
1248	A Basal Tone of 2-Arachidonoylglycerol Contributes to Early Oligodendrocyte Progenitor Proliferation by Activating Phosphatidylinositol 3-Kinase (PI3K)/AKT and the Mammalian Target of Rapamycin (MTOR) Pathways. Journal of NeuroImmune Pharmacology, 2015, 10, 309-317.	2.1	36
1249	A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10. Journal of NeuroImmune Pharmacology, 2015, 10, 318-332.	2.1	40
1250	The Role of the Brain's Endocannabinoid System in Pain and Its Modulation by Stress. International Review of Neurobiology, 2015, 125, 203-255.	0.9	33

#	Article	IF	Citations
1251	Evidence for a Role of Adolescent Endocannabinoid Signaling in Regulating HPA Axis Stress Responsivity and Emotional Behavior Development. International Review of Neurobiology, 2015, 125, 49-84.	0.9	14
1252	Endocannabinoid Regulation of Neuroendocrine Systems. International Review of Neurobiology, 2015, 125, 163-201.	0.9	29
1253	Receptome: Interactions between three pain-related receptors or the â€œTriumvirateâ€•of cannabinoid, opioid and TRPV1 receptors. Pharmacological Research, 2015, 102, 254-263.	3.1	24
1254	The cannabinoid system and visual processing: A review on experimental findings and clinical presumptions. European Neuropsychopharmacology, 2015, 25, 100-112.	0.3	51
1255	A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 2015, 162, 153-161.	1.1	200
1256	Cannabinoids and appetite (dys)regulation. , 2015, , 315-339.		2
1257	The role of endocannabinoid function in posttraumatic stress disorder. , 2015, , 247-288.		1
1258	Cannabinoids in Parkinsonâ€™s disease. , 2015, , 35-59.		7
1259	Endocannabinoids and epilepsy. , 2015, , 125-172.		4
1260	Cannabinoids and obsessive-compulsive disorder. , 2015, , 365-387.		2
1261	Acute administration of a cannabinoid CB1 receptor antagonist impairs stress-induced antinociception in fish. Physiology and Behavior, 2015, 142, 37-41.	1.0	10
1262	Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. Scientific Reports, 2015, 5, 7642.	1.6	91
1263	Role of endocannabinoid signalling in the dorsolateral periaqueductal grey in the modulation of distinct panic-like responses. Journal of Psychopharmacology, 2015, 29, 335-343.	2.0	14
1264	The endocannabinoid system within the dorsal lateral geniculate nucleus of the vervet monkey. Neuroscience, 2015, 288, 135-144.	1.1	15
1265	Cannabinoids & Stress: Impact of HU-210 on behavioral tests of anxiety in acutely stressed mice. Behavioural Brain Research, 2015, 284, 225-230.	1.2	10
1266	Activation of type-1 cannabinoid receptor shifts the balance between excitation and inhibition towards excitation in layer II/III pyramidal neurons of the rat prelimbic cortex. Pflugers Archiv European Journal of Physiology, 2015, 467, 1551-1564.	1.3	23
1267	Molecular imaging of levodopa-induced dyskinesias. Cellular and Molecular Life Sciences, 2015, 72, 2107-2117.	2.4	18
1268	Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats. Psychopharmacology, 2015, 232, 1545-1553.	1.5	18

#	Article	IF	Citations
1269	Cannabinoid Receptorâ€“Interacting Protein 1a Modulates CB₁ Receptor Signaling and Regulation. Molecular Pharmacology, 2015, 87, 747-765.	1.0	53
1270	Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Structure and Function, 2015, 220, 2721-2738.	1.2	82
1271	Increased tonic cannabinoid CB1R activity and brain region-specific desensitization of CB1R Gi/o signaling axis in mice with global genetic knockout of monoacylglycerol lipase. European Journal of Pharmaceutical Sciences, 2015, 77, 180-188.	1.9	23
1272	JWH-018 impairs sensorimotor functions in mice. Neuroscience, 2015, 300, 174-188.	1.1	59
1273	The intracerebroventricular injection of rimonabant inhibits systemic lipopolysaccharide-induced lung inflammation. Journal of Neuroimmunology, 2015, 286, 16-24.	1.1	4
1274	Modulatory effects by CB1 receptors on rat spinal locomotor networks after sustained application of agonists or antagonists. Neuroscience, 2015, 303, 16-33.	1.1	7
1275	Part II: Strain- and sex-specific effects of adolescent exposure to THC on adult brain and behaviour: Variants of learning, anxiety and volumetric estimates. Behavioural Brain Research, 2015, 288, 132-152.	1.2	27
1276	Disruption of peri-adolescent endocannabinoid signaling modulates adult neuroendocrine and behavioral responses to stress in male rats. Neuropharmacology, 2015, 99, 89-97.	2.0	21
1277	Endocannabinoid signaling mechanisms in the substantia nigra pars reticulata modulate GABAergic nigrotectal pathways in mice threatened by urutu-cruzeiro venomous pit viper. Neuroscience, 2015, 303, 503-514.	1.1	38
1278	Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?. Neurotherapeutics, 2015, 12, 778-787.	2.1	25
1280	A pivotal role for enhanced brainstem Orexin receptor 1 signaling in the central cannabinoid receptor 1-mediated pressor response in conscious rats. Brain Research, 2015, 1622, 51-63.	1.1	10
1281	Minireview: From the Bench, Toward the Clinic: Therapeutic Opportunities for Cannabinoid Receptor Modulation. Molecular Endocrinology, 2015, 29, 801-813.	3.7	44
1282	Regulation of neuronal communication by G proteinâ€coupled receptors. FEBS Letters, 2015, 589, 1607-1619.	1.3	92
1283	The Role of the Endocannabinoid System in Pain. Handbook of Experimental Pharmacology, 2015, 227, 119-143.	0.9	119
1284	Promising cannabinoid-based therapies for Parkinsonâ€™s disease: motor symptoms to neuroprotection. Molecular Neurodegeneration, 2015, 10, 17.	4.4	90
1286	Endocannabinoids and striatal function. Behavioural Pharmacology, 2015, 26, 59-72.	0.8	35
1287	Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. Journal of Pain, 2015, 16, 616-627.	0.7	164
1288	Paracetamol potentiates the antidepressant-like and anticompulsive-like effects of fluoxetine. Behavioural Pharmacology, 2015, 26, 268-281.	0.8	12

#	Article	IF	Citations
1289	Endocannabinoids and the Endocrine System in Health and Disease. Handbook of Experimental Pharmacology, 2015, 231, 317-339.	0.9	40
1290	Distribution of the Endocannabinoid System in the Central Nervous System. Handbook of Experimental Pharmacology, 2015, 231, 59-93.	0.9	122
1291	Endocannabinoids. Handbook of Experimental Pharmacology, 2015, , .	0.9	19
1292	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. Pharmacological Reviews, 2015, 67, 872-1004.	7.1	125
1293	An endocannabinoid system is present in the mouse olfactory epithelium but does not modulate olfaction. Neuroscience, 2015, 300, 539-553.	1.1	16
1294	Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. Journal of Psychopharmacology, 2015, 29, 1137-1145.	2.0	8
1295	Training-Associated Emotional Arousal Shapes Endocannabinoid Modulation of Spatial Memory Retrieval in Rats. Journal of Neuroscience, 2015, 35, 13962-13974.	1.7	58
1297	Cortical thinness and volume differences associated with marijuana abuse in emerging adults. Drug and Alcohol Dependence, 2015, 155, 275-283.	1.6	44
1298	Endocannabinoid signalling in reward and addiction. Nature Reviews Neuroscience, 2015, 16, 579-594.	4.9	370
1299	Cannabis use in early adolescence: Evidence of amygdala hypersensitivity to signals of threat. Developmental Cognitive Neuroscience, 2015, 16, 63-70.	1.9	54
1300	Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	42
1301	Effects of co-administration of 2-arachidonylglycerol (2-AG) and a selective Âµ-opioid receptor agonist into the nucleus accumbens on high-fat feeding behaviors in the rat. Brain Research, 2015, 1618, 309-315.	1.1	8
1302	Cannabinoid modulation of drug reward and the implications of marijuana legalization. Brain Research, 2015, 1628, 233-243.	1.1	69
1303	Endocannabinoids in Synaptic Plasticity and Neuroprotection. Neuroscientist, 2015, 21, 152-168.	2.6	95
1304	Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Neuropharmacology, 2015, 89, 298-307.	2.0	15
1305	The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. Neuropharmacology, 2015, 96, 105-112.	2.0	27
1306	Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats. Brain Structure and Function, 2016, 221, 407-419.	1.2	25
1307	Cannabis, Endocannabinoid CB1 Receptors, and the Neuropathology of Vision. , 2016, , 738-748.		1

#	Article	IF	Citations
1308	Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats. PLoS ONE, 2016, 11, e0153327.	1.1	71
1309	CB1 Receptor-Mediated Signaling Mechanisms in the Deleterious Effects of Spice Abuse. , 2016, , 760-770.		0
1310	Cannabinoid Agonists. , 2016, , 702-712.		0
1311	On the Role of the Endocannabinoid System in Cocaine Addiction. , 2016, , 48-62.		0
1312	Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease. Neural Plasticity, 2016, 2016, 1-12.	1.0	21
1313	Marijuana Compounds: A Nonconventional Approach to Parkinsonâ€™s Disease Therapy. Parkinson's Disease, 2016, 2016, 1-19.	0.6	17
1314	Cellular Mechanisms of Action of Drug Abuse on Olfactory Neurons. International Journal of Environmental Research and Public Health, 2016, 13, 5.	1.2	9
1315	Endocannabinoid Signaling in the Striatum. Handbook of Behavioral Neuroscience, 2016, 24, 197-215.	0.7	2
1316	The Substantia Nigra Pars Reticulata. Handbook of Behavioral Neuroscience, 2016, , 293-316.	0.7	7
1317	Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants. Frontiers in Neuroscience, 2016, 10, 153.	1.4	148
1318	Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging. Frontiers in Neuroscience, 2016, 10, 350.	1.4	20
1319	Endocannabinoid Signaling in Neural Circuits of the Olfactory and Limbic System. , 2016, , .		1
1320	Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychological Medicine, 2016, 46, 27-45.	2.7	32
1321	Endocannabinoid Signaling and the Hypothalamicâ€Pituitaryâ€Adrenal Axis. , 2016, 7, 1-15.		59
1322	Distinctive effects of eicosapentaenoic and docosahexaenoic acids in regulating neural stem cell fate are mediated via endocannabinoid signalling pathways. Neuropharmacology, 2016, 107, 387-395.	2.0	33
1323	Neural endocannabinoid CB1 receptor expression, social status, and behavior in male European starlings. Brain Research, 2016, 1644, 240-248.	1.1	9
1324	Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicology, 2016, 34, 329-343.	1.4	96
1325	Keep off the grass? Cannabis, cognition and addiction. Nature Reviews Neuroscience, 2016, 17, 293-306.	4.9	315

#	Article	IF	Citations
1326	Driving the need to feed: Insight into the collaborative interaction between ghrelin and endocannabinoid systems in modulating brain reward systems. Neuroscience and Biobehavioral Reviews, 2016, 66, 33-53.	2.9	43
1327	A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntingtonâ€™s disease. Journal of Neurology, 2016, 263, 1390-1400.	1.8	105
1328	Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze. Serbian Journal of Experimental and Clinical Research, 2016, 17, 61-66.	0.2	1
1329	Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors. European Neuropsychopharmacology, 2016, 26, 1590-1600.	0.3	32
1330	Endocannabinoid signaling in social functioning: an RDoC perspective. Translational Psychiatry, 2016, 6, e905-e905.	2.4	47
1331	Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a Â-Opioid Agonist in THC-Treated Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 334-341.	1.3	7
1332	Sex differences in alcohol consumption and alterations in nucleus accumbens endocannabinoid mRNA in alcohol-dependent rats. Neuroscience, 2016, 335, 195-206.	1.1	16
1333	Drug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions. Journal of Neuroscience, 2016, 36, 10230-10238.	1.7	52
1334	Interactive effects of AM251 and baclofen on synaptic plasticity in the rat dentate gyrus. Brain Research, 2016, 1651, 53-60.	1.1	15
1335	Bisphenol A induces hypothalamic down-regulation of the the cannabinoid receptor 1 and anorexigenic effects in male mice. Pharmacological Research, 2016, 113, 376-383.	3.1	24
1336	Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(Î±) and (m)VD-hemopressin(Î±) on memory in novel object and object location recognition tasks in normal young and AÎ² 1â€“42 -treated mice. Neurobiology of Learning and Memory, 2016, 134, 264-274.	1.0	22
1337	Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent. Neuropharmacology, 2016, 110, 407-418.	2.0	25
1338	Developmental regulation of fear learning and anxiety behavior by endocannabinoids. Genes, Brain and Behavior, 2016, 15, 108-124.	1.1	44
1339	Cannabinoidâ€“dopamine interactions in the physiology and physiopathology of the basal ganglia. British Journal of Pharmacology, 2016, 173, 2069-2079.	2.7	56
1340	The role of the cannabinoid receptor in adolescentsâ€² processing of facial expressions. European Journal of Neuroscience, 2016, 43, 98-105.	1.2	5
1341	Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia. Psychiatry Research, 2016, 245, 346-353.	1.7	16
1342	Heterologous regulation of the cannabinoid type 1 receptor by angiotensin <scp>II</scp> in astrocytes of spontaneously hypertensive rats. Journal of Neurochemistry, 2016, 139, 523-536.	2.1	14
1343	Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. Journal of Psychopharmacology, 2016, 30, 1321-1330.	2.0	71

#	Article	IF	Citations
1344	Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on â€œtetradâ€, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology, 2016, 233, 3685-3709.	1.5	63
1345	Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia. Brain Research Bulletin, 2016, 125, 211-217.	1.4	10
1346	Lifetime use of cannabis from longitudinal assessments, cannabinoid receptor (CNR1) variation, and reduced volume of the right anterior cingulate. Psychiatry Research - Neuroimaging, 2016, 255, 24-34.	0.9	24
1347	Stratification of Cannabinoid 1 Receptor (CB₁R) Agonist Efficacy: Manipulation of CB₁R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 329-339.	1.3	32
1348	Cannabis Use and Psychiatric Disorders: Implications for Mental Health and Addiction Treatment. Current Addiction Reports, 2016, 3, 450-462.	1.6	9
1349	Cannabinoid modulation of memory consolidation within the cerebellum. Neurobiology of Learning and Memory, 2016, 136, 228-235.	1.0	18
1350	The Structureâ€“Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspectives in Medicinal Chemistry, 2016, 8, PMC.S32171.	4.6	91
1351	Involvement of opioid system in antidepressantâ€like effect of the cannabinoid <scp>CB</scp>₁ receptor inverse agonist <scp>AM</scp>â€251 after physical stress in mice. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 203-212.	0.9	32
1352	Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. Neuroscience Research, 2016, 110, 49-58.	1.0	20
1353	Role of the endocannabinoid 2-arachidonoylglycerol in aversive responses mediated by the dorsolateral periaqueductal grey. European Neuropsychopharmacology, 2016, 26, 15-22.	0.3	12
1354	Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids. Current Topics in Behavioral Neurosciences, 2016, 39, 153-173.	0.8	14
1355	CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats. Psychopharmacology, 2016, 233, 99-109.	1.5	33
1356	Learning about stress: neural, endocrine and behavioral adaptations. Stress, 2016, 19, 449-475.	0.8	77
1357	The Multiple Waves of Cannabinoid 1 Receptor Signaling. Molecular Pharmacology, 2016, 90, 620-626.	1.0	68
1358	Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology, 2016, 41, 80-102.	2.8	453
1359	The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats. Psychopharmacology, 2016, 233, 1889-1899.	1.5	8
1360	Targeting the endocannabinoid system to treat anxiety-related disorders. Journal of Basic and Clinical Physiology and Pharmacology, 2016, 27, 193-202.	0.7	45
1361	The type-1 cannabinoid receptor modulates the hydroelectrolytic balance independently of the energy homeostasis during salt load. Hormones and Behavior, 2016, 78, 43-51.	1.0	2

#	Article	IF	Citations
1362	Major dorsoventral differences in the modulation of the local CA1 hippocampal network by NMDA, mGlu5, adenosine A2A and cannabinoid CB1 receptors. Neuroscience, 2016, 317, 47-64.	1.1	20
1363	Interplay between serotonin and cannabinoid function in the amygdala in fear conditioning. Brain Research, 2016, 1636, 142-151.	1.1	16
1364	Cannabinoid pharmacology in cancer research: A new hope for cancer patients?. European Journal of Pharmacology, 2016, 775, 1-14.	1.7	62
1365	Social defeat leads to changes in the endocannabinoid system: An overexpression of calreticulin and motor impairment in mice. Behavioural Brain Research, 2016, 303, 34-43.	1.2	15
1366	Delta-9-tetrahydrocannabinol (THC) affects forelimb motor map expression but has little effect on skilled and unskilled behavior. Neuroscience, 2016, 319, 134-145.	1.1	2
1367	Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice. Neuropharmacology, 2016, 101, 460-470.	2.0	12
1368	Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?. Annual Review of Neuroscience, 2016, 39, 1-17.	5.0	53
1369	Effect of JWH-250, JWH-073 and their interaction on â€œtetradâ€, sensorimotor, neurological and neurochemical responses in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 67, 31-50.	2.5	62
1370	Behavioral effects of D3 receptor inhibition and 5-HT4 receptor activation on animals undergoing chronic cannabinoid exposure during adolescence. Metabolic Brain Disease, 2016, 31, 321-327.	1.4	16
1371	Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology, 2016, 233, 1765-1777.	1.5	39
1372	Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug?. Neurotoxicity Research, 2016, 29, 173-196.	1.3	22
1373	Cannabinoids, cannabinoid receptors and tinnitus. Hearing Research, 2016, 332, 210-216.	0.9	18
1374	Roles for the endocannabinoid system in ethanol-motivated behavior. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 65, 330-339.	2.5	58
1375	Cognitive Development, Learning and Drug Use. , 2016, , 13-21.		0
1376	Cannabinoids to treat spinal cord injury. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 190-199.	2.5	20
1377	For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 167-180.	2.5	23
1378	CB1 cannabinoid receptor-mediated anandamide signalling reduces the defensive behaviour evoked through GABAA receptor blockade inÂthe dorsomedial division of the ventromedial hypothalamus. Neuropharmacology, 2017, 113, 156-166.	2.0	35
1379	Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain. Psychopharmacology, 2017, 234, 925-941.	1.5	13

#	Article	IF	Citations
1380	Activation of cannabinoid receptors elicits antidepressant-like effects in a mouse model of social isolation stress. Brain Research Bulletin, 2017, 130, 200-210.	1.4	29
1381	Co-localization of the cannabinoid type 1 receptor with corticotropin-releasing factor-containing afferents in the noradrenergic nucleus locus coeruleus: implications for the cognitive limb of the stress response. Brain Structure and Function, 2017, 222, 3007-3023.	1.2	10
1382	The endocannabinoid system, a novel and key participant in acupunctureâ€™s multiple beneficial effects. Neuroscience and Biobehavioral Reviews, 2017, 77, 340-357.	2.9	15
1384	Cannabinoid CB1 and CB2 receptors differentially modulate L- and T-type Ca 2+ channels in rat retinal ganglion cells. Neuropharmacology, 2017, 124, 143-156.	2.0	27
1385	Imaging in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 233-274.	0.9	21
1386	Mitochondria Bioenergetic and Cognitive Functions: The Cannabinoid Link. Trends in Cell Biology, 2017, 27, 391-392.	3.6	4
1387	Gî±_s signalling of the CB₁ receptor and the influence of receptor number. British Journal of Pharmacology, 2017, 174, 2545-2562.	2.7	75
1388	The cannabinoid system and pain. Neuropharmacology, 2017, 124, 105-120.	2.0	200
1389	Designing microorganisms for heterologous biosynthesis of cannabinoids. FEMS Yeast Research, 2017, 17, .	1.1	54
1390	Pharmacoâ€toxicological effects of the novel thirdâ€generation fluorinate synthetic cannabinoids, <scp>5Fâ€ADBINACA</scp>, <scp>ABâ€FUBINACA</scp>, and <scp>STSâ€135</scp> in mice. In vitro and in vivo studies. Human Psychopharmacology, 2017, 32, e2601.	0.7	40
1391	Structure-Activity Relationship Studies for the Six Regioisomeric 1-n-Pentyl-3-(dimethoxybenzoyl)Indoles at Cannabinoid 1 and 2 Receptors. Journal of Pharmaceutical Sciences and Pharmacology, 2017, 3, 113-123.	0.2	0
1392	Associations of plasma leptin to clinical manifestations in reproductive aged female patients with panic disorder. Psychiatry Research, 2017, 255, 161-166.	1.7	11
1394	Cannabinoid CB₂Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB₁Mechanism that is Independent of CB₂Receptors in Mice. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 296-305.	1.3	31
1395	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology, 2017, 42, 1752-1765.	2.8	190
1396	Neurotransmission systems in Parkinsonâ€™s disease. Reviews in the Neurosciences, 2017, 28, 509-536.	1.4	54
1397	Does exercise increase or decrease pain? Central mechanisms underlying these two phenomena. Journal of Physiology, 2017, 595, 4141-4150.	1.3	227
1398	Interactions of Cannabinoids With Biochemical Substrates. Substance Abuse: Research and Treatment, 2017, 11, 117822181771141.	0.5	6
1399	CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies Î”9-Tetrahydrocannabinol (Î”9-THC)-Induced Aversive Effects in Mice. Scientific Reports, 2017, 7, 12315.	1.6	48

#	Article	IF	Citations
1400	Linking Mitochondria and Synaptic Transmission: The CB1 Receptor. BioEssays, 2017, 39, 1700126.	1.2	36
1401	Systemâ€specific activity in response to Î”⁹â€tetrahydrocannabinol: a functional magnetic resonance imaging study in awake male rats. European Journal of Neuroscience, 2017, 46, 2893-2900.	1.2	7
1402	Role of vasopressin V1a receptor in âˆ†9-tetrahydrocannabinol-induced cataleptic immobilization in mice. Psychopharmacology, 2017, 234, 3475-3483.	1.5	0
1403	Class A GPCRs: Cannabinoid and Opioid Receptor Heteromers. , 2017, , 173-206.		1
1404	Endocannabinoids: Effectors of glucocorticoid signaling. Frontiers in Neuroendocrinology, 2017, 47, 86-108.	2.5	50
1405	Endocannabinoid Modulation of Stimulus-Specific Adaptation in Inferior Colliculus Neurons of the Rat. Scientific Reports, 2017, 7, 6997.	1.6	27
1406	Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events. Advances in Pharmacology, 2017, 80, 135-168.	1.2	40
1407	The effects of enhancing endocannabinoid signaling and blocking corticotrophin releasing factor receptor in the amygdala and hippocampus on the consolidation of a stressful event. European Neuropsychopharmacology, 2017, 27, 913-927.	0.3	24
1408	Chronic FAAH inhibition during nicotine abstinence alters habenular CB1 receptor activity and precipitates depressive-like behaviors. Neuropharmacology, 2017, 113, 252-259.	2.0	12
1409	The Endocannabinoid System and Anxiety. Vitamins and Hormones, 2017, 103, 193-279.	0.7	47
1410	Endocannabinoids in brain plasticity: Cortical maturation, HPA axis function and behavior. Brain Research, 2017, 1654, 157-164.	1.1	67
1411	Neuromodulatory effects of the dorsal hippocampal endocannabinoid system in dextromethorphan/morphine-induced amnesia. European Journal of Pharmacology, 2017, 794, 100-105.	1.7	12
1412	Cannabinoids and Pain: Sites and Mechanisms of Action. Advances in Pharmacology, 2017, 80, 437-475.	1.2	113
1413	The Endocannabinoid System and Human Brain Functions. , 2017, , 115-186.		3
1414	The Role of the Endocannabinoid System in Addiction. , 2017, , 187-236.		2
1415	Acute Î”-9-tetrahydrocannabinol administration in female rats attenuates immediate responses following losses but not multi-trial reinforcement learning from wins. Behavioural Brain Research, 2017, 335, 136-144.	1.2	4
1416	Endocannabinoids: A Promising Impact for Traumatic Brain Injury. Frontiers in Pharmacology, 2017, 8, 69.	1.6	69
1417	Dual Influence of Endocannabinoids on Long-Term Potentiation of Synaptic Transmission. Frontiers in Pharmacology, 2017, 8, 921.	1.6	25

#	Article	IF	Citations
1418	Daytime-Dependent Changes of Cannabinoid Receptor Type 1 and Type 2 Expression in Rat Liver. International Journal of Molecular Sciences, 2017, 18, 1844.	1.8	11
1419	Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology. Biomedicines, 2017, 5, 20.	1.4	88
1420	Binge Alcohol Exposure Transiently Changes the Endocannabinoid System: A Potential Target to Prevent Alcohol-Induced Neurodegeneration. Brain Sciences, 2017, 7, 158.	1.1	7
1421	Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Frontiers in Cellular Neuroscience, 2016, 10, 294.	1.8	219
1422	Regulation of the Hippocampal Network by VGLUT3-Positive CCK- GABAergic Basket Cells. Frontiers in Cellular Neuroscience, 2017, 11, 140.	1.8	48
1423	Glucose-Sensing in the Reward System. Frontiers in Neuroscience, 2017, 11, 716.	1.4	35
1424	Mice expressing a â€œhyper-sensitiveâ€•form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption. PLoS ONE, 2017, 12, e0174826.	1.1	15
1425	Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS ONE, 2017, 12, e0181064.	1.1	57
1426	Cannabinoids in the Cardiovascular System. Advances in Pharmacology, 2017, 80, 329-366.	1.2	33
1427	Cannabis: A Treasure Trove or Pandora's Box?. Mini-Reviews in Medicinal Chemistry, 2017, 17, 1223-1291.	1.1	67
1428	Delta-9-Tetrahydrocannabinol and Catalepsy-Like Immobilization. , 2017, , 326-334.		1
1429	The Role of Î”9-Tetrahydrocannabinol in Diabetes Mellitus. , 2017, , 779-786.		1
1430	New Ethological and Morphological Perspectives for the Investigation of Panicolytic-Like Effects of Cannabidiol. , 2017, , e140-e149.		7
1431	Analytical studies on the 2-naphthoyl substituted-1-n-pentylindoles: Regioisomeric synthetic cannabinoids. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1077-1078, 77-84.	1.2	6
1432	Phasic Dopamine Signals in the Nucleus Accumbens that Cause Active Avoidance Require Endocannabinoid Mobilization in the Midbrain. Current Biology, 2018, 28, 1392-1404.e5.	1.8	64
1433	Biphasic effects of THC in memory and cognition. European Journal of Clinical Investigation, 2018, 48, e12920.	1.7	85
1434	Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry Research, 2018, 262, 46-54.	1.7	20
1435	Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System. ACS Chemical Neuroscience, 2018, 9, 2146-2161.	1.7	79

#	Article	IF	Citations
1436	Effects of repeated longâ€term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders. CNS Neuroscience and Therapeutics, 2018, 24, 528-538.	1.9	11
1437	The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users. Cannabis and Cannabinoid Research, 2018, 3, 1-10.	1.5	17
1438	Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims. Neurotherapeutics, 2018, 15, 796-806.	2.1	44
1439	Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing. Journal of Psychopharmacology, 2018, 32, 283-295.	2.0	54
1440	Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia. Psychopharmacology, 2018, 235, 419-432.	1.5	21
1441	Pharmacological evaluation of new constituents of â€œSpiceâ€• synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicology, 2018, 36, 385-403.	1.4	88
1442	Mitochondrial cAMP-PKA signaling: What do we really know?. Biochimica Et Biophysica Acta - Bioenergetics, 2018, 1859, 868-877.	0.5	101
1443	The effects of antipsychotics on the density of cannabinoid receptors in selected brain regions of male and female adolescent juvenile rats. Psychiatry Research, 2018, 266, 317-322.	1.7	3
1444	CB1 Cannabinoid Receptor Expression in the Barrel Field Region Is Associated with Mouse Learning. ACS Chemical Neuroscience, 2018, 9, 1304-1316.	1.7	1
1445	Fatty-acidâ€“binding protein 5 controls retrograde endocannabinoid signaling at central glutamate synapses. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3482-3487.	3.3	59
1446	Endocannabinoid and Opioid System Interactions in Exercise-Induced Hypoalgesia. Pain Medicine, 2018, 19, 118-123.	0.9	69
1447	The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development. Neuropsychopharmacology, 2018, 43, 21-33.	2.8	139
1448	Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling. Neuropsychopharmacology, 2018, 43, 103-115.	2.8	104
1449	Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity-related Disorders. Chemical Senses, 2018, 43, 3-16.	1.1	19
1450	The role of the endocannabinoid system in the antihyperalgesic effect of Cedrus atlantica essential oil inhalation in a mouse model of postoperative pain. Journal of Ethnopharmacology, 2018, 210, 477-484.	2.0	20
1451	Effects of CB1 receptor antagonism and stress exposures in adolescence on socioemotional behaviours, neuroendocrine stress responses, and expression of relevant proteins in the hippocampus and prefrontal cortex in rats. Neuropharmacology, 2018, 128, 433-447.	2.0	14
1452	Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. Life Sciences, 2018, 192, 115-127.	2.0	56
1453	Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 299-308.	0.5	35

#	Article	IF	Citations
1454	Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression. Frontiers in Molecular Neuroscience, 2018, 11, 424.	1.4	34
1455	Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin. Physiological Reports, 2018, 6, e13927.	0.7	5
1456	Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer. Photodiagnosis and Photodynamic Therapy, 2018, 24, 185-191.	1.3	17
1457	A Predicted Molecular Model for Development of Human Intelligence. Neurochemical Journal, 2018, 12, 210-221.	0.2	0
1458	The Endocannabinoid System in the Vervet Monkey Retina. , 0, , .		2
1460	The endocannabinoid 2-arachidonoylglycerol regulates oligodendrocyte progenitor cell migration. Biochemical Pharmacology, 2018, 157, 180-188.	2.0	25
1461	When orexins meet cannabinoids: Bidirectional functional interactions. Biochemical Pharmacology, 2018, 157, 43-50.	2.0	20
1462	Endocannabinoid CB1 receptors are involved in antiepileptogenic effect of low frequency electrical stimulation during perforant path kindling in rats. Epilepsy Research, 2018, 144, 71-81.	0.8	10
1463	Brain endocannabinoid signaling exhibits remarkable complexity. Brain Research Bulletin, 2018, 142, 33-46.	1.4	8
1464	Loren Parsons' contribution to addiction neurobiology. Addiction Biology, 2018, 23, 1207-1222.	1.4	6
1465	Oximes short-acting CB1 receptor agonists. Bioorganic and Medicinal Chemistry, 2018, 26, 4963-4970.	1.4	9
1466	Endocannabinoid system, stress and HPA axis. European Journal of Pharmacology, 2018, 834, 230-239.	1.7	113
1467	Selective effects of Î”9-tetrahydrocannabinol on medium spiny neurons in the striatum. PLoS ONE, 2018, 13, e0200950.	1.1	13
1468	European Pain Federation (<scp>EFIC</scp>) position paper on appropriate use of cannabisâ€based medicines and medical cannabis for chronic pain management. European Journal of Pain, 2018, 22, 1547-1564.	1.4	149
1469	Electroacupuncture Potentiates Cannabinoid Receptor-Mediated Descending Inhibitory Control in a Mouse Model of Knee Osteoarthritis. Frontiers in Molecular Neuroscience, 2018, 11, 112.	1.4	41
1470	The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. Handbook of Experimental Pharmacology, 2018, 252, 165-190.	0.9	73
1471	The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochemical Pharmacology, 2018, 157, 97-107.	2.0	53
1472	Effects of Cocaine Self-Administration and Its Extinction on the Rat Brain Cannabinoid CB1 and CB2 Receptors. Neurotoxicity Research, 2018, 34, 547-558.	1.3	23

#	Article	IF	Citations
1473	Acute foot-shock stress decreased seizure susceptibility against pentylenetetrazole-induced seizures in mice: Interaction between endogenous opioids and cannabinoids. Epilepsy and Behavior, 2018, 87, 25-31.	0.9	6
1474	Overlapping Distribution of Orexin and Endocannabinoid Receptors and Their Functional Interaction in the Brain of Adult Zebrafish. Frontiers in Neuroanatomy, 2018, 12, 62.	0.9	23
1475	Cannabinoid disruption of learning mechanisms involved in reward processing. Learning and Memory, 2018, 25, 435-445.	0.5	12
1476	Cannabinoids in Dystonias. , 0, , 420-424.		0
1477	The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra. PLoS ONE, 2018, 13, e0191436.	1.1	62
1478	Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells. British Journal of Pharmacology, 2019, 176, 1361-1369.	2.7	32
1479	The prefrontal cortical endocannabinoid system modulates fearâ€“pain interactions in a subregionâ€specific manner. British Journal of Pharmacology, 2019, 176, 1492-1505.	2.7	17
1480	The Acute Activation of the CB1 Receptor in the Hippocampus Decreases Neurotoxicity and Prevents Spatial Memory Impairment in Rats Lesioned with Î²-Amyloid 25â€“35. Neuroscience, 2019, 416, 239-254.	1.1	15
1482	The novel cannabinoid CB 1 receptor agonist AM11101 increases food intake in female rats. British Journal of Pharmacology, 2019, 176, 3972-3982.	2.7	4
1483	Characterization of cerebral cortical endocannabinoid levels in a rat inguinal surgery model using liquid chromatographyâ€“tandem mass spectrometry (LCâ€“MS/MS). Irish Journal of Psychological Medicine, 2019, , 1-10.	0.7	1
1484	Distinct functions of endogenous cannabinoid system in alcohol abuse disorders. British Journal of Pharmacology, 2019, 176, 3085-3109.	2.7	27
1485	Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules, 2019, 24, 3709.	1.7	16
1486	Endocannabinoids and Fear-Related Behavior in Mice Selectively Bred for High or Low Alcohol Preference. Brain Sciences, 2019, 9, 254.	1.1	6
1487	Cannabidiol as a potential treatment for psychosis. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531988191.	1.2	74
1488	Endocannabinoids Interact With the Dopaminergic System to Increase Sexual Motivation: Lessons From the Sexual Satiety Phenomenon. Frontiers in Behavioral Neuroscience, 2019, 13, 184.	1.0	16
1489	Experience during adolescence shapes brain development: From synapses and networks to normal and pathological behavior. Neurotoxicology and Teratology, 2019, 76, 106834.	1.2	66
1490	Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder. Brain Research, 2019, 1724, 146467.	1.1	12
1491	Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology. Bioorganic and Medicinal Chemistry, 2019, 27, 115096.	1.4	9

#	Article	IF	Citations
1492	Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. Cancers, 2019, 11, 129.	1.7	26
1493	Dark Classics in Chemical Neuroscience: Î”⁹-Tetrahydrocannabinol. ACS Chemical Neuroscience, 2019, 10, 2160-2175.	1.7	55
1494	Blockade of Serotonin 2C Receptors with SB-242084 Moderates Reduced Locomotor Activity and Rearing by Cannabinoid 1 Receptor Antagonist AM-251. Pharmacology, 2019, 103, 151-158.	0.9	6
1495	Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks. Neuropharmacology, 2019, 148, 284-290.	2.0	11
1496	Potential Mechanisms Underlying the Deleterious Effects of Synthetic Cannabinoids Found in Spice/K2 Products. Brain Sciences, 2019, 9, 14.	1.1	24
1497	Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis. International Journal of Molecular Sciences, 2019, 20, 2516.	1.8	45
1498	Cannabinoid receptor-mediated modulation of inhibitory inputs to mitral cells in the main olfactory bulb. Journal of Neurophysiology, 2019, 122, 749-759.	0.9	11
1499	Opioidâ€sparing effects of cannabinoids on morphine analgesia: participation of CB₁ and CB₂ receptors. British Journal of Pharmacology, 2019, 176, 3378-3389.	2.7	16
1500	Training for Change. , 2019, , .		8
1501	Endocannabinoids, stress signaling, and the locus coeruleus-norepinephrine system. Neurobiology of Stress, 2019, 11, 100176.	1.9	20
1503	Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain. Drugs, 2019, 79, 969-995.	4.9	49
1504	Bioactive Lipids and the Gut-Brain Axis: Diet as a Modulator of Bioactivity and Diversity of Lipids in the Brain. Advances in Experimental Medicine and Biology, 2019, 1127, 147-168.	0.8	1
1505	Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System Alignment. Frontiers in Endocrinology, 2019, 10, 311.	1.5	10
1506	Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit. Neuropharmacology, 2019, 155, 44-53.	2.0	15
1507	Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome. Toxins, 2019, 11, 275.	1.5	25
1508	Ultrastructural localization of cannabinoid CB1 and mGluR5 receptors in the prefrontal cortex and amygdala. Journal of Comparative Neurology, 2019, 527, 2730-2741.	0.9	22
1509	Cytotoxicity of the synthetic cannabinoids 5C-AKB48, 5F-MDMB-PINACA, ADB-CHMINACA, MDMB-CHMICA and NM-2201 in A549 and TR146 cell lines. Forensic Toxicology, 2019, 37, 398-411.	1.4	2
1510	Modulatory effects of cannabinoids on brain neurotransmission. European Journal of Neuroscience, 2019, 50, 2322-2345.	1.2	64

#	Article	IF	Citations
1511	Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology. Molecules, 2019, 24, 1350.	1.7	28
1512	Aging circadian rhythms and cannabinoids. Neurobiology of Aging, 2019, 79, 110-118.	1.5	28
1513	Are periaqueductal gray and dorsal raphe the foundation of appetitive and aversive control? A comprehensive review. Progress in Neurobiology, 2019, 177, 33-72.	2.8	90
1514	Evidence for the involvement of opioid and cannabinoid systems in the peripheral antinociception mediated by resveratrol. Toxicology and Applied Pharmacology, 2019, 369, 30-38.	1.3	9
1515	Scoring Functions and Modeling of Structure-Activity Relationships for Cannabinoid Receptors. International Journal of Online and Biomedical Engineering, 2019, 15, 139.	0.9	3
1516	Exposure to tobacco smoke during the early postnatal period modifies receptors and enzymes of the endocannabinoid system in the brainstem and striatum in mice. Toxicology Letters, 2019, 302, 35-41.	0.4	12
1517	Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies. Psychopharmacology, 2019, 236, 201-226.	1.5	42
1518	Sex, THC, and hormones: Effects on density and sensitivity of CB1 cannabinoid receptors in rats. Drug and Alcohol Dependence, 2019, 194, 20-27.	1.6	50
1519	The Endogenous Cannabinoid System: A Cadre of Potential Therapeutic Targets. , 2019, , 21-29.		2
1520	Cannabinoid-induced lower lip retraction in rats. Psychopharmacology, 2019, 236, 1199-1206.	1.5	3
1521	Gene expression signature in brain regions exposed to long-term psychosocial stress following acute challenge with cannabinoid drugs. Psychoneuroendocrinology, 2019, 102, 1-8.	1.3	8
1522	Cannabinoid drugs: will they relieve or exacerbate tinnitus?. Current Opinion in Neurology, 2019, 32, 131-136.	1.8	15
1523	Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids. Pharmacological Research, 2019, 141, 291-297.	3.1	26
1524	Biâ€directional modulation of food habit expression by the endocannabinoid system. European Journal of Neuroscience, 2019, 49, 1610-1622.	1.2	12
1525	The neuropsychopharmacology of cannabis: A review of human imaging studies. , 2019, 195, 132-161.		165
1526	Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Molecular Pharmacology, 2019, 95, 155-168.	1.0	42
1527	Early life stress alters the developmental trajectory of corticolimbic endocannabinoid signaling in male rats. Neuropharmacology, 2019, 146, 154-162.	2.0	39
1528	Single and combined effects of plantâ€derived and synthetic cannabinoids on cognition and cannabinoidâ€associated withdrawal signs in mice. British Journal of Pharmacology, 2019, 176, 1552-1567.	2.7	18

#	Article	IF	Citations
1529	Endocannabinoid contributions to alcohol habits and motivation: Relevance to treatment. Addiction Biology, 2020, 25, e12768.	1.4	19
1530	Cannabinoid agonist administration within the cerebellar cortex impairs motor learning. Neurobiology of Learning and Memory, 2020, 170, 106896.	1.0	8
1531	Combined Loss of Ghrelin Receptor and Cannabinoid CB1 Receptor in Mice Decreases Survival but does not Additively Reduce Body Weight or Eating. Neuroscience, 2020, 447, 53-62.	1.1	3
1532	Cannabis in the Treatment of Traumatic Brain Injury: A Primer for Clinicians. Canadian Journal of Neurological Sciences, 2020, 47, 11-17.	0.3	11
1533	Intracerebellar cannabinoid administration impairs delay but not trace eyeblink conditioning. Behavioural Brain Research, 2020, 378, 112258.	1.2	5
1534	Cannabis and Epilepsy. Journal of Dual Diagnosis, 2020, 16, 75-82.	0.7	5
1535	The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice. Psychopharmacology, 2020, 237, 385-394.	1.5	27
1536	Endocannabinoid signaling and stress resilience. , 2020, , 349-362.		0
1537	Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinsonâ€™s Disease and l-DOPA-Induced Dyskinesia. Neurotoxicity Research, 2020, 37, 12-29.	1.3	33
1538	The novel MAGL inhibitor MJN110 enhances responding to reward-predictive incentive cues by activation of CB1 receptors. Neuropharmacology, 2020, 162, 107814.	2.0	17
1539	Remote CB1 receptor antagonist administration reveals multiple sites of tonic and phasic endocannabinoid neuroendocrine regulation. Psychoneuroendocrinology, 2020, 113, 104549.	1.3	9
1540	The globus pallidus as a target for neuropeptides and endocannabinoids participating in central activities. Peptides, 2020, 124, 170210.	1.2	9
1541	Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 339-353.	1.3	15
1542	Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases. International Journal of Molecular Sciences, 2020, 21, 7693.	1.8	70
1543	CB1-cannabinoid-, TRPV1-vanilloid- and NMDA-glutamatergic-receptor-signalling systems interact in the prelimbic cerebral cortex to control neuropathic pain symptoms. Brain Research Bulletin, 2020, 165, 118-128.	1.4	16
1544	Developmentally Transient CB1Rs on Cerebellar Afferents Suppress Afferent Input, Downstream Synaptic Excitation, and Signaling to Migrating Neurons. Journal of Neuroscience, 2020, 40, 6133-6145.	1.7	7
1545	Sexual dimorphic distribution of cannabinoid 1 receptor mRNA in adult C57BL/6J mice. Journal of Comparative Neurology, 2020, 528, 1986-1999.	0.9	28
1546	Does cannabis alleviate tinnitus? A review of the current literature. Laryngoscope Investigative Otolaryngology, 2020, 5, 1147-1155.	0.6	9

#	Article	IF	Citations
1547	Cannabinoids, Inner Ear, Hearing, and Tinnitus: A Neuroimmunological Perspective. Frontiers in Neurology, 2020, 11, 505995.	1.1	9
1548	Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimerâ€™s Disease in a Preclinical Model: A Therapeutic Opportunity. Biology, 2020, 9, 377.	1.3	21
1549	Highly Efficient Separation of Methylated Peptides Utilizing Selective Complexation between Lysine and 18-Crown-6. Analytical Chemistry, 2020, 92, 15663-15670.	3.2	5
1550	Astroglia-specific contributions to the regulation of synapses, cognition and behaviour. Neuroscience and Biobehavioral Reviews, 2020, 118, 331-357.	2.9	70
1551	Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy. Pharmaceuticals, 2020, 13, 174.	1.7	32
1552	Chronic Use of Synthetic Cannabinoids Is Associated With Impairment in Working Memory and Mental Flexibility. Frontiers in Psychiatry, 2020, 11, 602.	1.3	17
1553	Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell. Pharmacology Biochemistry and Behavior, 2020, 197, 173002.	1.3	2
1554	Neural and Behavioral Correlates Associated with Adolescent Marijuana Use. Current Addiction Reports, 2020, 7, 475-485.	1.6	0
1555	Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinsonâ€™s Disease: A Perspective on Associated Therapeutic Interventions. International Journal of Molecular Sciences, 2020, 21, 6235.	1.8	22
1556	Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments. Journal of Neuroscience Research, 2020, 98, 2496-2509.	1.3	11
1557	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. Molecules, 2020, 25, 4036.	1.7	52
1558	THC Regulates Tearing via Cannabinoid CB1 Receptors. , 2020, 61, 48.		10
1559	Druggable Targets in Endocannabinoid Signaling. Advances in Experimental Medicine and Biology, 2020, 1274, 177-201.	0.8	13
1560	The naked mole-rat has a functional purinergic pain pathway despite having a non-functional peptidergic pain pathway. Neurobiology of Pain (Cambridge, Mass), 2020, 8, 100047.	1.0	5
1561	Neural substrates underlying the negative impact of cannabinoid exposure during adolescence. Pharmacology Biochemistry and Behavior, 2020, 195, 172965.	1.3	3
1562	Endocannabinoid neuromodulation in the neostriatum decreases the GABAergic striato-nigral disinhibitory function and increases the nigro-collicular inhibitory pathway activity. Journal of Neural Transmission, 2020, 127, 1199-1208.	1.4	3
1563	The Role of the Cannabinoid System in Pain Control: Basic and Clinical Implications. Current Pain and Headache Reports, 2020, 24, 35.	1.3	9
1564	NADPH Oxidase Inhibition in Fibrotic Pathologies. Antioxidants and Redox Signaling, 2020, 33, 455-479.	2.5	20

#	Article	IF	Citations
1565	Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R). Frontiers in Molecular Neuroscience, 2020, 13, 108.	1.4	22
1566	Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models. Neuroscience and Biobehavioral Reviews, 2020, 116, 202-220.	2.9	11
1567	Effect of cannabinoid-serotonin interactions in the regulation of neuropeptide Y1 receptors expression in rats: the role of CB1 and 5-HT2C receptor. Comparative Clinical Pathology, 2020, 29, 561-571.	0.3	2
1568	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinsonâ€™s Disease. Molecules, 2020, 25, 453.	1.7	30
1569	The Influence of Anandamide on the Anterior Pituitary Hormone Secretion in Ewesâ€”Ex Vivo Study. Animals, 2020, 10, 706.	1.0	2
1570	Cannabinoid Control of Olfactory Processes: The Where Matters. Genes, 2020, 11, 431.	1.0	11
1571	Cannabinoids as therapeutics for PTSD. , 2020, 211, 107551.		32
1572	The interaction between cannabis use and a CB1-related polygenic co-expression index modulates dorsolateral prefrontal activity during working memory processing. Brain Imaging and Behavior, 2021, 15, 288-299.	1.1	11
1573	Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110118.	2.5	36
1574	Aerobic exercise reduces anxiety and fear ratings to threat and increases circulating endocannabinoids in women with and without PTSD. Mental Health and Physical Activity, 2021, 20, 100366.	0.9	14
1575	Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology, 2021, 238, 9-28.	1.5	129
1576	Cannabinoids: A New Perspective on Epileptogenesis and Seizure Treatment in Early Life in Basic and Clinical Studies. Frontiers in Behavioral Neuroscience, 2020, 14, 610484.	1.0	6
1577	Opioid-sparing effects of cannabinoids: Myth or reality?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110065.	2.5	12
1578	The endocannabinoid system in humans: significant associations between anandamide, brain function during reward feedback and a personality measure of reward dependence. Neuropsychopharmacology, 2021, 46, 1020-1027.	2.8	5
1579	Control of synaptic transmission and neuronal excitability in the parabrachial nucleus. Neurobiology of Pain (Cambridge, Mass), 2021, 9, 100057.	1.0	12
1580	Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues. Advances in Experimental Medicine and Biology, 2021, 1297, 43-64.	0.8	1
1581	Pipette tip microâ€solid phase extraction (octylâ€functionalized hybrid silica monolith) and ultraâ€highâ€performance liquid chromatographyâ€tandem mass spectrometry to determine cannabidiol and tetrahydrocannabinol in plasma samples. Journal of Separation Science, 2021, 44, 1621-1632.	1.3	9
1582	Circadian rhythms and substance use disorders: A bidirectional relationship. Pharmacology Biochemistry and Behavior, 2021, 201, 173105.	1.3	32

#	Article	IF	Citations
1583	The endocannabinoid system and drug-associated contextual memories. Behavioural Pharmacology, 2022, 33, 90-104.	0.8	6
1584	Inhibition of Fatty Acid Amide Hydrolase (FAAH) During Adolescence and Exposure to Early Life Stress may Exacerbate Depression-like Behaviors in Male and Female Rats. Neuroscience, 2021, 455, 89-106.	1.1	13
1585	A review on the syntheses of Dronabinol and Epidiolex as classical cannabinoids with various biological activities including those against SARS-COV2. Journal of the Iranian Chemical Society, 2021, 18, 2517-2534.	1.2	5
1586	Cannabinoids in Audiogenic Seizures: From Neuronal Networks to Future Perspectives for Epilepsy Treatment. Frontiers in Behavioral Neuroscience, 2021, 15, 611902.	1.0	9
1587	Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 2021, 7, 16.	18.1	179
1588	The modulation of striatonigral and nigrotectal pathways by CB1 signalling in the substantia nigra pars reticulata regulates panic elicited in mice by urutu-cruzeiro lancehead pit vipers. Behavioural Brain Research, 2021, 401, 112996.	1.2	13
1589	Endocannabinoid system in trauma and psychosis: distant guardian of mental stability. Reviews in the Neurosciences, 2021, 32, 707-722.	1.4	2
1590	Distribution of the Cannabinoid Receptor Type 1 in the Brain of the Genetically Audiogenic Seizure-Prone Hamster GASH/Sal. Frontiers in Behavioral Neuroscience, 2021, 15, 613798.	1.0	8
1591	Activation of astroglial CB1R mediates cerebral ischemic tolerance induced by electroacupuncture. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2295-2310.	2.4	19
1592	Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain, 2021, 162, S5-S25.	2.0	92
1593	The Endogenous Cannabinoid and the Nitricoxidergic Systems Differently Influence Heat and Cold Stress-Induced Analgesia. Acta Medica Bulgarica, 2021, 48, 34-39.	0.0	0
1595	A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis. Translational Psychiatry, 2021, 11, 217.	2.4	12
1596	Inhaled Cannabis Suppresses Chemotherapy-Induced Neuropathic Nociception by Decoupling the Raphe Nucleus: A Functional Imaging Study in Rats. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 479-489.	1.1	11
1597	In it together? The case for endocannabinoidâ€“noradrenergic interactions in fear extinction. European Journal of Neuroscience, 2022, 55, 952-970.	1.2	14
1598	The endocannabinoid system, cannabis, and cannabidiol: Implications in urology and men's health. Current Urology, 2021, 15, 95-100.	0.4	8
1599	Cannabinoid Signaling in Auditory Function and Development. Frontiers in Molecular Neuroscience, 2021, 14, 678510.	1.4	6
1600	Mechanisms of endocannabinoid transport in the brain. British Journal of Pharmacology, 2022, 179, 4300-4310.	2.7	23
1601	Phytocannabinoids Biosynthesis in Angiosperms, Fungi, and Liverworts and Their Versatile Role. Plants, 2021, 10, 1307.	1.6	11

#	Article	IF	Citations
1602	Zerumbone Ameliorates Neuropathic Pain Symptoms via Cannabinoid and PPAR Receptors Using In Vivo and In Silico Models. Molecules, 2021, 26, 3849.	1.7	11
1603	Cannabinoid receptors distribution in mouse cortical plasma membrane compartments. Molecular Brain, 2021, 14, 89.	1.3	8
1604	CB1R activation in nucleus accumbens core promotes stress-induced reinstatement of cocaine seeking by elevating extracellular glutamate in a drug-paired context. Scientific Reports, 2021, 11, 12964.	1.6	7
1605	Cannabinoids Regulate Sensory Processing in Early Olfactory and Visual Neural Circuits. Frontiers in Neural Circuits, 2021, 15, 662349.	1.4	7
1606	Lifestyle Interventions Improving Cannabinoid Tone During COVID-19 Lockdowns May Enhance Compliance With Preventive Regulations and Decrease Psychophysical Health Complications. Frontiers in Psychiatry, 2021, 12, 565633.	1.3	4
1607	Principles of odor coding in vertebrates and artificial chemosensory systems. Physiological Reviews, 2022, 102, 61-154.	13.1	34
1608	Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats. Behavioural Brain Research, 2021, 410, 113342.	1.2	6
1609	The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics. Revista Brasileira De Psiquiatria, 2022, 44, 81-93.	0.9	2
1610	Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry. , 0, , .		3
1611	Marijuana Use during Pregnancy and Lactation and Long-term Outcomes. NeoReviews, 2021, 22, e521-e530.	0.4	2
1612	Gamma-Aminobutyric Acid (GABA) and the Endocannabinoids: Understanding the Risks and Opportunities. , 0, , .		1
1613	Central administration of endocannabinoids exerts bimodal effects in food intake of rainbow trout. Hormones and Behavior, 2021, 134, 105021.	1.0	7
1614	HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Cannabinoid (Î”9-Tetrahydrocannabinol)-Induced Deficits. International Journal of Neuropsychopharmacology, 2021, 24, 894-906.	1.0	6
1615	Neuronal Dystroglycan regulates postnatal development of CCK/cannabinoid receptor-1 interneurons. Neural Development, 2021, 16, 4.	1.1	13
1616	A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain, 2022, 163, 834-851.	2.0	17
1617	Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology, 2021, 195, 108626.	2.0	34
1618	New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of typeâ€1 cannabinoid receptor (CB1R) activity and function. Journal of Neuroendocrinology, 2022, 34, e13034.	1.2	13
1619	The CB2 cannabinoid receptor as a therapeutic target in the central nervous system. Expert Opinion on Therapeutic Targets, 2021, 25, 659-676.	1.5	11

#	Article	IF	Citations
1620	Design and Synthesis of Highly Potent and Specific ABHD6 Inhibitors. ChemMedChem, 2021, , .	1.6	3
1621	Effect of dexamethasone on gene expression of cannabinoid receptor type 1 and adenosine monophosphate-activated protein kinase in the hypothalamus of broilers (Gallus domesticus). Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2021, 260, 111018.	0.8	0
1622	Maternal omega-3 intake differentially affects the endocannabinoid system in the progeny`s neocortex and hippocampus: Impact on synaptic markers. Journal of Nutritional Biochemistry, 2021, 96, 108782.	1.9	5
1623	A review of the effects of acute and chronic cannabinoid exposure on the stress response. Frontiers in Neuroendocrinology, 2021, 63, 100945.	2.5	6
1624	Endocannabinoid system contributions to sex-specific adolescent neurodevelopment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110438.	2.5	7
1625	Modulation of Noradrenergic and Serotonergic Systems by Cannabinoids: Electrophysiological, Neurochemical and Behavioral Evidence. Advances in Experimental Medicine and Biology, 2021, 1297, 111-132.	0.8	7
1627	Automated GMP production and longâ€term experience in radiosynthesis of CB₁ tracer [¹⁸F]FMPEPâ€d₂. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 408-418.	0.5	6
1628	Role of the endocannabinoid system in learning and memory. , 2005, , 111-140.		5
1629	Anatomical Distribution of Receptors, Ligands and Enzymes in the Brain and in the Spinal Cord: Circuitries and Neurochemistry. , 2008, , 161-201.		46
1630	The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia. , 2008, , 423-483.		14
1632	Cannabinoid Modulation of Dopaminergic Circuits in Neurodegenerative and Neuropsychiatric Disorders. , 2013, , 73-101.		1
1634	Endocannabinoid-Mediated Modulation of Excitatory and Inhibitory Synaptic Transmission. , 2003, , 99-109.		2
1635	A Novel Neuromodulator in Basal Ganglia. Advances in Behavioral Biology, 2002, , 661-673.	0.2	1
1636	Pharmacology of Cannabis. , 1998, , 113-129.		3
1637	Cannabinoid-Alcohol Interactions. , 2015, , 363-391.		3
1638	Dependence, Tolerance, and Alteration in Gene Expression. , 1999, , 207-211.		1
1639	Cannabinoid Geometry and Biological Activity. , 1999, , 65-90.		9
1640	Pharmacology of Cannabinoids. , 2007, , 97-123.		4

#	Article	IF	Citations
1641	Neuromolecular Mechanisms of Cannabis Action. Advances in Experimental Medicine and Biology, 2021, 1264, 15-28.	0.8	4
1642	Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models. Advances in Experimental Medicine and Biology, 2021, 1264, 47-65.	0.8	7
1643	Endocannabinoid Signaling in Reward and Addiction: From Homeostasis to Pathology. , 2017, , 257-318.		3
1644	The Endocannabinoid System in Prefrontal Synaptopathies. , 2017, , 171-210.		10
1645	Cannabinoids and Mitochondria. , 2017, , 211-235.		3
1646	Cannabinoids and Pain. , 2007, , 265-306.		55
1647	Integration of Endocannabinoid Signaling into the Neural Network Regulating Stress-Induced Activation of the Hypothalamicâ€“Pituitaryâ€“Adrenal Axis. Current Topics in Behavioral Neurosciences, 2009, 1, 289-306.	0.8	26
1648	Endocannabinoid Receptor Pharmacology. Current Topics in Behavioral Neurosciences, 2009, 1, 37-63.	0.8	34
1649	Endocannabinoid Receptors: CNS Localization of the CB1 Cannabinoid Receptor. Current Topics in Behavioral Neurosciences, 2009, 1, 65-86.	0.8	26
1650	Endocannabinoid Modulation in the Olfactory Epithelium. Results and Problems in Cell Differentiation, 2011, 52, 139-145.	0.2	21
1651	PET Imaging of Endocannabinoid System. , 2014, , 249-319.		6
1652	Marihuana. Handbook of Experimental Pharmacology, 1996, , 83-158.	0.9	14
1653	Prenatal Exposure to Marihuana and Tobacco During Infancy, Early and Middle Childhood: Effects and an Attempt at Synthesis. Archives of Toxicology Supplement, 1995, 17, 233-260.	0.7	54
1654	Pharmacology of Endocannabinoids and Their Receptors. , 2020, , 415-445.		4
1655	The Brainstem and Nociceptive Modulation. , 2020, , 249-271.		4
1657	Estrogen improves response accuracy and attenuates the disruptive effects of Î”â¹-THC in ovariectomized rats responding under a multiple schedule of repeated acquisition and performance.. Behavioral Neuroscience, 2002, 116, 989-998.	0.6	32
1658	Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: A meta-analysis.. Experimental and Clinical Psychopharmacology, 2020, 28, 471-494.	1.3	48
1659	Ã‰tude des cinÃ©tiques sanguines et cÃ©rÃ©brales duÎ”9-tÃ©trahydrocannabinol, de ses mÃ©tabolites, du cannabidiol et du cannabinol chez la souris. Application Ã lâ€™homme. Toxicologie Analytique Et Clinique, 2011, 23, 193-204.	0.1	2

#	Article	IF	Citations
1660	Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation. Expert Opinion on Drug Discovery, 2020, 15, 1065-1080.	2.5	9
1661	Cannabis: pharmacology and toxicology in animals and humans. Addiction, 1996, 91, 1585-1614.	1.7	314
1662	Control of Ca(2+) influx by cannabinoid and metabotropic glutamate receptors in rat cerebellar cortex requires K(+) channels. Journal of Physiology, 2001, 537, 793-800.	1.3	29
1663	Identification of Endocannabinoids and Cannabinoid CB₁ Receptor mRNA in the Pituitary Gland. Neuroendocrinology, 1999, 70, 137-145.	1.2	78
1664	Contribution of Pharmacology to Development of Monoaminergic Hypotheses of Depression. , 2011, , 152-175.		2
1665	Neuroendocrinology of Hydromineral Homeostasis. Frontiers in Neuroscience, 2013, , 1-30.	0.0	1
1666	Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development (Cambridge), 1998, 125, 3179-3188.	1.2	148
1667	Cannabinoid receptor type-1: breaking the dogmas. F1000Research, 2016, 5, 990.	0.8	52
1668	Cannabinoids and Feeding: The Role of the Endogenous Cannabinoid System as a Trigger for Newborn Suckling. Journal of Cannabis Therapeutics, 2002, 2, 51-62.	1.2	21
1669	GABAergic and Cortical and Subcortical Glutamatergic Axon Terminals Contain CB1 Cannabinoid Receptors in the Ventromedial Nucleus of the Hypothalamus. PLoS ONE, 2011, 6, e26167.	1.1	19
1670	Differences in the Endocannabinoid System of Sperm from Fertile and Infertile Men. PLoS ONE, 2012, 7, e47704.	1.1	68
1671	The Natural Product Magnolol as a Lead Structure for the Development of Potent Cannabinoid Receptor Agonists. PLoS ONE, 2013, 8, e77739.	1.1	32
1672	The endocannabinoid system: critical for the neurotrophic action of psychotropic drugs. Biomedical Reviews, 2014, 21, 31.	0.6	7
1673	Components of Endocannabinoid Signaling System Are Expressed in the Perinatal Mouse Cerebellum and Required for Its Normal Development. ENeuro, 2020, 7, ENEURO.0471-19.2020.	0.9	11
1674	Presynaptically Located CB1 Cannabinoid Receptors Regulate GABA Release from Axon Terminals of Specific Hippocampal Interneurons. Journal of Neuroscience, 1999, 19, 4544-4558.	1.7	1,030
1675	Marijuana and Medicine. , 1999, , .		21
1677	Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimerâ€™s Disease and Less Well-Known Diseases. Current Medicinal Chemistry, 2019, 26, 3300-3340.	1.2	13
1678	Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness. Current Pharmaceutical Design, 2014, 20, 3795-3811.	0.9	58

#	Article	IF	Citations
1679	Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals. Current Pharmaceutical Design, 2014, 20, 2072-2088.	0.9	56
1680	Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies. Current Pharmaceutical Design, 2014, 20, 2114-2125.	0.9	68
1681	Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation. Current Pharmaceutical Design, 2014, 20, 4697-4706.	0.9	19
1682	Role of the Endocannabinoidome in Human and Mouse Atherosclerosis. Current Pharmaceutical Design, 2019, 25, 3147-3164.	0.9	7
1683	The Endocannabinoid System and Pain. CNS and Neurological Disorders - Drug Targets, 2009, 8, 403-421.	0.8	368
1684	Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System. CNS and Neurological Disorders - Drug Targets, 2012, 11, 624-641.	0.8	32
1685	Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview. The Open Neurology Journal, 2017, 11, 61-73.	0.4	6
1686	Chronic Delta-9-tetrahydrocannabinol Induces Monoamine Release but Not Conditioned Place Preference. The Open Behavioral Science Journal, 2012, 6, 31-36.	0.8	1
1687	A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug. Current Molecular Pharmacology, 2020, 14, 11-26.	0.7	6
1688	Role of the Endocannabinoid System in Alcohol-Related Behaviors. The Open Neuropsychopharmacology Journal, 2009, 2, 31-39.	0.3	3
1689	Regional Influence of Cannabinoid CB1 Receptors in the Regulation of Ethanol Self-Administration by Wistar Rats. The Open Neuropsychopharmacology Journal, 2009, 2, 77-85.	0.3	30
1690	Distribution of CB1 cannabinoid receptors in the rat amygdaloid complex. Acta Veterinaria, 2004, 54, 369-378.	0.2	4
1691	Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues in Clinical Neuroscience, 2020, 22, 241-250.	1.8	59
1692	Cannabis for peripheral neuropathy: The good, the bad, and the unknown. Cleveland Clinic Journal of Medicine, 2018, 85, 943-949.	0.6	15
1693	Locomotor Behaviour and Anxiety in the Open Field and Light/Dark Box in CD1 Mice Treated with Aspirin, Cataflam and Ethanolic Extract of Cannabis sativa. British Journal of Medicine and Medical Research, 2015, 6, 563-572.	0.2	7
1694	The changing landscape of the use of medical marijuana after traumatic brain injury: a narrative review. Brain Injury, 2021, 35, 1510-1520.	0.6	4
1695	Diverse role of endocannabinoid system in mammalian male reproduction. Life Sciences, 2021, 286, 120035.	2.0	6
1696	Sistema cannabinoide endÃ³geno: ligandos y receptores acoplados a mecanismos de transducciÃ³n de seÃ±ales. Revista De Psicologia De La Salud, 2000, 12, 59.	0.2	1

#	Article	IF	Citations
1697	Electrophysiological Effects of Cannabinoids in the Basal Ganglia. Advances in Behavioral Biology, 2002, , 275-296.	0.2	0
1698	Sites of Analgesic Action. , 2003, , .		0
1699	MODULATORY EFFECTS OF CANNABINOID RECEPTOR LIGANDS ON DOPAMINE RELEASE FROM SYNAPTOSOMES OF THE NUCLEUS ACCUMBENS, STRIATUM AND FRONTAL CORTEX IN RAT BRAIN. KANSEI Engineering International, 2006, 6, 43-50.	0.2	0
1700	Cannabinoids. , 2006, , 521-539.		1
1701	Endocannabinoid Mechanisms of Pain Modulation. , 2008, , 737-764.		0
1702	Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids. , 2008, , 719-729.		0
1703	Neuroinflammation and the Glial Endocannabinoid System. , 2008, , 331-359.		0
1704	Can We Change the Body Fat Distribution Phenotype? Lessons from PPAR Agonists. , 2008, , 125-130.		0
1705	Cannabimimetics. , 2009, , .		0
1706	Dopamine D3 Receptor Antagonist SB-277011A Influences Cell Firing in the Rat Ventral Tegmental Area, Parallel Role with the Cannabinoid System in Addiction and Neuropsychiatry Disorders?. The Open Neuropsychopharmacology Journal, 2009, 2, 86-92.	0.3	1
1707	Neurobiological Basis of Drug Reward and Reinforcement. , 2010, , 255-281.		1
1708	Review on Amygdala Neural Circuitry of Antinociception: On Actions of Opioids and Endocannabinoids. Korean Journal of Cognitive and Biological Psychology, 2010, 22, 387-404.	0.0	0
1710	The Endocannabinoid System in the Cochlear Nucleus and Its Implications for Tinnitus Treatment. , 2011, , 639-647.		1
1711	Role of the Endocannabinoid System in Anxiety and Stress-Related Disorders. , 0, , .		1
1712	DEVELOPING NEW MEDICINES FROM CANNABIS SATIVA: CHALLENGES AND PERSPECTIVES. BrasÃ!ia MÃ©dica, 2011, 48, 277-283.	0.0	0
1713	Chapter 8 Does Higher Potency of Cannabis Mean Higher Risk for Psychosis?. , 2012, , 97-101.		0
1714	Overview of Nonclassical Cannabinoid Receptors. Receptors, 2013, , 3-27.	0.2	4
1715	The Role of GPR55 in Bone Biology. , 2013, , 71-113.		0

#	Article	IF	Citations
1716	Chronic Effects of Cannabinoid Drugs on Monoaminergic Systems and the Role of Endocannabinoids and Cannabinoid Receptors in Human Brain Disorders. , 2013, , 213-238.		0
1717	Endocannabinoid Signaling and the Regulation of the Serotonin System. , 2013, , 239-254.		0
1718	Endocannabinoids and Monoamines: Modulating the Modulators. , 2013, , 1-9.		0
1719	Does Higher Potency of Cannabis Mean Higher Risk for Psychosis?. , 2013, , 101-105.		0
1720	Endocannabinoids, Monoamines and Stress. , 2013, , 173-212.		0
1721	Cannabinoids and Synaptic Transmission in the Cerebellum. , 2013, , 927-946.		0
1722	Anatomical, Biochemical, and Behavioral Evidence for Cannabinoid Modulation of Noradrenergic Circuits: Role of Norepinephrine in Cannabinoid-Induced Aversion. , 2013, , 135-156.		0
1723	The Genetics of Cannabis Use and Cannabis Use Disorders. , 2013, , 523-531.		0
1724	Pharmacological Induction of Hypothermia. , 2014, , 157-165.		0
1725	Studying chemical and electrical neuronal dynamics as a platform for understanding schizophrenia. Journal of Coupled Systems and Multiscale Dynamics, 2013, 1, 405-427.	0.2	0
1726	Central Analgesic Activity. , 2014, , 1-104.		0
1727	Acute Co-Administration of the Cannabinoid Receptor Agonist WIN 55- 212,2 does not Influence 3,4-Methylenedioxymetamphetamine (MDMA)- Induced Effects on Effort-Based Decision Making, Locomotion, Food Intake and Body Temperature. Biochemistry & Pharmacology: Open Access, 2014, 03, .	0.2	0
1729	Arachidonate Derivatives as Endogenous Cannabinoid Substances. Molecular Biology Intelligence Unit, 1996, , 167-195.	0.2	0
1730	Maternal Drug Abuse and Adverse Effects on Neurobehavior of Offspring. , 1998, , 617-629.		1
1731	Psychomimetic Drugs, Marijuana, and 5-HT Antagonists. , 1998, , .		0
1732	Analgesic Properties of THC and Its Synthetic Derivatives. , 1999, , 511-526.		0
1733	Nichtlineare Dynamik und das â€žUnerwarteteâ€œ in der Psychiatrie. , 1999, , 267-279.		0
1734	Neuroscience Perspectives on Addiction: Overview. , 2015, , 999-1023.		0

#	Article	IF	Citations
1735	Retrograde Tract-Tracing â€œPlusâ€: Adding Extra Value to Retrogradely Traced Neurons. Neuromethods, 2015, , 67-84.	0.2	1
1736	Endocannabinoid Modulation of Memory for Emotionally Arousing Experiences. , 2015, , 3-21.		0
1737	Central Analgesic Activity. , 2016, , 1785-1874.		0
1738	Endocannabinoid Systetm: Neuropharmacological Implications. Medicine Science, 2016, 5, 562.	0.0	1
1740	Endocannabinoids, Stress, and Negative Affect. , 2017, , 53-78.		0
1741	Endocannabinoid-Dependent Synaptic Plasticity in the Striatum. , 2017, , 109-153.		0
1742	Abuse of Cannabinoids. Ankara Medical Journal, 0, , .	0.1	0
1743	Anticancer Herbs for Improving the Quality of Life. International Annals of Science, 2018, 5, 1-11.	0.4	2
1744	Cannabinoids as a Therapeutic Approach in Multiple Sclerosis. RSC Drug Discovery Series, 2019, , 241-263.	0.2	0
1745	Cannabinoids Involvement in Neurodegenerative Diseases. Research Journal of Pharmacology, 2019, 13, 16-26.	0.3	1
1752	Hippocampal Cb₂ receptors: an untold story. Reviews in the Neurosciences, 2022, 33, 413-426.	1.4	3
1753	Quality of Life and a Surveillant Endocannabinoid System. Frontiers in Neuroscience, 2021, 15, 747229.	1.4	19
1754	Endogenous Opiates and Exercise-Related Hypoalgesia. Contemporary Endocrinology, 2020, , 19-39.	0.3	0
1755	Role and Function of Endocannabinoid System in Major Depressive Disease. Medical Cannabis and Cannabinoids, 2021, 4, 1-12.	1.2	8
1756	Cellular and behavioral basis of cannabinioid and opioid interactions: Implications for opioid dependence and withdrawal. Journal of Neuroscience Research, 2022, 100, 278-296.	1.3	12
1758	Functional role for preoptic CB1 receptors in breathing and thermal control. Neuroscience Letters, 2020, 732, 135021.	1.0	2
1776	Cannabinoid receptor activation in the nucleus tractus solitaries produces baroreflex-like responses in the rat. International Journal of Biomedical Science, 2008, 4, 229-37.	0.5	4
1779	Resilience to meet the challenge of addiction: psychobiology and clinical considerations. , 2012, 34, 506-15.		6

#	Article	IF	Citations
1783	Effect of interaction between acute administration of morphine and cannabinoid compounds on spontaneous excitatory and inhibitory postsynaptic currents of magnocellular neurons of supraoptic nucleus. Iranian Journal of Basic Medical Sciences, 2016, 19, 676-84.	1.0	0
1785	Parkinsonâ€™s disease related alterations in cannabinoid transmission. Brain Research Bulletin, 2022, 178, 82-96.	1.4	4
1786	Sexually Dimorphic Expression of Fear-conditioned Analgesia in Rats and Associated Alterations in the Endocannabinoid System in the Periaqueductal Grey. Neuroscience, 2022, 480, 117-130.	1.1	4
1787	Cannabis exposure during adolescence: A uniquely sensitive period for neurobiological effects. International Review of Neurobiology, 2021, 161, 95-120.	0.9	11
1788	Astroglial CB1 Cannabinoid Receptors Mediate CP 55,940-Induced Conditioned Place Aversion Through Cyclooxygenase-2 Signaling in Mice. Frontiers in Cellular Neuroscience, 2021, 15, 772549.	1.8	7
1789	Lipid endocannabinoids in energy metabolism, stress and developmental programming. Molecular and Cellular Endocrinology, 2022, 542, 111522.	1.6	11
1790	Cannabinoids and Synaptic Transmission in the Cerebellum. , 2022, , 1005-1023.		0
1791	Modulating the Endocannabinoid System as a Therapeutic Approach for Posttraumatic Stress Disorder: Could Translational Research on Fear and Extinction Learning Predict Clinical Benefit?. Biological Psychiatry, 2022, 91, 248-249.	0.7	0
1792	Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of Î±-Synuclein in the Rat Brain. Molecules, 2022, 27, 507.	1.7	6
1793	Prefrontal cortical distribution of muscarinic M2 and cannabinoid-1 (CB1) receptors in adult male mice with or without chronic adolescent exposure to Î”9-tetrahydrocannabinol. Cerebral Cortex, 2022, , .	1.6	1
1795	Accumulation of systematic TPM1 mediates inflammation and neuronal remodeling by phosphorylating PKA and regulating the FABP5/NFâ€ºB signaling pathway in the retina of aged mice. Aging Cell, 2022, 21, e13566.	3.0	11
1796	Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond. Advances in Pharmacology, 2022, 93, 275-333.	1.2	8
1797	Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?. In Vivo, 2022, 36, 543-555.	0.6	2
1798	Opioid Reinforcement: What It Is And How It Can Be Modulated By Cannabinoids. , 2022, , 1-28.		0
1799	Activation of CNR1/PI3K/AKT Pathway by Tanshinone IIA Protects Hippocampal Neurons and Ameliorates Sleep Deprivation-Induced Cognitive Dysfunction in Rats. Frontiers in Pharmacology, 2022, 13, 823732.	1.6	7
1800	Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination. Biomedicines, 2022, 10, 539.	1.4	16
1801	Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells. Glia, 2023, 71, 103-126.	2.5	15
1802	The effects of prenatal nicotine and THC E-cigarette exposure on motor development in rats. Psychopharmacology, 2022, 239, 1579-1591.	1.5	7

#	Article	IF	Citations
1803	Adolescent THC exposure: effects on pain-related, exploratory, and consummatory behaviors in adult male vs. female rats. Psychopharmacology, 2022, 239, 1563-1578.	1.5	2
1804	Changes in brain structure and function following chronic exposure to inhaled vaporised cannabis during periadolescence in female and male mice: A multimodal MRI study. Addiction Biology, 2022, 27, e13169.	1.4	6
1805	Repeated Restraint Stress and Binge Alcohol during Adolescence Induce Long-Term Effects on Anxiety-like Behavior and the Expression of the Endocannabinoid System in Male Rats. Biomedicines, 2022, 10, 593.	1.4	2
1807	Synaptic changes induced by cannabinoid drugs and cannabis use disorder. Neurobiology of Disease, 2022, 167, 105670.	2.1	16
1808	A Systematic Review and Meta-Analysis on the Effects of Exercise on the Endocannabinoid System. Cannabis and Cannabinoid Research, 2022, 7, 388-408.	1.5	19
1809	Striatonigrostriatal Spirals in Addiction. Frontiers in Neural Circuits, 2021, 15, 803501.	1.4	0
1810	Endocannabinoid signaling in oligodendroglia. Glia, 2023, 71, 91-102.	2.5	7
1811	Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain. International Journal of Molecular Sciences, 2022, 23, 4407.	1.8	5
1812	Neuroplastic alterations in cannabinoid receptors type 1 (CB1) in animal models of epileptic seizures. Neuroscience and Biobehavioral Reviews, 2022, 137, 104675.	2.9	3
1823	Cannabinoid Receptor mRNA Expression in Central and Peripheral Tissues in a Rodent Model of Peritonitis. Cannabis and Cannabinoid Research, 2022, , .	1.5	1
1824	The CannTeen study: verbal episodic memory, spatial working memory, and response inhibition in adolescent and adult cannabis users and age-matched controls. Psychopharmacology, 2022, 239, 1629-1641.	1.5	8
1825	Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. European Neuropsychopharmacology, 2022, 59, 58-67.	0.3	17
1826	Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection. Frontiers in Pharmacology, 0, 13, .	1.6	4
1827	Augmented anandamide signalling in the substantia nigra pars reticulata mediates panicolytic-like effects in mice confronted by Crotalus durissus terrificus pit vipers. Psychopharmacology, 2022, 239, 2753-2769.	1.5	5
1828	Maternal Drug Abuse and Adverse Effects on Neurobehavior of Offspring. , 1998, , 617-629.		0
1829	Cannabis abuse and dependence. , 0, , 315-329.		0
1830	Alcohol-Endocannabinoid Interactions: Implications for Addiction-Related Behavioral Processes. Alcohol Research: Current Reviews, 2022, 42, .	1.9	5
1831	Sparse genetically defined neurons refine the canonical role of periaqueductal gray columnar organization. ELife, 0, 11, .	2.8	9

#	Article	IF	Citations
1832	Basolateral amygdala cannabinoid CB1 receptors mediate the antinociceptive activity of harmaline in adolescent male mice. Physiology and Behavior, 2022, 254, 113886.	1.0	1
1833	Cannabinoids. Advances in Neurotoxicology, 2022, , .	0.7	0
1834	Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs, 2022, 36, 819-858.	2.7	10
1836	Magnetic restricted-access carbon nanotubes for SPME to determine cannabinoids in plasma samples by UHPLC-MS/MS. Analytica Chimica Acta, 2022, 1226, 340160.	2.6	5
1837	Molecular and cellular mechanisms underlying brain region-specific endocannabinoid system modulation by estradiol across the rodent estrus cycle. Progress in Molecular Biology and Translational Science, 2023, , 27-45.	0.9	1
1838	DNA methylation changes associated with cannabis use and verbal learning performance in adolescents: an exploratory whole genome methylation study. Translational Psychiatry, 2022, 12, .	2.4	1
1839	Endocannabinoid System in the Neuroendocrine Response to Lipopolysaccharide-induced Immune Challenge. Journal of the Endocrine Society, 2022, 6, .	0.1	3
1840	Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors. Neurochemical Research, 2022, 47, 2899-2908.	1.6	5
1841	Cannabis use is associated with sexually dimorphic changes in executive control of visuospatial decision-making. Frontiers in Integrative Neuroscience, 0, 16, .	1.0	0
1842	Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility. Cells, 2022, 11, 2569.	1.8	9
1843	Task-independent acute effects of delta-9-tetrahydrocannabinol on human brain function and its relationship with cannabinoid receptor gene expression: A neuroimaging meta-regression analysis. Neuroscience and Biobehavioral Reviews, 2022, 140, 104801.	2.9	4
1844	Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB1 receptor density in cell membranes: an alternative to radioligand binding methods. Microbial Cell Factories, 2022, 21, .	1.9	2
1845	The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology, 2022, 63, 47-59.	0.3	6
1846	Nociceptive sensitivity under stress influence. Russian Journal of Pain, 2022, 20, 42.	0.2	1
1847	Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. Advances in Experimental Medicine and Biology, 2022, , 89-103.	0.8	3
1848	Investigating the â€œtwo-hit hypothesisâ€• Effects of prenatal maternal immune activation and adolescent cannabis use on neurodevelopment in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 120, 110642.	2.5	7
1849	CB1 as a novel target for Ginkgo bilobaâ€™sÂterpene trilactone for controlling chemotherapy-induced peripheral neuropathy (CIPN). Journal of Molecular Modeling, 2022, 28, .	0.8	3
1850	Anandamide in the dorsal periaqueductal gray inhibits sensory input without a correlation to sympathoexcitation. Neurobiology of Pain (Cambridge, Mass), 2022, 12, 100104.	1.0	1

#	Article	IF	Citations
1852	Prefrontal cortex and putamen grey matter alterations in cannabis and tobacco users. Journal of Psychopharmacology, 2022, 36, 1315-1323.	2.0	3
1853	Effects of Î² -caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction. Current Neuropharmacology, 2023, 21, 213-218.	1.4	2
1854	Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications. Journal of Cannabis Research, 2022, 4, .	1.5	3
1855	Opioid Reinforcement: What It Is and How It Can Be Modulated by Cannabinoids. , 2022, , 1893-1920.		0
1856	Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. Antioxidants, 2022, 11, 2049.	2.2	17
1857	Toll-like receptor 4 in the interface between neuroimmune response and behavioral alterations caused by stress. , 0, , 182-209.		0
1858	Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery. International Journal of Molecular Sciences, 2022, 23, 13223.	1.8	9
1859	Pharmacognosy and Effects of Cannabinoids in the Vascular System. ACS Pharmacology and Translational Science, 2022, 5, 1034-1049.	2.5	3
1860	Endocannabinoid receptors are involved in enhancing food intake in rainbow trout. Hormones and Behavior, 2022, 146, 105277.	1.0	1
1861	Endocannabinoid System Biomarkers in Alzheimer's Disease. Cannabis and Cannabinoid Research, 0, , .	1.5	0
1863	Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments. Advances in Clinical Chemistry, 2023, , 1-67.	1.8	8
1864	Potential Utility of Cannabidiol in Stress-Related Disorders. Cannabis and Cannabinoid Research, 0, , .	1.5	2
1865	Design, synthesis, and structureâ€“activity relationships of diindolylmethane derivatives as cannabinoid CB₂ receptor agonists. Archiv Der Pharmazie, 2023, 356, .	2.1	1
1866	Effect of Cannabis on Memory Consolidation, Learning and Retrieval and Its Current Legal Status in India: A Review. Biomolecules, 2023, 13, 162.	1.8	4
1867	Noradrenergic circuits. , 2023, , 373-408.		0
1868	Cannabinoid Tolerance in S426A/S430A xÎ²-Arrestin 2 Knockout Double-Mutant Mice. Journal of Pharmacology and Experimental Therapeutics, 2023, 385, 17-34.	1.3	3
1869	Endocannabinoid regulation of hippocampus-dependent memory. Experimental Neurology, 2023, 364, 114384.	2.0	4
1870	Effects of inhaled cannabis high in Î”9-THC or CBD on the aging brain: A translational MRI and behavioral study. Frontiers in Aging Neuroscience, 0, 15, .	1.7	7

#	Article	IF	Citations
1871	The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19. Viruses, 2023, 15, 573.	1.5	3
1872	Chronic exposure to inhaled vaporized cannabis high in Î”9-THC alters brain structure in adult female mice. Frontiers in Neuroscience, 0, 17, .	1.4	1
1873	Medicinal Cannabis for Alzheimer's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 1-47.	0.1	0
1874	Protective Effects of Cannabis in Neuroinflammation-Mediated Alzheimer's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 48-75.	0.1	1
1875	The Effects of Chronic Marijuana Administration on 6-OHDA-Induced Learning & Memory Impairment and Hippocampal Dopamine and Cannabinoid Receptors Interaction in Male Rats. Neurochemical Research, 0, , .	1.6	0
1876	Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation. Frontiers in Behavioral Neuroscience, 0, 17, .	1.0	4
1877	Cannabinoids. , 2023, , 221-224.		0
1878	Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. , 2023, 244, 108394.		8
1879	Expression of Cytokines and Neurodegeneration in the Rat Hippocampus and Cortex in the Lithium-Pilocarpine Model of Status Epilepticus and the Role of Modulation of Endocannabinoid System. International Journal of Molecular Sciences, 2023, 24, 6509.	1.8	1
1880	Activation of cannabinoid type 1 receptor (CB1) modulates oligodendroglial process branching complexity in rat hippocampal cultures stimulated by olfactory ensheathing glia-conditioned medium. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	1
1881	Ethanol enhances JWH-018-induced impairment of sensorimotor and memory functions in mice: From preclinical evidence to forensic implication in Driving Under the Influence of Drugs. Drug and Alcohol Dependence, 2023, 247, 109888.	1.6	1
1882	RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB₁, CB₂, GPR18 and GPR55 cannabinoid receptors. British Journal of Pharmacology, 0, , .	2.7	0
1888	Cannabis, neurodevelopment, and the â€œtwo-hitâ€•hypothesis. , 2023, , 457-472.		0
1889	Synthetic cannabinoid receptor agonists compared to Î”9-tetrahydrocannabinol: Neurological effects and beyond. , 2023, , 487-496.		0
1890	Insights into the endocannabinoid system from investigations of the development of social behavior in rodents of both sexes. , 2023, , 123-135.		0
1891	On the interplay among endocannabinoid, noradrenergic, and glucocorticoid systems: Evidence from aversive memory studies. , 2023, , 253-267.		0
1893	Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation. , 2023, , 271-282.		0
1894	Brain metabolic responses to cannabis use in people with multiple sclerosis: Insights from [18F]-FDG positron emission tomography and functional MRI. , 2023, , 301-312.		0

#	Article	IF	Citations
1895	The endocannabinoid system: Signaling and social motivation. , 2023, , 469-478.		0
1896	Genetic models of audiogenic seizures: What they are and how cannabinoids and Cannabis-derived compounds can be used to alleviate their symptomsâ€"An updated narrative. , 2023, , 245-263.		0
1897	Role of hippocampal CB1 and CB2 receptors in fear memory consolidation, extinction, and reconsolidation. , 2023, , 283-295.		0